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Onchocerciasis, caused by Onchocerca volvulus remains a major public health and 
socio-economic problem across the tropics, despite years of mass drug administration 
(MDA) with Ivermectin to reduce disease burden. Through modelling, it has been 
shown that elimination cannot be achieved with MDA alone and additional tools are 
needed, such as vaccination, which remains the most cost-effective tool for long-term 
disease control. The feasibility behind vaccination against O. volvulus can be 
demonstrated in the Litomosoides sigmodontis mouse model, which shows that 
vaccine induced protection can be achieved with immunisation using irradiated L3, the 
infective stage of L. sigmodontis and with microfilariae (Mf), the transmission stage 
of the parasite. There is further evidence of protective immunity in humans, with 
individuals living in endemic areas that show no signs of infection despite being 
exposed to the parasite (endemic normal).  
The protective efficacy of promising vaccine candidates were evaluated using an 
immunisation time course in the L. sigmodontis model, using either DNA plasmid or 
peptide vaccines. In immunisation experiments in L. sigmodontis, Mf numbers are 
used as a measure of protection and marks the end of an immunisation time course. 
However, when changes in gene expression were measured at the end of an 
immunisation time course, in attempts to identify gene signatures that could be used 
as markers of protection (correlates of protection) in the blood, no gene signatures were 
found to be associated with protection. This suggest that at the end of an immunisation 
time course, when protection is measured (change in Mf numbers), it is too late in 




Changes in gene expression were therefore measured in blood samples collected 
throughout an immunisation time course in the L. sigmodontis model, in order to 
identify the time point in an immunisation experiment which are the most indicative 
of protection. Two independent immunisation time courses were used, either using 
irradiated L3 or Mf as vaccine against L. sigmodontis, as these elicit the greatest 
protection. This generated a large high dimensional dataset, that was too large and 
complex for a differential fold-change analysis. Therefore, an analysis pipeline was 
created using machine learning algorithms, to detect changes in gene expression 
throughout the time courses to detect markers of protection.  
The 6 hour time point following immunisation showed the greatest change in gene 
expression, with the analysis pipeline identifying known pathways associated with 
vaccine-induced immunity. The pipeline was applied to gene expression data from 
human samples obtained from individuals living in endemic areas who were either 
infected with O. volvulus or endemic normal (naturally protected), this was to identify 
pathways associated with protective immunity in humans. When comparing vaccine 
induced immunity seen in mice and natural protective immunity in humans there was 
some overlap in pathways being triggered, suggesting that similar pathways are needed 
for protection and that if a vaccine can trigger the right pathways in mice, it is likely 
to be effective in humans.  
Overall the machine learning analysis of the gene expression data, not only shows that 
it is feasible to measure change in gene expression in blood during filarial infections, 
but that during an immunisation time course it is the early time points following 




One of the vaccine candidates, cysteine protease inhibitor-2 (CPI), is a known 
immuno-modulator that inhibits MHC-II antigen presentation on antigen presenting 
cells such as dendritic cells (DC). This candidate has consistently been shown to 
induce protection if its immuno-modulatory active site was modified. In in vitro 
studies, it was shown that modification of the active site of CPI rescues antigen 
presentation in DC. This shows the importance of DC activation before the onset of 
infection, demonstrating the importance of triggering protective responses early in 





Onchocerciasis, also known as river blindness is a major public health and socio-
economic problem in Africa and in small areas in South America, and despite years of 
effort from control programmes this debilitating disease is still present. Therefore, an 
alternative control method is needed, such as a vaccine, if one day this disease it to be 
eliminated. In this study, potential vaccine candidates were tested in an animal model 
for onchocerciasis, and at the end of the vaccination time course presence or absence 
of parasites were measured. Although this measure is a good indicator of protective 
efficacy, it does not give an indication of what the immunology behind this protection 
is. Further studies were done to look at indicators in the blood of animals vaccinated 
with known protective vaccines. Since this produced a large dataset, computational 
tools were used to identify what the kind of protective immunity was being triggered 
throughout this time course. Samples taken at time points immediately after the 
vaccine was given, provided the most information, of the immune pathways being 
triggered. Overall this thesis has validated certain vaccine candidates against 
onchocerciasis and shown that markers of protection can be measured in the blood 
during a vaccination time course. This will be useful in the future to measure the 
efficacy of vaccine after vaccination instead of having to wait till the end of vaccination 
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Chapter 1. General Introduction 
1.1 Overview of Onchocerciasis 
Onchocerciasis, also known as river blindness, is caused by the filarial nematode 
Onchocerca volvulus, which is transmitted from person to person by a blackfly 
(Simulium spp). Onchocerciasis is endemic in 30 African countries, as well as in 
Yemen and localised foci in six Latin American countries (Figure 1.1). It is suggested 
that 95% of O. volvulus infected individuals were living in Africa, and with the use of 
REMO (rapid epidemiological mapping of onchocerciasis) it is estimated that 37 
million people are infected, and 90 million are at risk in Africa (APOC, 2013; World 
Health Organization, 2016b). Onchocerciasis is a debilitating neglected tropical 
disease, imposing a global health burden of 0.5 million disability-adjusted life-years 
(DALYs) (Murray et al., 2012). Although onchocerciasis is mostly associated with a 
chronic infection, with varying degrees of mild pathology, a proportion of individuals 
do develop severe symptoms including visual impairment, which can lead to 
irreversible blindness; severe itching with secondary infections if scratched; and 
hyperactive dermatitis which is termed sowda (blackening of the skin). As a 
consequence of this debilitating pathology there is stigma and fear of this disease, 
historically causing people to abandon fertile lands creating an even bigger socio-
economic impact (Houweling et al., 2016). 
The prevalence of onchocerciasis infection and disease in a community is correlated 
to the proximity to rivers in which the blackflies breed, with microfilariae (Mf) 




years old, after which infection profiles vary between geographical regions and age 
(Duerr et al., 2004; Filipe et al., 2005). Endemicity is split depending on prevalence of 
infection, with areas hyper-endemic for onchocerciasis having more than 60% of the 
population present with Mf in the skin, with high Mf density levels (<50 Mf/mg skin). 
A prevalence between 35-65% of onchocerciasis within a population is classified as 
meso-endemic, and hypo-endemic areas have less than 35% of the population with 
detectable Mf in the skin. 
  
Figure 1.1. Worldwide distribution of onchocerciasis, 2013 (WHO). Map showing different 
distribution of onchocerciasis around the world, dark green represents meso-or hyper-endemic 
areas, classified as a prevalence of greater then 20%; light green as hypo-endemic areas, 
classified as a prevalence less than 20%. Map obtained from World Health Organisation 
http://www.who.int/onchocerciasis/epidemiology/en/.  
  
The boundaries and names shown and the designations used on this map do not imply the expression 
of any opinion whatsoever on the part of the World Health Organization concerning the legal status 
of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers 
or boundaries. Dotted lines on maps represent approximate border lines for which there may not 
yet be full agreement. © WHO 2014. All rights reserved
Data Source: World Health Organization
Map Production: Control of Neglected 
Tropical Diseases (NTD)
World Health Organization
Distribution of onchocerciasis, worldwide, 2013
Not applicable
Non-endemic countries
Endemic countries (former OCP countries)
Hypo-endemic (prevalence < 20%)




1.2 Overview of related human filarial nematodes 
Other filarial species that have a human host include Wuchecheria bancrofti, Brugia 
malayi, Brugia timori which are the causative agents of lymphatic filariasis; Loa loa 
which causes Loiasis; and other less known but well distributed species are Mansonella 
streptocerca, Mansonella perstans and Mansonella ozzardi (Table 1.1).  
Lymphatic filariasis is another cause of chronic morbidity with a negative social 
impact, and as its name suggests it affects the lymphatics, with severe symptoms such 
as hydroceles, an accumulation of fluid in the scrotum; and elephantiasis, an 
obstruction of lymphatic vessels resulting in extreme swelling of skin and tissues, 
typically in the legs (Otabil, Tenkorang, 2015). 
Loiasis is characterised by migration of adult worms across the eye and “Calabar 
swelling”. Calabar swelling are subcutaneous oedemas that are often associated with 
localised and general itching, frequently found on the limbs, especially on the 
forearms. These oedemas can cause restricted movement of the nearest joint, and can 
disappear spontaneously and re-appear at irregular intervals. Compared to 
onchocerciasis and lymphatic filariasis, loiasis has been much less studied, despite 
having been known for a long time, most likely due to loiasis being less wide-spread, 
restricted to equatorial west and central Africa, and severe pathology is rare 
(Boussinesq, 2013). More recently, it has emerged as a disease of significant public 
health importance because of its potential negative impact on onchocerciasis control 
programmes. Individuals with high levels of L. loa Mf in their blood (<30,000 Mf/ml), 
that take the drug Ivermectin, the treatment used for onchocerciasis, have an increased 




Therefore, in areas with high intensity L. loa infections co-endemic for onchocerciasis 
(Figure 1.2), Ivermectin cannot be used for mass drug administration (MDA), hence 
hindering control campaigns.  
Mansonella species have received even less attention, despite being widespread in 
many parts of sub-Saharan Africa, notably M. perstans which is found in 33 countries 
within this region, often with a very high prevalence within the population. Mansonella 
perstans is responsible for serous cavity filariasis in humans; infections are often 
asymptomatic, but when symptoms are seen these include subcutaneous swelling, 
aches, pains, skin rashes, hormonal disturbances and hypereosinophilia. Despite it 
being considered as one of the most prevalent parasites in tropical Africa it has 
received very little attention, mainly because it causes few clinical symptoms, and no 
severe adverse reactions are detected with drugs used for lymphatic filariasis or 
onchocerciasis. However, M. perstans might be interfering with the host regulatory 
mechanisms, influencing the outcome of other infections such as malaria, tuberculosis, 
and HIV, but also potentially influencing vaccine mediated immunity, however this 






Figure 1.2. Map of estimated prevalence of Loa loa in Africa. This map represents an 
estimate of the distribution of loiasis based on survey data (RAPLOA).  Darker areas represent 
areas of hyper endemicity, demonstrating that there are two zones of high endemicity (dark 
red). Areas with a prevalence of 40% were classified as high risk areas for Ivermectin 




Table 1.1. Filarial species with human host 
Disease & filarial 
nematode 














America and Yemen 
95% of infected 
people live in 30 
African countries 
• Estimated 187 
million people at 
risk in 37 countries. 
• 37 million people 
infected. 
• 4 million suffer from 
severe itching or 
dermatitis 
• 265, 000 are blind 
Adult worms reside 
within subcutaneous 
nodules, and Mf 




Onchocerciasis can cause 
severe skin itching 
(dermatitis) and 
onchocercomas (subcutaneous 
nodules), as well as ocular 
lesions that can progress to 
blindness. 
• Severely debilitating 
pathology 
• APOC in Africa 
• OEPA in the 
Americas 
Their main strategy 


























tropics & accounts 
for 90% of the LF 
cases in Africa 
• 1 billion at risk in 73 
countries 
• 67 million infected  
• 35 million suffering 
from severe 
pathology: 
• 25 million men with 
genital disease 
• 15 million 
elephantiasis of the 
leg 
Adult worms reside 
within the lymphatic 
vessels, and Mf 
migrate to the blood, 
in a periodical 
pattern to match 




accumulation of lymphatic 
fluid generally in limbs.  
Hydrocele: fluid accumulation 
in the scrotal sac 
Annual MDA with 
combination of 
either albendazole 
and Ivermectin or 















Brugia malayi  
Southeast Asia 











• Loa Loa 
Present in 10 
counties in Africa: 
restricted to 
equatorial rain forest 
of Central and West 
Africa 
• 30 million people at 
risk 
• 13 million infected  
Adults live in 
subcutaneous tissues. 
Mf have diurnal 
periodicity (in the 
blood during the day, 
and non-circulating 
Mf reside in the 
lungs. 
 Vector: Deerfly 
(Chrysops spp) 
Adult worms pass through the 
sub-conjunctiva of the eye, 
migration of adult worm can 
cause oedema (Calabar 
swelling) and skin itching. 
 
DEC1 is given to 
patients with low 
Mf loads. In patients 
with high Mf 




albendazole can be 
given. 












New world, humid, 
warm regions from 
Mexico till north 
Argentina 
• Not known L3 are transmitted 
during vector blood 
meal. Adults appear 
to live in the serous 
body cavities, 
females produce Mf, 





In rare cases can cause 
symptoms: headaches, fever, 
pulmonary symptoms, 
swelling of lymph nodes and 
liver, and skin itching. 
Single dose of 
Ivermectin, DEC1 
has no effect, 
doxycycline has no 





regions in West and 
Central Africa, 
South and Central 
America 
• 580 million live in 
endemic areas* 
• 114 million possibly 
infected* 
In rare cases from tourist or 
expatriates in endemic areas, 
show signs of abdominal pain 
and some allergic reactions 
resembling L. loa ‘Calabar 
swellings’ 
If Wolbachia is 
present then treated 
with doxycycline, if 
no Wolbachia then 






Cameroon, Congo  
• Not known Mostly asymptomatic, but can 
cause skin manifestations 
including itching, papular 
(nodules) and pigmentation 
changes 
A single round of 
Ivermectin can 
suppress Mf loads 
(Fischer et 
al., 1997) 
* These are most likely gross estimate since not many epidemiological studies have been carried out (Simonsen et al., 2011), similarly CDC treatment 





1.3 Human filarial nematode life cycles 
1.3.1 Onchocerciasis 
Onchocerciasis is transmitted by an infected bite of a blackfly vector (Simulium spp) 
(Blacklock, 2016), which can be found around fast-flowing and well-oxygenated 
streams and rivers. Blackflies transmit the infective third-stage larvae (L3) onto the 
skin of the human host when taking a blood meal. The L3 then enter the vertebrate host 
through the bite wound, and once inside the host the L3 reside within the subcutaneous 
tissue, where they mature into fourth-stage larvae (L4) and then into adults. Adult 
females reside in subcutaneous nodules called onchocercomas, whereas adult males 
migrate through the subcutaneous tissues between nodules fertilising different females. 
Within the nodules male and females mate, and subsequently female worms will 
release microfilariae (Mf). Mf migrate throughout the body via the subcutaneous 
tissues, and the lymphatic vessels of connective tissue  (Murdoch, Murdoch, 2016), 
with most the disease symptoms associated with onchocerciasis, induced by the death 
of Mf passing through the skin or eyes (Taylor et al., 2010). A blackfly will take a 
blood meal from an infected vertebrate host and ingest Mf from the dermis. 
Within the blackflies, the Mf penetrate the midgut and migrate through haemocoel 
(circulatory system in arthropods) to the thoracic muscles, were they moult first into 
the first-stage larvae (L1), then the second-stage larvae (L2) and finally into L3. The 
L3 migrate to the blackflies head and finally emerge in the proboscis, from where they 






Figure 1.3. Onchocerca volvulus life cycle. 1) During a blood meal, an infected blackly 
(Simulium spp) will introduce the infected third stage larvae (L3) to the skin of the human host, 
and these will enter the host via the bite wound, as blackflies take a blood meal by cutting into 
the skin and feeding on the blood pool that forms. 2) Once in the subcutaneous these L3, will 
molt fourth stage larvae (L4) and then again into adult worms. 3) The adults reside in nodules 
within the subcutaneous connective tissue, for up to 15 years. 4) In these nodules, the females 
and males mate, and females produce thousands of microfilariae (Mf), these are the 
transmission stages of the parasite. Mf can live up to 2 years, and migrate through the skin and 
lymphatics of connective tissues, and in some occasion travel to the eyes. 5) Blackflies will 
ingest Mf during a blood meal. 6) Within the blackflies, the Mf migrate to midgut, 7) where 
they will molt into the first larval stage (L1), following with the second larval stage (L2), 8) 
and then into L3 infective stage. 9) The L3 migrate to the blackflies mouth parts, 10) and 
during the subsequent blood meal will infect another human host. Diagram taken from CDC 





1.3.2 Lymphatic filariasis  
Transmission of lymphatic filariasis whether W. bancrofti, B. malayi or B. timori, 
begins with the inoculation of infective larvae (L3) into the skin of the human host 
during a mosquito bite. The L3 larvae enter through the puncture wound and migrate 
through the lymphatics towards the lymph nodes. The parasites reside within the 
lymphatics and lymph nodes, where they mature and molt first into the fourth larval 
stage (L4) and then adult worms. Adult worms mate, and females release live Mf. Mf 
periodicity in the blood, coincides with the time of feeding of their vector, as a wide 
range mosquito species act as vectors of lymphatic filariasis (e.g. Anopheles gambiae, 
Culex quinquefasciatus and Aedes polynesiensis). Once ingested by the respective 








Figure 1.4. Wuchereria bancrofti life cycle. W. bancrofti, B. malayi and B. timori have very 
similar life cycles. They are all transmitted by mosquitoes, with different mosquito species 
depending of the geographical distribution. 1) During a blood meal, an infected mosquito 
transmits the infected third-stages larvae (L3) onto the skin of a human host, these will then 
penetrate the bite wound. 2) The L3 migrate through the subcutaneous tissue to the lymphatic 
vessels, were they develop into fourth-stage larvae (L4) and then into adults. 3) Adults mate, 
and females produce microfilariae. These Mf are sheathed and have a nocturnal periodicity, 
meaning that Mf migrate between the lymph and blood, and are found in the blood at night. 4) 
When Mf are in the blood, a mosquito will ingest them after a blood meal. 5) After ingestion, 
the Mf lose their sheaths and migrate to the thoracic muscles. 6) Mf then develop into first-
stage larvae, second-stage larvae, 7) and finally into L3. 8) The L3 migrate to the mosquitoes 
proboscis, 9) and infect another human host in the subsequent blood meal. Diagram taken from 






Loa loa is transmitted by a tabanid fly (Chrysops spp). During a blood meal, L3 escape 
from the proboscis of the fly and are deposited on the surface of the skin. The L3, then 
enter the skin via the bite wound, and within the subcutaneous tissue, the L3 moult to 
L4, and then to adults. The adult worms live between the layers of loose connective 
tissue under the skin, where they mate, and female worms release Mf. The Mf have a 
diurnal periodicity to coincide with their vectors feeding habit, during the day they are 
found in the peripheral blood and at night they are found in the lungs. During a 
subsequent blood meal, the tabanid flies will ingest the Mf. In the fly the Mf will 
mature into L3, ready to infect a new host following a subsequent blood meal (Figure 
1.5) (Boussinesq, 2013). 
Although, O. volvulus and L. loa are transmitted by different vectors, their modes of 
transmission and life cycles share similarities. In both cases, L3 are deposited onto the 
skin and migrate into the bite wound, once in the human host, they mature and develop 
into adults within the subcutaneous tissue. In both nematodes, adults mate, and females 
produce thousands of Mf. However, O. volvulus produce unsheathed Mf that can be 
found in the skin at any time of the day, as they do not exhibit any form of periodicity, 
whereas in L. loa, the Mf are sheathed and found in the peripheral blood during the 







Figure 1.5. Loa loa life cycle. 1) Loa loa is transmitted by a tabanid fly (Chrysops spp), during 
a blood meal, third-stages larvae (L3) escape the proboscis of the flies and are deposited onto 
the skin of a human host, these will then penetrate the bite wound. 2) The L3 develop into 
fourth-stage larvae (L4), by day 9 post-infection and then into adults by day 19 post infection. 
The adults reside in the subcutaneous tissue for up to 17 years. 3) Adults mate, and females 
produce microfilariae. These Mf are sheathed and pass into the host lymphatic system before 
accumulating the lungs. From this reservoir, the Mf migrate to the peripheral blood during the 
day, to coincide with the tabanid fly feeding habit. In some cases, Mf can be found in urine, 
saliva and spinal fluid. 4) When Mf are in the blood, the tabanid fly will ingest them. 5) After 
ingestion, the Mf lose their sheaths and migrate to the thoracic muscles. 6) Mf then develop 
into first-stage larvae, second-stage larvae, 7) and finally into L3. 8) The L3 migrate to the 
fly’s proboscis, 9) and infect another human host in the subsequent blood meal. Diagram taken 





1.4 Wolbachia  
Wolbachia is an endosymbiotic bacterium living in many species of insects (52% of 
terrestrial arthropods) and some nematodes. It is restricted to living within the host 
cells and in nematodes it is transovarially transmitted (from females to progeny) 
(Makepeace, Gill, 2016). Wolbachia has gained attention in the recent years, because 
they cause reproductive alterations in insect, which can be manipulated for vector 
control purposes, and because they are present in nematodes, and can therefore be 
targeted for treatment (antibiotics). Wolbachia pipientis is the only formally 
recognised species within the genus, however W. pipientis has been divided into 
different strains, termed “supergroups” (Makepeace, Gill, 2016). 
Most filarial species that infect humans co-exist with Wolbachia within their tissue, 
such as B. malayi, B. timori, O. volvulus, O. ochengi and W. bancrofti, but not L. loa 
(Slatko et al., 2014). In O. volvulus, Wolbachia is found in the adult worms body wall, 
oocytes, all embryonic stages and in the Mf (Hoerauf et al., 2000). This bacterium is 
not only essential for growth and development of the nematodes, but also plays a key 
role in the fecundity of the adult female worms, and triggers inflammatory responses 
within the host. Depletion of Wolbachia by antibiotics can not only block 
embryogenesis but also kill adult worms, providing a new route for therapeutic 





1.5 Diagnostic tools 
For onchocerciasis 
Detection of onchocerciasis mostly still relies on identification of Mf in skin snips 
(small biopsies that are restricted to the upper dermis). Other diagnostic methods 
include the use of diethylcarbamazine (DEC) patch test, in which itchy patches appear 
where topical DEC kills Mf, these are however invasive methods with low sensitivity 
(Eberhard et al., 2017). 
An immunodiagnostic test based on the detection of human IgG4 antibodies to the O. 
volvulus specific antigen Ov-16 also exist, and is one of the recommended tools for 
determining whether transmission has been interrupted (WHO guidelines, (WHO, 
2016). However, the diagnostic accuracy of Ov-16 antibody test has mostly been 
assessed in populations with high onchocerciasis prevalence, and therefore might not 
be as sensitive in low-prevalence areas, such as at the end-stage of control programmes 
or in hypo-endemic areas (Lipner et al., 2006).  
More sensitive and less invasive alternative diagnostics are desperately needed, to 
determine when to stop control interventions, in particular in areas which have become 
hypo-endemic following MDA (Vlaminck et al., 2015; Golden et al., 2016; Eberhard 
et al., 2017).  
For lymphatic filariasis  
For lymphatic filariasis, traditional diagnostic methods involve the examination of 
blood slides for Mf, collected at night, due to the periodicity of lymphatic filariasis. 





for lymphatic filariasis, these include a W. bancrofti antigen-based test and a Brugia 
spp antibody tests, which have been tremendously useful for national mapping surveys 
of lymphatic filariasis (Cano et al., 2014). 
For loiasis 
L. loa is distinguished by the examination of blood, for the presence of Mf. 
Determining the number of circulating Mf is important for the successful 
implementations of control programmes for onchocerciasis. MDA programmes have 
been limited in areas with O. volvulus and L. loa co-endemicity, because of risk of 
developing severe adverse events (SEA) following treatment with Ivermectin (used for 
onchocerciasis control) in individuals harbouring high levels of L. loa Mf in the blood 
(<30, 000 Mf/ml) (Twum-Danso, 2003; Boussinesq et al., 2003; Boussinesq, 2013). A 
majority of the population infected with L. loa have Mf levels below the threshold 
(Pion et al., 2006). Therefore, a simple and fast diagnostic methods capable of 
identifying individuals at risk of SEA is needed, so that these individuals with high Mf 
counts can be excluded from Ivermectin treatment, as this would aid in increasing 
MDA coverage for onchocerciasis. 
Mf burdens in the blood of L. loa infected individuals, are detected by counting Mf 
numbers in blood smears under a microscope, however this is time consuming and not 
useful in large scale MDA programmes, where fast diagnostic tools are preferred. 





• The use of loop-mediated isothermal amplification (LAMP), which is a nucleic 
acid-based method that can detect individuals with high Mf loads, but requires 
training (Drame et al., 2014);  
• A cell counter chamber, which works by allowing blood to pass through but not 
Mf, making them easy to quantify (Bennuru et al., 2014);  
• A cell phone microscope, which uses a software that can determine Mf numbers 
(D'Ambrosio et al., 2015). 
These diagnostic tools under development all provide a rapid method of identifying 
individuals with high Mf loads, to exclude them from Ivermectin treatment, however 
these all require blood samples. A less invasive diagnostic tool is under development, 
with the possibilities to quantifying Mf loads, using an antigen detection assay in urine 





1.6 Treatments available 
Current treatments for filarial infections involve the use of diethylcarbamazine (DEC), 
Ivermectin, albendazole and doxycycline. For lymphatic filariasis, control 
programmes rely on the use of DEC, albendazole or Ivermectin depending on whether 
the treatment area is co-endemic for onchocerciasis, whereas onchocerciasis primarily 
relies of the use of Ivermectin, but doxycycline could be used in areas co-endemic with 
L. loa (Wanji et al., 2009). 
DEC is the mainstay drug for the global programme to eliminate lymphatic filariasis 
(GELF) in areas not co-endemic for onchocerciasis (i.e. all Asian and Pacific regions; 
and some African and South American countries). A single dose of DEC is effective 
in reducing acute and chronic microfilaremia, although a single does not clear all Mf 
nor kill all adults, a regimen for 12 consecutive days will lead to absence of Mf in the 
blood (Gyapong et al., 2005). Some adverse reaction can occur, due to the rapid killing 
of adult worms and Mf caused by the release of Wolbachia. 
Albendazole, is an anthelmintic effective against a broad spectrum of nematodes and 
flatworms (i.e. Cestodes). The combination of albendazole with DEC or Ivermectin in 
lymphatic filariasis infected individuals, reduced Mf loads in the peripheries for a 
longer period, compared to a single treatment, however the combination of Ivermectin 
and albendazole has no effect in onchocerciasis patients (Awadzi et al., 2013).  
DEC was recognised early on to induce severe adverse reaction in individuals infected 
with O. volvulus (Greene et al., 1985; Lariviere et al., 1985), with adverse events 





et al., 1985). However, it continued to be the drug of choice for onchocerciasis, because 
better alternatives are not available.  
In the 1980, a single dose of Ivermectin was found to be more effective than DEC at 
clearing O. volvulus Mf, and therefore became the drug of choice for onchocerciasis 
(Albiez et al., 1988). Ivermectin can be given to both onchocerciasis and lymphatic 
filariasis infected individuals. Ivermectin is a microfilaricidal (kills Mf), it is effective 
at killing the Mf stage, but not the adults, although repeated treatment has been 
suggested to render adult females infertile. However, it cannot be given to children 
<15kg; to pregnant woman; nor in areas co-endemic with L. loa due to sever adverse 
reactions of Mf dying (Basáñez et al., 2008; Chesnais et al., 2017).  
Since lymphatic filariasis and onchocerciasis nematodes carry the Wolbachia 
bacterium, doxycycline and other antibiotics can be used as treatments (Gilbert et al., 
2005; Hoerauf, 2008; Wanji et al., 2009). In lymphatic filariasis, patients treated with 
doxycycline resulted in long-term sterility and eventual death of adult worm, and 
further decreased pathology. In onchocerciasis, treatment with doxycycline resulted in 
sterilisation of adult females and an absence of Mf in the skin (Abegunde et al., 2016). 
Doxycycline is the first drug to show macrofilaricidal (kills adult stages) activity in 
onchocerciasis, with no severe adverse events, but it is a long treatment (6 week), and 
cannot be given to children under 9 years old nor pregnant woman. Therefore, 
doxycycline is a good treatment strategy on an individual basis, but not practical for 
mass drug administration campaigns (Slatko et al., 2014), unless greater investment is 
made to train community workers to ensure compliance with treatment regime (Wanji 





1.7 Control programmes for onchocerciasis and 
lymphatic filariasis  
1.7.1 Lymphatic filariasis control 
Most control programmes for filarial diseases, rely on mass drug administration 
(MDA). For lymphatic filariasis, the global programme to eliminate lymphatic 
filariasis (GPELF) was launched in 2000, with the aim to eliminated lymphatic 
filariasis by 2020. GPELF strategy is to interrupt transmission of infection using MDA 
of DEC or Ivermectin combined with albendazole, as well as managing morbidity and 
preventing disability (Ottesen et al., 2008; Ramaiah, Ottesen, 2014). In 2014, 73 
countries were classified as being endemic for lymphatic filariasis, with an estimated 
71% MDA coverage by August 2015, and since the creation of GPELF, 18 of these 
countries have now entered post-MDA surveillance, due to infection having being 
reduced to below target threshold, following high coverage of five or more rounds of 
MDA (World Health Organization, 2015). Lymphatic filariasis is arguably easier to 
control and perhaps eliminate compared to onchocerciasis, principally because 59% of 
the lymphatic filariasis burden is found in 9 Asian countries, where MDA coverage is 
high (66%) (SEARO, 2010; World Health Organization, 2015). Moreover, in Asia 
there is no co-endemicity with onchocerciasis, meaning that MDA can rely on the use 
of DEC alone or in combination with albendazole, this treatment regime has proven 
the most effective and so far, has averted 175 million DALY’s, and possibly the key 
factor that makes lymphatic filariasis control more successful compared to 
onchocerciasis (Turner et al., 2016). Treatment coverage, sustainability, and 





particularly challenging in poor resource settings of sub-Saharan Africa. Mathematical 
modelling suggest that lymphatic filariasis transmission could be interrupted using 
MDA alone, but over a longer period of time then the 4-6 years that were initially 
suggested, due to some lack of compliance in certain areas (Stolk et al., 2015a). 
1.7.2 Onchocerciasis control 
For onchocerciasis, the story is more complicated, with 95% of the global burden in 
Africa, where compliance and sustained MDA coverage is notoriously low due to: 
•  civil strife and conflict;  
• insufficient health infrastructure and resources;  
• low political commitment and insufficient funds to sustain national programmes 
for years;  
• growing public fear of using Ivermectin due to the risk of developing severe 
adverse reaction, in L. loa infected patients (Gardon et al., 1997; Boussinesq et 
al., 2003; Wanji et al., 2015b).  
These factors have prevented long-term and sustained programmes throughout much 
of Africa (Cheke, 2017).  
The first large scale control of onchocerciasis started in 1974, with the creation of 
Onchocerciasis Control Programme (OCP) in West Africa, which employed vector 
control through aerial spraying of organophosphate larvicide to target Simulium spp 





effective against O. volvulus microfilariae, which greatly contributed to the OCP’s 
activities (Cupp et al., 2011). This initial wave of control proved successful, with tens 
of millions of cases of onchocerciasis prevented, according to the WHO.  
With the end of OCP approaching (2002), a second major initiative emerged the 
African Programme for Onchocerciasis Control (APOC), which started in 1995 
focusing on community-directed mass drug administration (MDA) of Ivermectin in 19 
countries throughout Africa. Between 1995 and 2010, APOC prevented more than 8.2 
million disability-adjusted life years (DALYs) (Coffeng et al., 2013).  
In parallel, the Onchocerciasis Elimination Program for the Americas tackled 
onchocerciasis with Ivermectin treatment twice a year, with consistently high rates of 
coverage which has led to the interruption of transmission or elimination in 11 of 13 
foci (in Latin America). By 2015, 60% of the population needing Ivermectin received 
treatment, which was slightly lower than the minimum therapeutic target of 65% 
(World Health Organization, 2016b). 
Although onchocerciasis control has shown much less success in Africa compared to 
the Americas, due to the differences in size of endemic foci, vector competence, 
duration and consistency of treatment coverage (Cupp et al., 2011; Cheke, 2017). 
There has been some success in Africa, with interruption of seasonal transmission in 
three hyper-endemic foci in Mali and Senegal, where only a few infections remained 
in the human population, after 15 to 17 years of annual or bi-annual Ivermectin 
treatment (Diawara et al., 2009). In follow up studies (22 months after last treatment), 





producing Mf. Furthermore, in two foci in Nigeria, which had meso-endemic pre-
control endemicity, elimination was also achieved following by 15-17 years of annual 
Ivermectin treatment (Tekle et al., 2012). Although this provides evidence of 
elimination could work in certain foci, it does not imply that elimination is feasible in 
the other onchocerciasis endemic areas in Africa.  
The pre-control endemicity level is an important factor that influences the likelihood 
of interruption transmission and eliminating of onchocerciasis (Basáñez et al., 2016). 
Although in Mali and Senegal pre-endemicity was classified as hyper-endemic (22-48 
mf/mg skin), there are many foci in Africa with significantly higher endemicity levels. 
Furthermore, in the foci in Mali and Senegal there was seasonal transmission, which 
allows for treatment strategies to be optimised, i.e. distributing Ivermectin before the 
rainy season. In the Nigerian foci, not only was the initial endemicity relatively low 
but there was also high Ivermectin treatment coverage (<75%), all contributing factors 
to elimination.  
The studies in Mali, Senegal and Nigeria provided some evidence that it could be 
possible stop transmission and ensure onchocerciasis elimination after 15-17 years of 
annual treatment, under certain conditions. However, studies in Ghana (Lamberton et 
al., 2015), Cameroon (Wanji et al., 2015a; Kamga et al., 2016), and north-western 
Uganda (Katabarwa et al., 2013), show that despite 15 years of MDA with Ivermectin 
and in some cases vector control, the burden of onchocerciasis might have been 





Several mathematical models have been created to determine the minimum duration 
of Ivermectin mass treatment and the number of treatment rounds required to reach a 
defined threshold of Mf prevalence (<1.4%) below which treatment can be stopped 
(Coffeng et al., 2014; Turner et al., 2014a; Basáñez et al., 2016). Several simulations 
have been conducted under a variety of scenarios, such as using different:  
• Pre-control endemicity levels – With higher endemicity levels having longer 
programme durations (Coffeng et al., 2014; Turner et al., 2014a). 
• Treatment frequency – Switching to biannual treatment would reduce the 
duration of the programmes (30-40% reductions) but high compliance would 
need to be maintained (Coffeng et al., 2014), which is not always feasible twice 
a year especially in hard to reach communities (Turner et al., 2014b). 
• Treatment coverage – Typically 15% of the population are non-eligible for 
Ivermectin treatment, because of their age (under5 5 years old), weight (<5 Kg), 
pregnancy or illness (Basáñez et al., 2016). The effect of three coverage levels, 
40% (poor), 60% (moderate) and 80% (high), were investigated, and maintaining 
a high level of coverage is necessary to reach elimination within a reasonable 
time (15 years). 
There are however scenarios were elimination may not be feasible within 15-18 years, 
even under biannual Ivermectin MDA with high coverage (Coffeng et al., 2014; Stolk 
et al., 2015a), particularly in areas with intense transmission, most often due to high 





Furthermore, there is now emergence of possible resistance to Ivermectin in foci in 
Cameroon (Pion et al., 2013) and Ghana (Osei-Atweneboana et al., 2011), with adult 
females from areas having received multiple Ivermectin treatments, recovering Mf 
production earlier, compared to female worms from areas having received only one 
dose of Ivermectin.  
Furthermore, MDA with Ivermectin also cannot be given in areas co-endemic with 
loiasis, due to the risk of sever adverse reaction associated with L. loa death (Chesnais 
et al., 2017). If Ivermectin treatment were to be implemented in loiasis co-endemic 
areas, each individual person would need to be tested for the prevalence of L. loa 
infection, as individuals with high Mf burdens would need to be excluded to avoid the 
risk of adverse reactions. Even by excluding individuals at risk, additional measures 
would need to be put in place in case individuals with low Mf burdens developed 
adverse reaction, and this would raise the cost of Ivermectin MDA campaigns (Turner 
et al., 2015). The alternative treatment doxycycline, cannot be given to children under 
9, and is also a long treatment, that needs more trained community workers, also 
increasing the cost of campaigns. Therefore, this leaves a reservoir of onchocerciasis 
infections which gives the opportunity for reintroduction of onchocerciasis in 
neighbouring areas with ongoing MDA treatment or in areas where MDA has been 
stopped due successful in elimination.  
Now that the London Declaration on Neglected Tropical Disease and the WHO have 
set goals for  onchocerciasis elimination by 2020 in selected African countries (World 
Health Organization, 2012; Uniting to Combat NTDs, 2012), a novel health 





administrable to children and individuals co-infected with L. loa, is needed. 
Mathematical modelling has suggested that a vaccine complimentary to MDA efforts, 
would not only reduce onchocerciasis burden in the populations that cannot receive 
Ivermectin, but also decrease the chance of re-emergence in areas where Ivermectin 
MDA has been successful and treatment has stopped (Turner et al., 2015).  
Table 1.2. Comparison of onchocerciasis and lymphatic filariasis control. 
 Onchocerciasis Lymphatic filariasis 
Treatments 
used in control 
programmes 
Annual or biannual treatment 
with: 
• Ivermectin (in areas not co-
endemic with L. loa) 
(Doxycycline can be used in 
areas co-endemic with loiasis, 
but it is a long treatment so not 
used in control programmes) 
Annual MDA: 
• DEC & albendazole 
• Ivermectin & albendazole (in 
areas co-endemic with 
onchocerciasis) 
• Albendazole alone (in areas co-
endemic with loiasis) 
Majority of 
disease burden 
95% in 30 African countries 58% in 9 Asian countries 
Success • 4 countries in Latin America 
were acknowledged by WHO 
as achieving onchocerciasis 
elimination: Colombia (2013), 
Ecuador (2014), Mexico (2015) 
and Guatemala (2016)  
• 10 countries in Latin America 
have interrupted transmission 
• 6 countries were acknowledged 
by WHO as achieving lymphatic 
filariasis elimination: Colombia 
(2013), Ecuador (2014), Mexico 
(2015) and Guatemala (2016)  
• 13 countries in Asia, Latin 
America and Caribbean do not 
require preventative 
chemotherapy anymore and are 
under surveillance to demonstrate 





• Children under 5 years old  
• Pregnant women 
• Individuals with high density L. 
loa infections 
• Children under 2 years old  





15-17 years, although due to low 
coverages more than 30 years 
would be needed. 
In many case’s annual MDA for 5-6 






1.7.3 Using Onchocerca volvulus vaccines in Loa loa co-
endemic regions 
Severe side effects following Ivermectin treatment for onchocerciasis in areas co-
endemic with loiasis, has side tract the work of APOC. Although other onchocerciasis 
treatment exist that could be used in this region, they have limitations that make them 
impractical to use in MDA campaigns. Vaccine against onchocerciasis provides a good 
alternative or complementary control strategy, and with modelling it was shown that 
using a vaccine in onchocerciasis and loiasis co-endemic areas, would have a 
beneficial impact for onchocerciasis control, especially reducing Mf burden in under 
20 year olds (Turner et al., 2015).  
Although there is a lot of cross-reactivity between O. volvulus and L. loa, there is 52-
72% similarity in amino acid, between the potential vaccine candidates (Ov-Ral-2, Ov-
103) identified for O. volvulus in the L. loa counterparts, and was suggested that it was 
unlikely that there would be enough cross-efficacy to cause adverse effects in L. loa 
infected individuals (Turner et al., 2015). However, this issue has yet to be tested in 
animal models, more so because of the lack of suitable animal to study L. loa 
infections. Through the use to knockout mice it is now possible to look at effects of L. 
loa in murine models (Tendongfor et al., 2012), and therefore measure cross-efficacy 






1.8 Animal models used to study immune responses 
to filarial parasites 
A major constraint in vaccine development, is the need of an animal model, not only 
to understand the immune response to onchocerciasis, but there also needs to be a way 
to evaluate vaccine candidates. Since it is difficult and unethical to test in humans, 
research turns to animal models, however a major obstacle is that O. volvulus only 
infects humans and in some cases primates. Experimental infections have been 
attempted in several animals with only chimpanzees (Pan troglodytes) and mangabey 
monkeys (Cercocebus atys) developing a successful infection, both of which are 
impractical and unethical to screen vaccine candidates (Eberhard et al., 1991; Abraham 
et al., 2002).  
One approach to overcome this problem was the development of the diffusion chamber 
model, which allows immunity against early larval stages (L3) of O. volvulus or B. 
malayi in mice to be investigated  (Lange et al., 1993). In this model live L3 are 
implanted subcutaneously in diffusions chambers, which can be recovered after a 
period of time, to analyse the parasites survival and microenvironment (cytokines, cells 
recruited) (Abraham et al., 2004). The advantage of this system is that immune 
responses to human parasites can be investigated. However, the disadvantages are that 
only the early stages of infections (larval stages) can be investigated, and the insertion 
of the chamber (14mm in diameter) itself does cause inflammatory responses, biasing 
subsequent immune responses. 
Alternatively, other filarial species may be used, such as B. malayi which is permissive 





(African mouse). The advantage of these systems is that vaccine efficacy against a 
human filarial nematode can be tested in a fully permissive host, but immunological 
readouts are difficult to measure due to the lack of reagents available for the animals 
(Morris et al., 2013).  
A close relative to O. volvulus is Onchocerca ochengi, which naturally infects cattle. 
These two Onchocerca spp share many similarities, such as transmitted by the same 
group of insect vector (Simulium damnosum complex); they both form collagenous 
nodules with similar histological structure, although O. ochengi forms intradermal 
nodules, whereas O. volvulus are subcutaneous nodules (Makepeace, Tanya, 2016); in 
both human and in cattle there are individuals that are naturally protected from 
infection (EN) (Tchakouté et al., 2006). O. volvulus and O. ochengi are sympatric 
species (evolved from a single ancestral species, in the same geographic region) 
(Morales-Hojas et al., 2006), with cross-reactive immunity between cattle and human 
species (Renz et al., 1994). Therefore, O. ochengi model is useful for investigating 
vaccines efficacy against onchocerciasis under conditions of natural exposure, 
however cattle are impractical and too expensive for screening large numbers of 
vaccine candidates. 
The most attractive alternative for screening vaccine candidates is the use of 
Litomosoides sigmodontis which is the only filarial species in which the full 
development cycle can take place in BALB/c mice (Petit et al., 1992), with extensive 
immunological cross-reactivity with Onchocerca spp (Manchang et al., 2014), 
allowing important immunological as well as parasitological readouts to be measured 





helped elucidate many of the immunological mechanisms that determine susceptibility 
or resistant to filarial parasites. 
Table 1.3. Filarial animal models used to evaluate vaccine candidates 
Animal model Advantages Disadvantages 
O. volvulus or B. 
malayi in diffusion 
chamber in mice 
(Used to look at 
early larval stages 
(L3/L4)) 
Effect of vaccine can be 
determined directly on human 
parasite, and since chambers 
are in mice reagents exist to 
measure immunological 
readouts. 
Not a permissive model, so 
vaccine effect can only be 
examined on larval stages of 
parasite. Further chamber itself 
may cause inflammatory 
responses, which may influence 
the development of specific 
filarial responses. 
B. malayi in gerbils 
(Permissive model) 
Effect of vaccine can be 
determined directly on human 
parasite, and on all stages of 
parasite life cycle 
Not many reagents exist for 
gerbils therefore it is difficult to 
measure immunological effects of 
vaccines 
L. sigmodontis in 
mice 
(Permissive model) 
Effect of vaccine can be 
determined on all stages of 
parasite life cycle, and since it 
is in mice reagents exist to 
measure immunological 
readouts. 
It is not a human filarial 
nematode 
O. ochengi in cattle 
(Permissive model) 
Can measure effect of vaccine 
efficacy with natural 
infections, closest relative to 
human onchocerciasis parasite 
and allows to study effect of 
vaccine on all life stages 
Can be logistically difficult to 
trial many vaccine candidates. 
1.8.1 L. sigmodontis model of infection 
In susceptible BALB/c mice, infective third-stage larvae (L3) are transmitted to the 
mouse during a blood meal by the mite, Ornitonyssus bacoti. Once in the subcutaneous 
tissue, L3 migrate to the lymphatics, reaching the pleural cavity around day 4 post 
infection. In the thoracic cavity, the L3 moult into fourth-stage larvae (L4) by day 10 





These adults mate, and females start producing Mf around day 55 post infection, which 
are detected in the peripheral blood, where they can be taken up by a mite during a 
blood meal. Within the mite, the Mf moult into L3 completing the life cycle (Figure 
1.6). Although BALB/c mice are classified as having susceptible infection, not all mice 
have detectable Mf found circulating in the blood stream (47% presenting patent 
microfilaremia) and the adults get cleared around day 90 post infection (Petit et al., 
1992). 
Whereas, in CBA/Ca and C57BL/6 mice L. sigmodontis worm mature, but patency is 
never reached. In CBA/Ca mice Mf are present in the uteri of female worms and 
sometimes in high densities but they are not found circulating in the blood (Table 1.4) 
(Petit et al., 1992). These differences in mouse strain susceptibility to L. sigmodontis 
infections, provides a great model to investigate the immunological and genetic 
determinants of susceptibility or resistant to infection. Furthermore, Hoffmann et al 
showed that independent to the mouse strain, survival of L. sigmodontis Mf is 
dependent on the presence of adult female worms (Hoffmann et al., 2001). 
The L. sigmodontis animal model remains arguable the best experimental system for 
developing anti-filarial vaccines, as it has similar patterns of infection including larval 
migration, with some immunological cross-reactivity with human filariasis (Brugia 






Figure 1.6. Litomosoides sigmodontis life cycle. L. sigmodontis can complete a full life cycle 
in either BALB/c mice or gerbil host, using Ornitonyssus bacoti (mite) as the vector. (1) An 
infected mite takes a blood meal transferring third-stage larvae (L3) into the subcutaneous 
tissue of mice or gerbils (Day 0). (2) The L3 migrate to the lymphatics and arrive to the pleural 
cavity by day 4 post infection (Day 4 p.i.). (3) By day 7 these have moulted into fourth-stage 
larvae (L4), (4) and then develop into adults reaching sexual maturity by day 28 p.i. (5) 
Females release 1000 of microfilariae (Mf), which can be detected in peripheral blood by day 
55 p.i., ready to be (6) taken up by the vector during a blood meal. (7) In the vector the Mf 
develop into L1 and subsequently moult into L3 taking about 15 days. The L3 are then ready 
to infect a new host through a blood meal completing the life cycle. (Adapted from EPIAF 









Table 1.4. Susceptibility to L. sigmodontis in different mice strain (Petit et al., 1992) 
Mouse 
Strain 
Susceptibility to L. sigmodontis infection 
Presence of Adults Patent infection 
BALB/c +              + (47%) 
B10.D2 - - 
CBA/J + - 
C3H/He + - 
C57BL/6    - * - 
DBA/1    - * - 
*(worms never reach full adult form) 
1.9 O. volvulus infections in humans  
Human studies show that type 2 immune responses are associated with protection, 
although in a small proportion of individuals it can also lead to severe pathology 
(Murdoch, Murdoch, 2016). However, filarial nematodes have developed mechanisms 
to avoid theses immune responses, by regulating the immune system. The exact 
mechanisms by which filarial nematodes are killed in vivo and how these parasites 
avoid these mechanisms are still being investigated. 
1.9.1 Pathology induced by O. volvulus 
Disease pathogenesis for onchocerciasis is linked to host inflammation invoked by the 
death of the parasite, especially the Mf stage. In onchocerciasis, much of the pathology 
is found in the skin due to inflammation induced by Mf dying, resulting in intense 
itching, starting with acute papular dermatitis (swelling, itching and inflammation), 
followed by chronic itching (pruritus), more papular dermatitis and scarring, which 





premature ageing, such as lichenification or hanging groin (Taylor et al., 2010). Patchy 
depigmentation of the legs can lead to a condition known as leopard skin and in 
extreme cases, there is severe papular dermatitis with hyperpigmentation (darkening 
of the skin), termed sowda (Taylor et al., 2010). In some cases, O. volvulus infections 
can cause ocular lesion, due to Mf migrating to the posterior and anterior regions of 
the eye and evoking an in inflammatory responses with their death, this leads to severe 
visual impairment, with sclerosing keratitis (inflammation of the cornea) and 
iridocyclitis (inflammation of the iris), and finally blindness (Hise et al., 2003; Brattig, 
2004; Taylor et al., 2010). In highly endemic regions, rates of skin disease increase 
with age until 20 years and then plateau, with the younger individuals exhibiting 
itching and chronic papular onchodermatitis, whereas the more severe form of 
depigmentation, visual impairment and blindness is more common in older individuals 
(<40 years) (Murdoch et al., 2002).  
1.9.2 Spectrum of immune responses to O. volvulus in 
humans  
The parasites complex life cycle leads to a complicated host immune response, which 
is thought to explain the spectrum of clinical manifestations of onchocerciasis. O. 
volvulus infected individuals who have not received treatment exhibit a spectrum of 
disease manifestations (Table 1.5), from generalized onchocerciasis (GEO) a 
hyporesponsive response to O. volvulus, to a hyperreactive response showing severe 
pathology (Figure 1.8). GEO individuals tend to have palpable nodules 
(onchocercomas, the subcutaneous nodules containing adult O. volvulus worms) under 





hyperreactive individuals have severe pathology but lower Mf density in the skin 
(Hoerauf, Brattig, 2002). Around 1-5% percentage of the population are naturally 
protected, because despite living in endemic areas, they show no signs of infection, 
neither clinical pathology nor detectable parasites, these individuals are termed 
endemic normal (EN) (Hoerauf, Brattig, 2002; Brattig, 2004). 
1.9.2.1 Hyporesponsive response to O. volvulus - GEO 
GEO individuals make up most the infected population, they have chronic infection 
with little pathology and this is thought to be due to O. volvulus ability to modulate 
immune responses, a common strategy of filarial nematodes (Hoerauf et al., 2005). A 
study in rural Nigeria endemic for onchocerciasis, found that the population with low 
prevalence of visual impairments was associated with low CD4+ T cell counts (Nmorsi 
et al., 2007). A reduced antigen-specific T cells responses and T cell proliferation is 
common trait of onchocerciasis patients with heavy infections, as well as low 
production of interferon gamma (IFN-g), interleukin 13 (IL-13) and IL-5, which 
decreases with increasing Mf densities (Brattig et al., 2002), on the other hand these 
patients have elevated production IL-10 and TGF-β (Hoerauf et al., 2005; Korten et 
al., 2010). 
This immunosuppression in GEO individuals is associated with regulatory T cells, and 
several subsets have been identified in onchocerciasis infected patients (Figure 1.7). 
Analysis of onchocercomas obtained from GEO patients, confirmed the presence of 
Foxp3+ regulatory T cells (Treg) (Korten et al., 2008) and TGF-β+ T cells (Th3),  





vitro from onchocercomas of GEO patients, these had typical characteristics of type 1 
regulatory T cells (Tr1), such as elevated IL-10 production, variable amounts of IL-5 
and IFN-g, but zero to low production of IL-4 and IL-2 (Doetze et al., 2000; Satoguina 
et al., 2002). These Tr1 cells have an upregulated expression of CTLA-4 following 
stimulation, which were able to suppress proliferation of other T-cell clones in co-
cultures (Satoguina et al., 2002). CTLA-4 is a known marker of down-regulation and 
these CTLA-4+CD4+IL-10 producing Tr1 cells have often been found in higher 
number in GEO individuals (Steel, Nutman, 2003; Katawa et al., 2015). The Tr1 and 
Th3 cells have been associated with isotype switching to IgG4 production by B cells, 
involving IL-10 and TGF-β (Satoguina et al., 2008). 
Elevated levels of IgG4 is a hallmark of GEO patients. IgG4 is an antibody subclass 
that does not fix complement but binds rather weakly to effector cell Fc receptors, and 
is therefore able to clear antigen without strong stimulation of effector cells. In 
onchocerciasis, it is a marker of patency as IgG4 levels correlate with peripheral Mf 
loads (Hoerauf et al., 2005). IgG4 may help Mf survival by binding to the Mf and 






Figure 1.7. Regulatory T cells identified in filarial infections. There are different regulatory 
T cell subsets found in filarial infections, these were found in both human infections and the 
L. sigmodontis mouse model. Two CD4+CD25+Foxp3+ Tregs subsets were identified, the 
Tregs derived from the thymus and are sometimes termed naturally Tregs and those induced 
in the periphery from naïve T cells are induced Tregs. In addition to the Foxp3 expressing 
Tregs, two other subsets of regulatory T exist which do not express Foxp3. These can be 
classified based on the regulatory cytokines they produce. Type 1 regulatory T cells (Tr1) 
express mainly IL-10, and Th3 regulatory T cells express TGF-b (Metenou, Nutman, 2013).  
1.9.2.2 Hyperreactive responses to O. volvulus - Sowda 
Hyperreactive form of onchocerciasis is characteristic of low parasite burden, but 
protective responses tend to lead to severe pathology sometimes referred to as the 
sowda form of onchocerciasis. These individuals exhibit a dominant Th17/Th2 
phenotype with: high levels of IgE; elevated levels of eosinophils and mast cells in 
nodules; increased activated CD4+ T helper; dense infiltrates with T cells and B cells 
and extensive fibrous nodules termed onchocercomas; but low parasite burden (Korten 





(peripheral blood mononuclear cell) from infected individuals showed that 
hyperreactive individuals had elevated levels of IL-13, IL-5 and IFN-g, but low IL10 
and/or TGF-β, and had cutaneous pathology associated with pronounce systemic Th2 
type responses to O. volvulus (Brattig et al., 2002; Hoerauf et al., 2005; Korten et al., 
2010). As well as elevated Th2 responses hyperreactive individuals have a pronounced 
Th17 phenotype, with greater number of CD4+IL-17A secreting T cells compared to 
GEO individuals but decreased regulatory T cells (CD4+ CD25hi Foxp3+) (Katawa et 
al., 2015). Environments which trigger IL-17/IL-17R signalling favour alloreactivity 
and autoreactive T cells by inhibiting regulatory T cells. This agrees with the reduced 
local expression of TGF-b, MHC-II and IgG4 detected around pathology and the 
reduced numbers of regulatory T cells (both Foxp3+ T cells and Tr1 cells) in patients 








Figure 1.8. Model of balance between effector and suppressor mechanism, seen in GEO 
and hyperreactive individuals. Generalised onchocerciasis (GEO), has a dominant 
regulatory T cells immune responses, with increased numbers of regulatory T cells (Foxp3+, 
Th3 and Tr1 cells); increased levels of IL-10 and TGF-β cytokines; and higher levels of IgG4. 
Counterbalancing this, there is lower levels of IL-13, IL-5 and IL4. Whereas in hyperreactive 
there are strong Th2/Th17 responses, with increased eosinophil and mast cell numbers; 
increased IL-13, IL-5, IL-4 and IL-17 cytokines levels; and elevated levels of IgE, but with 
lower suppression mechanism seen with lower levels of IL-10 and TGF-β. (Diagram adapted 
from (Hoerauf, Brattig, 2002) and (Katawa et al., 2015)) 
Dermatitis and ocular keratitis immunopathology seen in onchocerciasis patients is 
associated with dying Mf in skin and eyes, respectively. Neutrophils are the major 
components of the early inflammatory infiltrate around damaged Mf in the cornea and 
skin, their recruitment and activation is dependent on the release of Wolbachia derived 
antigen from Mf present at those sites (Turner et al., 2009). A lipoprotein on the surface 
of Wolbachia has been identified as being the main trigger of neutrophil inflammatory 
responses via the activation of Toll-like receptor (TLR) -2/6, during ocular keratitis 





surrounding adult worms, these are found attached to worms containing Wolbachia. 
Nodules derived from doxycycline treated patients where Wolbachia would have been 
depleted, neutrophils can still be found but in lower numbers (Tamarozzi et al., 2016). 
Neutrophils in nodules do not appear to be detrimental to living adults, and recently 
the formation of neutrophil extracellular traps (NETs) have been identified 
surrounding the worms. NETs exact role is still undetermined, it has been hypothesised 
to be the host protective mechanisms to any Wolbachia release from the worm’s uteri 
or in excretory / secretory products; from Wolbachia released from Mf; or as method 
of trapping Mf and consequently limiting the Mf being released each day. 
1.9.2.3 Protective immunity to O. volvulus – Endemic normal 
Evidence of protective immunity in onchocerciasis is derived principally from the 
existence of non-infected individuals living in endemic areas, known as endemic 
normal. When comparing GEO patients to EN individuals, the latter display stronger 
antigen-specific proliferation and a mixed Th1/Th2 response. Immune protected 
individuals living in Ecuador presented with increased IFN-g to O. volvulus antigen 
compared to Mf+ individuals, but lower levels of IL-5 and IL-10 (Elson et al., 2008). 
Similar results were found in individuals living in onchocerciasis hyperendemic areas 
in Cameroon. When comparing specific anti-larval and anti-adult cytokine levels, 
endemic normal had higher levels of GM-CSF (granulocyte-macrophage colony-
stimulating factor) and IL-5 compared to infected individuals, and high levels of IFN-
g which were not detected in infected individuals (Turaga et al., 2000). Overall EN 
individuals had stronger Th1 phenotype, with IFN-g producing T cells expressing T-





infected individuals (Katawa et al., 2015). Suggesting that naturally resistant 
individuals are protected from O. volvulus by their ability to produce a mixed Th1/Th2 
type response, although little is known about how an individual is predisposed to be 
protected. 
1.9.2.4 Genetic determinants of susceptibility in humans 
Onchocerca volvulus like many nematode parasites, are capable of influencing the host 
immune response, through secretion of potent immunomodulators (proteins). The 
extent of any immunomodulation largely depends on the intensity of infection, but the 
host genetics may also play a role. Genetic studies have linked HLA-DQ expression 
with the level of immune response (cutaneous reactions) the host mounts to parasite 
antigens (Murdoch et al., 1997). Further, the promoter haplotype of IL-10 was found 
to influence in vitro PBMC proliferative response to O. volvulus antigen (Timmann et 
al., 2004). Hyperreactive patients were association with a polymorphism in the IL-13 
gene, which could lead to enhanced induction of the Th2 pathway. Studies, showed 
that the Th2 dominant sowda form of onchocerciasis was associated with the same 
mutation in the IL-13 gene (Arg110Gln) that is linked to allergic hyper-sensitivity 
(atopy, asthma). The presence of Arg110Gln variant of IL-13 is a significant risk factor 
for the development of sowda, although these individuals had higher IgE levels, these 
were found to be two independent factors. This IL-13 variant is thought lead to higher 






1.9.2.5 Immune responses in Ivermectin treated individuals 
Since the introduction of MDA with Ivermectin, another group of patience can be 
categorized, these are patients that have been treated with Ivermectin, and thus have 
adult worms and nodules present but no detectable dermal Mf (Mf -ve). These 
individuals have been referred to as amicrofilaremic or as having an occult infection 
(Lechner et al., 2012; Arndts et al., 2014). Ivermectin treatment triggers an immediate 
immune response, with elevated chemokine (eotaxin and MCP-4) profiles responsible 
for promoting the migration of effector cells such as eosinophils and macrophages into 
patient’s skin, prompting a purported cellular mediated Mf death. During the year 
following treatment there is a gradual rise in chemokines associated in neutrophil 
recruitment, suggesting that these are recruited to the adult worms, possibly due to the 
release of Wolbachia derived molecules, resulting in a reduction in numbers of  Mf 
released into the dermal tissue (Lechner et al., 2012). Following repeated Ivermectin 
treatment, there is a decrease in circulating and tissue eosinophils linked to a decrease 
in eotaxin; with a decrease in Th2 promoting cytokines (IL-5), and regulatory makers 
such as IL-10, since there is an expiring O. volvulus infection (Lechner et al., 2012; 





Table 1.5. Summary of spectrum of disease manifestation in individuals living in 
onchocerciasis endemic areas. 
Group Adult worms 
Mf 




Present High Low / no pathology 
Modulated immune 
response. 
High levels: IL-10, TGF-β, 
Tregs, AAMs and IgG4 
Low levels: IgE, IFN-g 
Hyperreactive: 
Sowda  
Present Low Severe pathology 
Strong Th2 and Th17 
response   












response, and a mixed 
Th1/Th2 response. 
Balanced: IFN-g /IL-4 
Low levels: IL-10 & IgE, 
Ivermectin treated: 
Amicrofilaridermic  Present None 
No 
pathology 
High levels: neutrophils  
Low levels: eosinophilia, 






1.10 Immune responses to filarial infections in animal 
models 
Animal models such as L. sigmodontis infection in mice are used to elucidate some of 
the complex interactions between the filarial nematode and its host.  
1.10.1 Protective immune responses to filarial infection in 
animal models 
It is accepted that the host immune response to filarial parasites in both animal models 
and humans is of the T helper 2 (Th2) type, which promotes parasite killing of the 
different life stages (Allen et al., 2008).  
Innate immune responses to L3 
Innate responses to infection have been associated with the rapid destruction of L3 
larvae within two days’ post-infection, with neutrophils recruited to the invading L3 
in the skin (Pionnier et al., 2016). Neutrophil recruitment following a primary infection 
was shown to be in response to Wolbachia, an endosymbiotic bacterium living within 
L. sigmodontis worms. Mice deficient for NOD2, an intracellular pattern recognition 
receptor (PRR) to gram-negative and -positive bacteria, had increased worm burden at 
the early stage of infection caused by impaired neutrophil recruitment (Ajendra et al., 
2016). Furthermore, using CXCR4 gain in function mutant, on C57BL/6 mice 
background who are naturally more resistant to L. sigmodontis infections, it was 
demonstrated that resistance to infection is associated with an elevated number of 
dermal neutrophils, and where L3 were able to promote an oxidative bursts response 





This NET formation was also found in human filarial infection with O. volvulus around 
nodules containing adults worms (Tamarozzi et al., 2016).  
Although, in in vitro studies, eosinophils were found to adhere to the L3 and Mf of O. 
volvulus (Brattig et al., 1991), in in vivo studies eosinophils were not present in innate 
immune responses to invading L3. As mice lacking eosinophils due to a deficiency in 
IL-5 had no change in worm burdens compared to wild types (Volkmann et al., 2003). 
The chemokine, CCL17, has been shown to be involved in early immune responses, 
limiting parasite invasion in the host. Deficiencies in CCL17, induced a recruitment 
and degranulation of mast cells, which led to increased vascular permeability, 
facilitating L. sigmodontis larval migration through the lymphatics to the pleural 
cavity. This mechanism was dependent on the presence of Wolbachia in L3 and 
promoted by TLR2 signalling (Specht et al., 2011a). 
Immune responses in the pleural cavity (to L3, L4 and adults) 
To evade the innate immune responses, L3 migrate to lymphatics within hours of 
infection, through the heart and lung before reaching the pleural cavity (Babayan et 
al., 2003; Karadjian et al., 2017). In the pleural cavity of BALB/c mice, L3 can be 
detected as early as 2 hours post-infection, with 20% of the L3 reaching the pleural 
cavity between day 4-8 post-infection (Karadjian et al., 2017). Following arrival of L3 
within the pleural cavity, there is a recruitment of neutrophils to the pleural cavity via 






The L3 will moult into L4 around day 9-10 post-infection. Then depending on the 
mouse genetic backgrounds, L4 will develop into adults and then mature or will stay 
as immature adults. The differences in susceptibility to L. sigmodontis infections, can 
be detected by day 30 post infection between susceptible BALB/c mice and resistant 
C57BL/6 mice (Table 1.6), with less that 15% of the parasites at the L4 stage in 
BALB/c, compared 30% of the parasites in C56BL/6 (Petit et al., 1992; Babayan et 
al., 2003). This difference leads to BALB/c mice producing patent infections around 
day 55-60, while in C57BL/6 mice, worms are progressively encysted in granulomas 
and destroyed from day 40 post-infection. The lack in parasite maturation seen in 
C57BL/6 mice has been associated with a mixed Th1/Th2 immune response early on 
infection (day 10) compared to BALB/c mice who already have predominant Th2 
response. The exact mechanisms dictating C56BL/6 resistant are not completely 
understood, but increased cellular recruitment and elevated CXCL12 concentration in 
the pleural cavity have been implicated. Blockage of the CXCL12/CXCR4 axis caused 
a decrease in cellular recruitment to the pleural cavity and an increase in worm burden, 
suggesting that indeed CXCL12 is important in resistance (Bouchery et al., 2012a) 
Granuloma formation within the pleural cavity 
Different cell types are recruited to the pleural cavity in L. sigmodontis infection, and 
although the exact trigger or sequence of events that causes granuloma formation 
around the worms that leads to them eventually being cleared, are not fully known. 
What is known is that granuloma formation is an important part of the immune 





In L. sigmodontis time course studies, in both resistant and susceptible mice showed 
that granulomas were not present around larval stages, but were formed around the 
shed cuticle from these larval stages and consist mostly of eosinophils (Attout et al., 
2008).  
In BALB/c mice, granulomas are found around ageing adult worms consisted mostly 
of neutrophils, as neutralizing IL-5 or G-CSF (chemokine for neutrophils) led to failure 
of neutrophil recruitment to the pleural cavity and hence the survival of adult worms 
for a longer period of time (Al-Qaoud et al., 2000; Volkmann et al., 2003). Similar 
results can be seen in IFNg deficient mice, which showed that neutrophils were 
essential for granuloma formation (Saeftel et al., 2001). Corroborating what is seen in 
O. volvulus infections where neutrophils form the inner layer around live adult worms 
(Tamarozzi et al., 2016), and high levels of IL-5 are found in hyperreactive form of 
onchocerciasis (Brattig et al., 2002; Korten et al., 2010).  
In resistant CBA/Ca and C57BL/6 mice, granulomas formed around the young adults 
and consisted mostly of eosinophils, that would degranulate in the presence of the host 
antibodies (Martin et al., 2000b; Attout et al., 2008).  
Granulomas formed in different mouse strains contain different proportion of 
neutrophils, the percentage of neutrophils was greater in granulomas around worms in 
susceptible BALB/c mice compared to resistant C57BL/6, 47% and 17.8% 
respectively. The difference in percentage of neutrophils could be due to Mf release, 
as adult worms in BALB/c mice will release Mf which is another source Wolbachia 





in C57BL/6 do not reach patency there is no release of Mf, and therefore no recruitment 
of neutrophils. The link between Wolbachia and neutrophils can be further 
demonstrated using the O. ochengi cattle models, in which nodules formed around 
adult worms have an inner layer of neutrophils, and with the depletion of Wolbachia 
by antibiotic treatment, there is switch from neutrophils to degranulating eosinophils, 
found adjacent to the worms surface (Nfon et al., 2006; Hansen et al., 2011). 
Eosinophils made up 70% of the cell population in the granulomas surrounding young 
adults in C57BL/6. The origin of the different granulomas and how cells attach to the 
worms is not well known, so far it is hypothesised that neutrophils are recruited by a 
LPS-like dependent mechanism, whereas for eosinophils a glycan dependent process 
could be implicated, but it has been suggested that for cellular recruitment and 
granulomas to formation alteration/damage of the filarial worm is needed. (Attout et 
al., 2008). 
Altogether there seems to be a balance between eosinophils and neutrophils, as they 
are both associated with filarial infections, with eosinophils involved in parasite killing 
whereas neutrophils appearing to be involved in the nodule formation around the 
adults, attracted to the Wolbachia derived molecules secreted by the worms. Following 
antibiotic chemotherapy, neutrophils are replaced with eosinophils that degranulate on 
the worm cuticle (Hansen et al., 2011). 
Immune responses to microfilariae 
Around day 55 post infection with L. sigmodontis in BALB/c mice, adult females will 
start releasing Mf, which can be detected in peripheral blood. Protective immunity to 





Infections in IFN-g deficient mice caused an increase in Mf in the peripheral blood 
compared to wild type controls (Saeftel et al., 2001), and in BALB/c mice an increase 
in IFN-g RNA levels in splenocytes can be seen following onset of patency (Taubert, 
Zahner, 2001). Furthermore, following Mf immunisation, IFN-g was found associated 
with vaccine mediated protection (Ziewer et al., 2012), and in the related filarial 
species B. malayi, Mf injections in BALB/c mice induced IFN-g production as well 
IgG2a production which was not seen when adult worms were implanted (Lawrence 
et al., 2000). Th2 cytokines such as IL-4 and IL-5 have also been associated with 
control of Mf, however the action of both of these cytokines are more associated with 
a decreased in adult female fertility or adult worm containment than Mf killing 
(Volkmann et al., 2001).  
Organs associated with clearance of Mf in L. sigmodontis infections are the lungs, 
spleen and liver (Pfaff et al., 2000), with more resistant mice strains being able to clear 
Mf faster than in BALB/c mice due to a rapid accumulation of Mf in spleen, liver and 
lungs (Bouchery et al., 2012b). Although the exact mechanism of Mf clearance is 
relatively unknown, the receptor for IL-33 (ST2) was found to be important in splenic 
clearance of Mf (Ajendra et al., 2016). In the non-permissive B. malayi mouse model, 
where Mf were either inoculated in the blood stream or female adults producing Mf 
were implanted into the pleural cavity, clearance of Mf  was associated with antibodies 
(Gray, Lawrence, 2002) and eosinophils (Simons et al., 2005). However, L. 
sigmodontis infection in the ST2 deficient mice which saw a impaired splenic 
clearance, levels of IgM, IgG1, IgG2a and IgG2b as well as Th2 cytokine levels, did 





mice is not antibody mediated nor did it correlate with impaired Th2 cytokine 
responses, but was due to impaired splenic clearance of Mf (Ajendra et al., 2016). 
Antibody responses in L. sigmodontis infections 
B-cells have an important role in L. sigmodontis immunity, with mice lacking of B1 
cells showing increased susceptibility to filarial infections seen as a higher Mf and 
adult worm burdens (Carter et al., 2007). B1 cells are implicated in resistance in both 
L. sigmodontis (Al-Qaoud et al., 1998) and human filariasis (B. malayi) (Mishra et al., 
2014). Although IgE is an important antibody in human helminth infections, and has 
been linked to parasite death and pathology, mice eosinophils however do not express 
the surface receptor that bind IgE, and further overexpression of IgE in L. sigmodontis 
infections had no effect on L. sigmodontis infections (Martin et al., 2000b). When 
measuring levels of IgE, IgG1 (Th2 antibody) and IgG2 (Th1 antibody) in plasma of 
L. sigmodontis infected BALB/c mice, total IgE levels were increased compared to 
non-infected mice as early as day 5 and levels increased throughout the course of 
infection. Levels IgG1 (Th2 marker in mice) increased around day 14 of infection and 
remained elevated up to patency, whereas IgG2 (Th1 marker in mice) were low and no 
difference were seen between non-infected mice (Boyd et al., 2015). In the same 
infection time course, levels of IL-5 were detected in plasma at day 42 and remained 
high at day 60. Therefore, the high levels of IL-5 and IgG1 detected in plasma illustrate 
that L. sigmodontis infection induce a systemic Th2 responses which peaks prior to the 





Role of Th1 / Th2 in L. sigmodontis infections 
Th2 responses are absolutely necessary for resistance to infection, as full parasite 
development and patency was achieved in IL-4 deficient C57BL/6 mice, which would 
otherwise be resistant (Le Goff et al., 2002). Furthermore, in susceptible BALB/c 
mice, deficiencies in IL-4, IL-5 or IL-4Ra (receptor for IL-4 or IL-13) led to an 
increase in Mf numbers following L. sigmodontis infection compared to wild type 
controls (Volkmann et al., 2003), and upon administration of anti-CD4 antibodies in 
BABL/c there was increase in worm burden and circulating Mf associated with 
reduced Th2 responses (Al-Qaoud et al., 1997). This fits with human onchocerciasis, 
where Th2 induction in sowda patients leads to string reduction of both Mf and adult 
worm nodules (Hoerauf, Brattig, 2002).  
This is not to say that Th2 responses are the only effector mechanism against filarial 
parasites. Pro-inflammatory Th1 responses have been associated with adult worm 
death and Mf clearance (Babu et al., 2000). BALB/c mice deficient in IL-4Ra, had 
accelerated death of the adult stages compared to wild type controls, due to a change 
to a Th1 phenotype at the site infection (pleural cavity) (Volkmann et al., 2001) and 
IFNg was found to be essential for encapsulation of adult worms (Saeftel et al., 2001). 
Furthermore, IFNg and IL-5 appear to act synergistically to destroy the adult parasites 
and this effect is mediated by neutrophils (Saeftel et al., 2003). Therefore, both Th1 





Initiation of Th2 responses 
The exact sequence of events that initiate a Th2 responses in filarial infections is still 
largely unknown, it has been hypothesized that dendritic cells, basophils and type 2 
innate lymphoid cells (ILC2) have a role in inducing Th2 immunity. Basophils in L. 
sigmodontis infections seem to be more involved in the amplification of type 2 
responses such as increased eosinophil levels and IgE production (Torrero et al., 2010; 
2013). 
Recently, the role of ILC2 in initiating Th2 responses has been suggested, with 
evidence of local ILC2 expansions in the pleural cavity of infected mice from as early 
as day 5 post infection, with  increasing numbers during the course of infection peaking 
in the pre-patent stage (day 36 and 44 post-infection) (Boyd et al., 2015). ILC2 act 
primarily by initiating and maintaining Th2 responses at site of infection (pleural 
cavity) in L. sigmodontis infections, with the majority of ILC2 producing IL-5, 
possibly driving eosinophil recruitment to the pleural cavity seen in L. sigmodontis 
infections (Boyd et al., 2015). IL-33 is known to promote Th2 responses, and has been 
suggested to do this through the activation ILC2. However, mice lacking the IL-33 
receptor do not have an impaired Th2 response following a L. sigmodontis infection, 
suggesting that IL-33 is not responsible for driving the localized Th2 response seen in 
L. sigmodontis infections (Ajendra et al., 2016).  
The absence of IL-33 signalling had no effect on adult worm burden, but led to a higher 
Mf burden. This increase in circulating Mf did not correlate with any change in Th2 
response, but was shown to be due to impaired splenic clearance of Mf. When 





sigmodontis infection, there was no change in macrophage proliferation, but 
alternatively activated macrophages failed to be induced (Jackson-Jones et al., 2016). 
Both IL-4Ra and IL-33 are needed to alternative activation of macrophages. Therefore, 
IL-33 does have a role in parasite clearance but not in Th2 induction and further studies 
are need to determine the mechanisms responsible for the induction of ILC2s in L. 
sigmodontis infections and subsequently Th2 responses. 
1.10.2 Regulatory immune responses induced by filarial 
infections 
Helminth infections including Onchocerca spp, are master regulators of the host 
immune response, this allows them to maintain chronic infection within its host, and 
in the case of O. volvulus this can be up to 15 years. Immunosuppressive responses 
induced by filarial parasite are considered responsible for these chronic infections, and 
the lack of pathology seen in some individuals. This immune suppression has been 
demonstrated in both mice and cattle models of infection (Maizels et al., 2001b; 
Hoerauf et al., 2005). 
Litomosoides sigmodontis infections in mice are known to induce inflammatory 
responses, with protection mediated by the Th2 arm of immunity. Litomosoides 
sigmodontis also induce regulatory immune responses which allows them to establish 
patent infections in mice, these immune regulatory responses happen early on 
infection. While invading L3 induce innate immune responses, they also cause a rapid 
recruitment and increased proliferation of a natural population of CD4+ CD25+Foxp3+ 





pleural cavity where the larval stages migrate to (Taylor et al., 2009). These Foxp3+ 
Treg cells continue to be present in the pleural cavities during the adult stage of L. 
sigmodontis infections in BALB/c mice.  
Alongside the Foxp3+ Treg responses in the pleural cavity there is also loss of antigen-
responsiveness by CD4+CD25- effector T (Teff) cells, these hypo-responsive Teff cells 
exhibit increased expression of the co-inhibitory receptor CTLA-4 and GITR (Taylor 
et al., 2005). Both the Foxp3+ Tregs and hypo-responsive Teff cells contribute to 
parasites survival, as depletion/neutralisation of these cells types alone in the pleural 
cavity of infected mice had little effect on worm survival, but the combined depletion 
of Foxp3+ Tregs and neutralization of CTLA-4 on the hypo-responsive Teff cells 
enhanced parasite killing (Taylor et al., 2007).  
Although the depletion of Foxp3+ Treg in the pleural cavity during infection had no 
effect on parasites survival, their depletion prior to infection caused a reduction in adult 
parasite burdens, as well as causing an anti-fecundity effects on the surviving female 
adults, but no effect on larval stages. This increase in protection was associated with 
an early increase in expression of GITR on CD4+ Teff cells, followed with an increase 
in L. sigmodontis specific Th2 responses seen around day 60 post infection (Taylor et 
al., 2009). Suggesting that early priming of T cells is important in determining the 
outcome of infection.  
The difference in CD4+ Teff cell priming can also explain why difference in protection 
is seen between different mice strain (Table 1.6). Although both the resistant 





CD4+CD25- Teff cells from the resistant mice have greater expression of GITR within 
the first 12 days of infection which was associated with greater in vivo proliferation of 
CD4+ T cells, compared to susceptible mice. Implying that C57BL/6 mice are either 
better at priming CD4+ T cells or better at overcoming the initial suppressive effect of 
the filarial L3 parasites (Taylor et al., 2009).  
In susceptible mice strain hypo-responsive Teff cells loss of function was mediated by 
programmed cell death protein-1 (PD-1, a cell surface receptor, which suppresses T 
cells) co-inhibition by PD-L2, and induced a progressive loss of IL-4, IL-5 and IL-2 
cytokine production, which could be recovered in vivo by blocking of PD-1/PD-L2 
pathway (van der Werf et al., 2013). The mechanisms that induce these intrinsic 
changes in Th2 effector cells are thought to be mediated by immune cells, it has been 
suggested that B cells might be inducing these changes as opposed to alternatively 
activated macrophages (AAM), however this still has not been proven (Taylor et al., 
2006). Another possibility is through dendritic cells (DC), as demonstrated during 
Schistosoma japonicum, which induces TLR-2 signalling in DC that leads to PD-L2 
expression and through PD-1/PD-L2 interaction inhibits T cell response to S. 
japonicum (Gao et al., 2013). 
When a single immature female L. sigmodontis worm was implanted in susceptible 
BALB/c mice it promotes the survival of co-injected Mf, however in IL-10 deficient 
mice Mf survival was drastically reduced, suggesting that adult females aid survival of 
Mf in a IL-10 dependent manner (Hoffmann et al., 2001). The role of IL-10 can be 
further demonstrated in resistant C57BL/6 mice, which are rendered susceptible by 





however the addition of IFNg in these double IL-4/-10 deficient mice had no effect and 
these mice remained resistant (Specht et al., 2004). The cytokines, TGF-b and IL-10 
play an important role in the suppression, as in L. sigmodontis infections the absence 
of functional TGF-β and IL-10 receptor signalling rescued T cell proliferation 
(Hartmann et al., 2015). 
In L. sigmodontis infections, T cell derived IL-10 is particularly associated with 
suppression of CD4+ T cell proliferation, whereas B cell derived IL-10 is not (Haben 
et al., 2013). These IL-10 producing T cells, are termed T regulatory type 1 (Tr1) cells, 
and although they are regulatory T cells they do not express Foxp3 or CD25. Tr1 cells 
are derived from naïve T cells in the periphery following antigen challenge, one of 
their characteristics is that they produce high levels of IL-10, compared to naturally 
occurring CD4+CD25+Foxp3+ Tregs that emerge from the thymus (Roncarolo et al., 
2006). These Tr1 can be found in onchocercomas of O. volvulus infected humans, and 
ex vivo studies show that they are able to induce B cells to secrete the “regulatory” 
isotype IgG4 (Satoguina et al., 2005), in a GITR/GITR-L dependent mechanism with 
both IL-10 and TGF-β required (Satoguina et al., 2008).  
T cell are not the only source of IL-10, transgenic overexpression of IL-10 by 
macrophages in resistant L. sigmodontis infected mice leads to an increase 
susceptibility with higher number of adult worms and converted resistant FVB mice 
towards a patent phenotype, supporting the suppressive role of IL-10 (Specht et al., 
2011b). These macrophages overexpressing IL-10 in the pleural cavity of infected 
mice had characteristics of alternatively activation. Alternatively activated 





defined as a macrophage population that rely on IL-4 and IL-4Ra signalling to initiate 
proliferation and express arginase-1, Ym1 and Fizz1(Rückerl, Allen, 2014). In L. 
sigmodontis infection proliferation of AAM is restricted to the sites of parasites 
migration and the pleural cavity before the onset of patency, however following release 
of Mf, AAM are also found in the draining lymph node (Taylor et al., 2006). The 
specific contribution of AAM in killing and expulsion of helminths is still unknown. 
It has been suggested that L. sigmodontis infections induce suppressive AAM, that can 
block T cell proliferation (Taylor et al., 2006), however these are not the cause of the 
PD-1 associated Teff cell hypo-responsiveness in the pleural cavity (van der Werf et 
al., 2013). Therefore, AAM are not thought to be the drivers of T cell hypo-
responsiveness. An alternative theory is that B cells or dendritic cells are conditioning 
Th2 T cells to a hypo-responsiveness phenotype. 
Altogether immunosuppression during L. sigmodontis infection consists of several 
independent overlapping mechanisms, from the different CD4+ T cell regulation 
(Foxp3+ Tregs and Tr1 Tregs), the intrinsically hyporesponsive effector T (Teff) cells, 


















































young adults.  





Eosinophils The L3 that have escaped immune responses (~10%), will 






1.10.3 Role of dendritic cells in filarial infections 
Dendritic cells (DC) are professional antigen-presenting cells which are often the first 
cells to encounter foreign antigens, and therefore play a crucial role in presenting 
antigen to T cells to initiate immune responses. Their exact role in initiating Th2 
protective responses or regulatory responses have been relatively overlooked in L. 
sigmodontis infection. 
In helminth infections, depletion of DC severely impaired Th2 immunity to 
Heligmosomoides polygyrus a gastrointestinal nematode and Schistosoma mansoni a 
trematode (Smith et al., 2011; Méndez-Samperio, 2016), suggesting that DC have a 
potential role in induction of Th2 immunity. Parallel to this, helminths and their 
excretory and secretory (E/S) products have been linked to functional impairment of 
DC, which has been suggested as a potential mechanism for nematode induced 
suppression. In non-helminth models, DC were able to expand Foxp3+ Tregs 
(Yamazaki et al., 2006; Na et al., 2016), and certain parasite antigen were able to 
modulate DC function (Silva et al., 2006; Segura et al., 2007; Sun et al., 2013). In 
human, B. malayi L3 were able to induce cell death in human dendritic cells, inhibit 
their ability to produce IL-10 and IL-12, as well as inhibiting their ability to activate 
CD4+ T cells (Semnani et al., 2003). Similar results were seen in live infections in 
mice, where B. malayi L3 induced different patterns of maturation and activation in 
DC subsets, correlating with impaired antigen uptake and presentation, and to some 
degree the attenuation of T cell proliferation (Sharma et al., 2016). Despite the small 
number of studies investigating the role of DC in filarial infections, it is being 





infection, by impairing DC antigen presentation and therefore rendering DC 
ineffective in initiating strong adaptive immune response (Segura et al., 2007; Sun et 
al., 2013; Sharma et al., 2016).  
 
Figure 1.9. Summary of the main immune responses triggered during L. sigmodontis 




1.11 Vaccine induced immunity 
Vaccine induced protection in naïve animals can be induced using immunisation with 
irradiated L3, as demonstrated in several animal models, including L. sigmodontis in 
mice, O. ochengi in cattle and O. volvulus in the mice diffusion model (Table 1.7). 
With irradiated L. sigmodontis L3 immunisation, protection is associated with a rapid 
reduction of invading L3 within the first 2 days, leading to a 70% reduction in worm 
burden (Le Goff et al., 2000). This rapid L3 death has been linked to eosinophils and 
antibody mediated degranulation of eosinophils. Following immunisation with 
irradiated L. sigmodontis L3, there is an increase in IL-5 levels and subcutaneous 
eosinophils compared to non-immunised controls (Martin et al., 2000a). However, in 
mice with impaired B-cell maturation and antibody production (µMT strain) there is a 
lack of protection, associated with impaired eosinophils degranulation although these 
are recruited to the site of infection (Martin et al., 2001). This also helps explain the 
difference between primary infection and immunisation with respect to eosinophils, as 
during the primary infection there is a delay in inducing IL-5 dependent mechanisms 
and production of specific antibodies, and by the time eosinophils arrive at the site of 
infection and have the ability to degranulate, the L3 have already migrated to the 
lymphatic vessels to escape the inflammatory responses (Marechal et al., 1996). 
Furthermore, basophils have been linked to the establishment of the vaccine protective 
immunity, because when basophils were depleted prior to immunisation this 
diminished protective efficacy, suggesting early amplification of Th2 before 





Repeated vaccination with irradiated L3 followed by repeated exposure to challenge 
L3 infections was carried out, to investigated if repeated exposure would induce 
immunological tolerance and reduce Th2 vaccine induced immune responses. 
However, IgE levels; antigen driven basophils release of IL-4; and Th2 skewing of the 
cellular immune responses remained the same throughout the repeated exposure to the 
parasite and protective efficacy of the irradiated vaccine was maintained. Suggesting 
that vaccines which induce a strong Th2 immune response could maintain efficacy 
through repeated parasite exposure (Hübner et al., 2010). 
Subcutaneous immunisation of BALB/c mice with L. sigmodontis Mf, inhibits 
embryogenesis in females worms causing a reduction in Mf found in the peripheral 
blood, without any effect on adult worm burden (Ziewer et al., 2012). Protection 
induced Mf immunisation was associated with a shift towards a Th1 environment, 
mediated through IFN-g promoted IgG2a. The role of IFN-g has been linked to immune 
responses to Mf several times (Lawrence et al., 2000; Saeftel et al., 2001; Taubert, 
Zahner, 2001). 
O. volvulus is not permissive to mice, therefore implantation of O. volvulus larval 
stages into chambers within mice, are used to measure immunological changes linked 
to parasite death or survival. By immunising mice with irradiated O. volvulus L3, 
protective immunity was developed to subsequent L3 implanted in subcutaneous 
diffusion chambers. The initial observations found large numbers of eosinophils 
present in the chambers, and that immunity was dependent on IL-5 and IL-4, thus a 
Th2 responses (Lange et al., 1994; Johnson et al., 1998). When similar studies were 





had impaired protective immunity, whereas no difference was seen in protective 
immunity when eosinophil peroxidase or B1 cells were absent. Therefore adaptive 
protective immunity to larval O. volvulus in diffusion chambers was due to eosinophil 
recruitment and IgE, corroborating L. sigmodontis irradiated L3 mouse studies 
(Abraham et al., 2004). 
The protective efficacy of irradiated L3 immunisation, was successfully translated into 
field trials using the O. ochengi cattle model (Tchakouté et al., 2006). Further cross-
protection between O. volvulus and O. ochengi filarial species can be demonstrated in 
cattle using immunisation with O. volvulus L3, which can induce partial protection of 
cattle to challenge infections with O. ochengi L3 (Achukwi et al., 2007), suggesting 
that there is antigenic homology between the two species. 
Table 1.7. Immunisation with irradiated L3 in different filarial models 
Parasite Model Protection following L3 irradiated 
vaccination 
B. malayi  
Jirds (permissive host) 56-91% reduction in worm burden following challenge infection. (Yates, Higashi, 1985) 
BALB/c mice (non-
permissive host) – 
Diffusion chamber 
95-100% reduction in L3 challenge survival. 
(Hayashi et al., 1984; Abraham et al., 1989) 
L. sigmodontis  BALB/c mice (permissive host) 
70% reduction in worm burden following 
challenge infection. (Le Goff et al., 1997; 
2000) 
O. ochengi   Cattle (permissive host) 
84% protection against natural infections 
compared to non-vaccinated controls. 
(Tchakouté et al., 2006) 
O. volvulus  
BALB/c mice (non-
permissive host) – 
Diffusion chamber 
64% reduction in L3 challenge survival. 






1.12 Vaccine development 
Vaccines have undeniably played an important role in improving public health by 
reducing morbidity and mortality to infectious disease. However, most of the 
commercially available vaccines for humans are against single cell organisms such as 
bacteria (Tuberculosis, BCG vaccine) and virus (measles, mumps and rubella, MMR 
vaccine), with more often or not the use live attenuated or inactivated (killed) vaccines 
(Table 1.8). For filarial disease, protective immunity can also be induced using live 
attenuated vaccines in animal models, using irradiated L3 (Table 1.7). Although there 
is an irradiated L3 vaccine commercially available against the nematode Dictyocaulus 
viviparus (lungworm) in cattle (Bain, 1999), the use on an irradiated L3 vaccine would 
not be feasible for the use against onchocerciasis in humans. This is because there 
would be technical and production constraints, ethical consideration when 
administering to humans, and further protection associated with irradiated L3 vaccine 
is limited to the infective larval stage (Babayan et al., 2006), which does not stop adults 





Table 1.8. Examples of commercially available vaccines 
Vaccine 
(Pathogen) 
Type  Protective immunity / Correlates of protection 







Specific IFN-g production  by CD4+ T cell 
necessary for protection but not a good correlate of 







Possible antibody mediated, but not good correlate 
of protection 
Hepatitis A 














Neutralising antibodies prevent mucosal and skin 
invasion, but not good correlate of protection 
(Romanowski, 2014) 
IPV –Polio  Live inactivated 
vaccine 
Antibody mediated preventing viremia, correlates 







cellular immunity preventing viremia, correlates of 
protection not known 
RV –Rotavirus  Live attenuated 
vaccine 






Baseline Salmonella typhi specific CD8+ responses 
associated with protection and delayed disease 
onset, however upregulation regulatory T cells have 
also been linked, and the correlates of protection are 






Vi-specific IgG antibody levels are used for the 
assessment of protection, but no correlates of 
protection have been identified for the Vi-based 
vaccine (Ochiai et al., 2014). 
Yellow fever  Live attenuated 
vaccine 
Type I interferon pathways during the first two 
weeks post vaccination, as well complement 
pathways, inflammasomes and some regulatory 












Taenia ovis – 
Sheep 
Taenia saginata 
– Cattle  




Lysis of early developmental stages by antibody 
and complement (Lightowlers et al., 2016) 
Boophilus 
microplus – 
against tick for 
Cattle 
Recombinant 
tick gut antigen 
(Bm86) 
Antibody mediated binding and lysis of intestinal 
cells interfering with blood feeding activity (Dalton, 
Mulcahy, 2001) 
 
These live/attenuated vaccines can be referred to as first generation vaccines, although 
they have been tremendously useful for the control of disease such as smallpox and 
polio, they cannot be used for onchocerciasis. Therefore, second generation vaccines 
such as subunit vaccines, referring to recombinant proteins and peptides could be a 
possible alternative strategy. In immunisation experiment against filarial nematode, 
the use of recombinant proteins have shown some promise (Table 1.10) (Hewitson, 
Maizels, 2014). However, they can be difficult to produce and can include unnecessary 
epitopes, not all epitopes found in a protein may contribute to protective responses, as 
protective immunity is usually dependent on a few antigenic epitopes. If anything, 
these extra antigenic epitopes complicated the situation by inducing increased 
immunogenicity to antigens that could cause hypersensitivity and adverse reactions 
(Linhart et al., 2014; Skwarczynski, Toth, 2016).  
Alternatively, peptides based on protective antigen epitope of a vaccine candidates 





immune responses, incidentally are also cheaper and easier to produce (Li et al., 2014). 
In a peptide vaccine, amino acid sequences are synthesised to form an immunogenic 
peptide molecule representing the specific epitope of an antigen. Since these are the 
antigenic determinants within larger proteins, they should be considered sufficient for 
activation of the appropriate cellular and humoral responses. In reality, because they 
contain one antigenic epitope, immunisation with a single peptide may not be capable 
of producing an appropriate response against the filarial parasites, that have complex 
life cycles and are masters at immunomodulation, therefore the use of multivalent 
vaccines are necessary to achieve protection.  
Epitope-based vaccines containing well-characterised immunogenic regions has 
shown success against human papilloma virus (HPV), with two multivalent peptide 
based vaccines commercially available against HPV (Romanowski, 2014). Although 
no peptide vaccines are commercially available for filarial parasites, some are being 
investigated as potential vaccines candidates (Madhumathi et al., 2010). 
Third generation vaccines, such as DNA plasmids could potentially be another 
approach, they have certain advantages over live attenuated or recombinant proteins. 
DNA vaccines allow protein expression in mammalian cells after introduction of 
plasmid (Shedlock, Weiner, 2000), which are then able generate cellular and humoral 
responses (Li et al., 2004). These are simple to produce and purify in large quantities, 
with low production cost, and easily transported since they do not require a cold chain, 
these features make DNA vaccines desirable for large scale use in areas endemic to 
onchocerciasis. Although no human vaccine is commercially available, two DNA 





Infectious Haematopoietic Necrosis Virus (IHNV) in Atlantic salmon in Canada, and 
the other against West Nile virus in horses, in the United States (Kurath, 2008). In 
onchocerciasis research, several immunisation experiments in mice with DNA 
vaccines, have showed potential with signs of protective immunity (Harrison et al., 
2000; Babayan et al., 2012; Joseph et al., 2012; Steisslinger et al., 2015). 
1.12.1 Strategies for vaccine candidate discovery 
Mathematical modelling has shown that a vaccine would greatly complement ongoing 
efforts to control and eliminate onchocerciasis (Turner et al., 2015), and would benefit 
in different control settings: 
• A prophylactic vaccine, that targets the incoming infective L3, would prevent 
the establishment of parasites. Preferably a vaccine targeted to children under 
the age of 5, as to not only protect a vulnerable set of the population but also 
eliminate a possible reservoir source. 
• Immunoprophylaxis vaccine, similar to a prophylactic vaccine, but given to 
communities who have successfully achieved elimination and therefore 
protecting them from re-infection (from neighbouring infected communities). 
• Therapeutic vaccine targeting the Mf stage, given to infected individuals to 
prevent severe pathology as well as reducing transmission, and could be an 
important tool in areas of co-endemicity with loiasis. 
Ideally a vaccine would target different life stages of the parasite such as the infective 





Historically vaccine antigens would have been identified by immunoscreening cDNA 
libraries using serum of naturally protected individuals. For onchocerciasis, 26 
recombinant antigens were identified by immunoscreening, including Ov-CPI-2, Ov-
Ral-2 and Ov-103, these were then validated with immunisation experiment in several 
animal models (Table 1.10) (Lustigman et al., 2002; Manchang et al., 2014).  
Due to whole genome sequencing, stage-specific transcriptional profiling, and 
proteomic analysis (Table 1.9), there is now an abundance of proteomic and genomic 
data on filarial nematodes. This not only provides valuable biological insight into these 
parasite, but also allows for the identification of potential vaccine candidates (Seib et 
al., 2012). Knowing that helminth produce excretory-secretory product (ES) that are 
critical for parasite establishment within the host, as these have been shown to 
modulate the immune system (Harnett, 2014), in particular adult female ES (Hoffmann 
et al., 2001), and therefore these can be investigated as potential vaccine targets.  
Targeting immunomodulatory molecules as vaccine candidates has shown some 
success against Teladorsagia circumcinta in sheep and L. sigmodontis in mice, and by 
removing the parasite modulatory function it allows for enhanced immune response to 
the parasite (Babayan et al., 2012; Nisbet et al., 2013; Arumugam et al., 2014b). Some 
immunomodulatory targets have already been extensively investigated such as a 
cysteine protease inhibitor (CPI). Whereas other products have been hypothesised as 
being important due to being highly abundant in female ES, such as Ls-ShK, or being 
homologues of human immunomodulatory molecules, such as the TGF-β homologue, 
TGH-2 (Table 1.10) (Gomez-Escobar et al., 1998; McSorley et al., 2009; Armstrong 





Targeting the nematodes immunomodulation is one way of removing its defensive 
mechanism against the host, but helminths do have other defence mechanism, such as 
antioxidants and detoxification enzymes (Maizels et al., 2001a). These enzymes were 
initially studied for their use as chemotherapeutics, however their immunogenicity in 
animal models suggested they might be potential vaccine candidates, such as 
thioredoxin peroxidase (TPX) which showed some promise in immunisation 





Table 1.9. Genomic, transcriptomic and proteomic data available of different filarial 
species (Adapted from (Grote et al., 2017)) 







of ES products of: 
B. malayi   
 L3, L4, AF, AM, 
Immature Mf 
Wolbachia (in all 
stages) (Bennuru et 
al., 2011) 
L3, L3 to L4 
moulting, AF, AM, 
Mf  
(Hewitson et al., 
2008; Moreno, 
Geary, 2008; 
Bennuru et al., 
2009) 
L. 
sigmodontis   
L3 (Allen et al., 
2000) 
 
L3, AM, pre-gravid 
AF, gravid AF, 
immature Mf 
Wolbachia (in all 
stages) 
(Armstrong et al., 
2014) 
L3, AM, pre-gravid 
AF, gravid AF, 
immature Mf 
Wolbachia (in all 
stages) 
(Armstrong et al., 
2014) 
O. volvulus  
L3, L4, AF, 




(Bennuru et al., 
2016) 
L3, L4, AF, AM, 
Embryonic stages, 
Mf 
Wolbachia (in all 
stages) 
(Bennuru et al., 
2016) 
 
O. ochengi    
 L3, AF, AM, 
immature Mf 
Wolbachia (in all 
stages) (Armstrong 
et al., 2016) 
L3, AF, AM, 
immature Mf, 
intradermal nodules 
Wolbachia (in all 
stages) (Armstrong 
et al., 2016) 











Localisation in L. sigmodontis and 
related species* 
Immunogenicity & Vaccination experiments 




function of antigen 
presenting cells. 
Bm, Ov, Oo, Ls-CPI-2 secreted by adult 
female worm (ES) and present in all life 
stages of the parasite.  
Ov-CPI-2 – Protective antibody responses increases with age (Cho-
Ngwa et al., 2010)  
Ls-CPI-2 (mutated) – DNA vaccine, reduced Mf numbers 
(Babayan et al., 2012) 
Bm-CPI-2 (mutated) – Recombinant protein vaccine, reduced 
worm burden (~48%) and worm fecundity. (Arumugam et al., 
2014b) 
Ov-CPI-2 – Recombinant protein vaccine, reduced L3 survival in 













Bm, Ov and Ls-TPX-2 Expressed by L3 
stages (Allen et al., 2000) 
Bm-TPX-2 also found expressed by Mf 
and in ES products (Anand et al., 2012) 
Bm-TPX-2 – Protection against larval stages in B. malayi chamber 
model using DNA vaccine, and enhanced efficacy in a multivalent 
vaccines (Anand et al., 2008)  
Vaccination with recombinant Bm-TPX-2 induces a Th-2 biased 
response, with IgG3 and IgG1 being elevated in vaccinated mice 
(Anand et al., 2012) 
EN individuals carry IgG1, IgG2 and IgG3 Bm-TPX-2 antibodies, 
with higher levels compared to infected individuals (Anand et al., 
2012) 
Ls–Ral-2 Unknown function Bm-Ral-2 and Ov-Ral-2 localised in 
hypodermis and cuticle of adult female 
worms, and the surface of L3 and Mf 
(Lustigman et al., 1992b; 1992a) 
Ls-RAL-2 and Oo-RAL-2 found in ES of 
adults. (Armstrong et al., 2014) 
Ov-Ral-2 – Recombinant protein vaccine, reduced L3 survival in 
diffusion chamber (Hess et al., 2014) 
Bm-Ral-2 – Recombinant protein vaccine in B. malayi gerbil 
showed a reduction in adult worm and Mf numbers seen as a 
reduction in embryonic development stages in female worms 









Function / potential 
role 
Localisation in L. sigmodontis and 
related species* Immunogenicity & Vaccination experiments 
Ls–103 
Microfilariae surface 
associated protein but 
function is unknown. 
Bm-103 and Ov-103 localised in 
hypodermis and cuticle of adult female 
worms, L3 and Mf (Lustigman et al., 
1992b; 1992a) 
Ov-103 – Recombinant protein vaccine, reduced L3 survival in 
diffusion chamber (Hess et al., 2014) 
Bm-103 – Recombinant protein vaccine in B. malayi gerbil 
showed a reduction in adult worm but no change in Mf numbers 
(Arumugam et al., 2016) 
Ls-103 – DNA vaccination in L. sigmodontis showed no change 
in worm numbers but reduction in number of Mf circulating in 
the blood of mice (Unplublished, J Peace MRes Thesis, 2012) 
Ls–Tgh-2 
Transforming growth 
protein 2-like protein, 
potentially an 
immunomodulatory by 
binding to TGF-β 
receptors 
Oo-Tgh-2 found secreted by adult 
worms (found in nodule fluid) 
(Armstrong et al., 2016) 
Bm-Tgh-2 found expressed throughout 
the B. malayi life cycle, and also found 
secreted by adult worms (Gomez-
Escobar et al., 2000) 
 
Ls–ShK 
Binds to Kv1.3 gate 
channels on memory T 
cells 
Oo-ShK (found in nodule fluid) 
(Armstrong et al., 2016) 
Ls-ShK found in ES of gAF 
(Armstrong et al., 2014) 
Ls-ShK immunisation in L. sigmodontis model showed a 
reduction in Mf numbers found in blood after vaccination 
experiment using DNA plasmid vaccines (Duprez. J, MRes 
Thesis, 2013, University of Edinburgh). 
*Localisation of vaccine candidates and its orthologues.  





1.13 Systems biology and its role in vaccine 
development 
The goal of vaccination is to confer long-term protection in a population at risk of 
infection and disease, despite their tremendous success, most commercially available 
vaccines were designed without knowing the mechanisms by which they mediate 
protection (Table 1.8), and are only now being investigated. Understanding the 
immunological mechanism following vaccination, could be used to predict vaccine 
efficacy, or used to improve the immunogenicity of vaccine, allowing for a more 
rational vaccine development.  
Recent studies, have used a systems biology or sometimes referred to as systems 
vaccinology approach to decipher the immune responses to vaccination in humans 
(Pulendran et al., 2010). The advantage of using a system biology approach is that it 
combines “omics” technology such as transcriptomic, proteomics, metabolomics and 
genomics, with advanced computation tools, to investigate the complex interactions 
between all parts of a biological systems. Whereas traditional molecular biology 
techniques only investigate parts of the systems (a gene, a protein, or a cell type), 
missing out on interactions seen within a system.  
A systems approach has the ability to identify early correlates or biological markers 
(biomarkers) of protection predictive of vaccine responses (Hagan et al., 2015). Since 
the effectiveness of a vaccine can only be determined once individuals have been 
infected, being able identifying biomarkers of protection following vaccination, could 





infection or before the end of a vaccine trial (Li et al., 2013a; Marino et al., 2016). 
Using high-throughput techniques, such as microarrays, it is now possible to measure 
the expression of tens of thousands of genes simultaneously, allowing for a deeper 
understanding of the molecular signatures induced by infection or vaccination. 
Microarrays produce high-dimensional data (tens of thousands of genes but usually 
few samples), requiring more advanced computational methods, such as machine 
learning (Nakaya et al., 2011a).  
Machine learning is subfield of artificial intelligence, and is concerned with 
developing computer algorithms (models) that learn from the data and can make 
predictions on new data (Libbrecht, Noble, 2015). It has been used to decipher the 
complex interaction within the immune system and predict which responses are 
associated with protection. For example, when machine learning methods were used 
analyse high dimensional gene expression data following immunisation with yellow 
fever vaccine (YF-17D), a deeper understanding on how the YF-17D vaccine induced 
protection was gained, and was able to predict high and low responders within the 
population studied (Gaucher et al., 2008; Querec et al., 2008). Similar machine 
learning methods were used to predict systemic adverse events in smallpox vaccine 
(Reif et al., 2008), and immunogenicity in seasonal influenza vaccine (Nakaya et al., 
2011b) 
A further use of gene expression data and machine learning tools, is to predict how 
translatable a vaccine developed in mice model are to humans. Although mouse 





immune responses to vaccines, these are not always predictive of human vaccine 




Chapter 2. Validation of vaccine candidates 
using either DNA or peptide vaccines in L. 
sigmodontis model 
2.1 Background 
Mathematical modelling of the impact of vaccination against Onchocerca volvulus 
suggested that a vaccine in addition to current controls effort would lead to reduced 
disease burden and aid in the elimination of onchocerciasis (Turner et al., 2015). In 
particular, a vaccine would protect vulnerable populations such as children under five 
and pregnant mothers who are omitted from mass drug administration (MDA) 
campaigns. Moreover, a vaccine would provide an answer to control of onchocerciasis 
in populations where Ivermectin cannot be used because of the risk of adverse 
reactions. By vaccinating individuals currently not receiving treatment but living in 
endemic areas, would decrease the chance of re-emergence of the parasite to 
neighbouring areas where MDA has been stopped (Turner et al., 2015). 
Since human filarial parasites cannot undergo a full life cycle in mice, several animal 
models have been used to test the efficacy of vaccine candidates, with Litomosoides 
sigmodontis being the most attractive model, as it is the only filarial species in which 
the full development cycle can take place in BALB/c mice (Petit et al., 1992), with 
high immunological cross-reactivity with Onchocerca spp (Manchang et al., 2014), 
allowing immunological and parasitological readouts to be measured during a 
vaccination trial. The infective larval stages are inoculated subcutaneously, and 




microfilariae (Mf), which enter the bloodstream around day 60 post infection (Petit et 
al., 1992). Mf and adult worm burdens are used as a measure of protection. 
Vaccine mediated protection was generated with live attenuated vaccines using Brugia 
malayi in gerbils, L. sigmodontis in BALB/c mice and Onchocerca ochengi in cattle 
models. The irradiated third-larval (L3) vaccine, mediates protection against the 
incoming infective L3 and subsequently reduces the adult worm burden, although it 
may reduce the prevalence of disease if not 100% efficacious some of the parasites 
may develop to maturity and produce Mf, which may not prevent pathology associated 
with the microfilariae (Mf) stage nor stop transmission. However, a vaccine that targets 
the Mf stage, while not preventing infection nor pathology may be more successful in 
reducing morbidity and transmission. Therefore, an ideal vaccine would be one that 
targets different life stages of the parasite, protecting individuals not only against 
infection but also pathology caused by the adult stages and Mf of the parasites and 
hence stop transmission. Despite these live attenuated vaccines inducing 70-91% 
reduction in adult worm burden, and providing proof-of-principle that a vaccine could 
induce protection, they cannot be used beyond laboratory setting due to the logistical 
difficulties of their production, attenuation, packaging, delivery and ethical 
considerations. Therefore, new strategies such as recombinant proteins, peptides or 
DNA vaccines are required.  
Recombinant proteins are an alternative to live attenuated vaccines, however these tend 
to present challenges in terms of safety and mass production (Li et al., 2014). Peptides 
based on the protective antigen epitope of vaccine candidates are an attractive 




not only induce a highly specific immune responses, but are also cheaper and easier to 
produce (Li et al., 2014). A peptide consists of amino acid sequences representing a 
specific epitope of an antigen, since these represent the antigenic epitope within larger 
proteins, it should be sufficient for activation of the appropriate cellular and humoral 
responses. However, in reality a single antigenic epitope (peptide) vaccination may not 
be strong enough, as filarial parasites have a complex life cycles with the ability to 
modulate the immune system. Therefore, the use of multivalent vaccines may be 
necessary to achieve protection. Two commercially available peptide vaccines are 
currently licensed against human papilloma virus the causal agent of cervical cancer, 
these are multivalent vaccine, a bivalent HPV-16/18 and the other a quadrivalent HPV-
6/11/16/18 (Romanowski, 2014).  
DNA vaccines allow protein expression in mammalian cells after introduction of  a 
plasmid, and subsequent induction of the immune system (Shedlock, Weiner, 2000). 
Advantages of DNA vaccines are that they are relatively simple and inexpensive to 
produce, although no DNA vaccines are currently licensed for human use, DNA 
vaccines have been used in vaccination trials for filariasis in animal models (Joseph et 
al., 2012; Babayan et al., 2012; Steisslinger et al., 2015).  
Different approaches have been used to discover vaccine targets, historically these 
would have been identified by immunoscreening cDNA libraries using serum of 
naturally protected individuals (Lustigman et al., 2002; Manchang et al., 2014). Using 
this approach two promising vaccine antigens Ls-103 and Ls-Ral-2, were discovered. 
These two candidates have homologues characterised in O. volvulus and B. malayi, 




combination (Hess et al., 2014; Arumugam et al., 2016). Both these proteins can be 
found on the surface and oesophagus of L3 of O. volvulus and B. malayi, as well as the 
hypodermis and cuticle of adult worms and the surface of Mf, although their functional 
properties are currently unknown. In O. volvulus using the mouse diffusion chamber 
model, immunisation with either recombinant proteins Ov-Ral-2 and Ov-103 in 
combination with alum as an adjuvant induced protection, seen as a 39% and 30% 
reduction in worm survival respectively, and 21% reduction was seen when proteins 
were administered as a fusion protein (Hess et al., 2014). However, in the absence of 
alum, protection was absent (Hess et al., 2016). Similar results were obtained using B. 
malayi recombinant proteins Bm-Ral-2 and Bm-103 in gerbils, with a 22-46% 
reduction in worm burden when proteins were administered alone, and 49-51% 
reduction when proteins were administered concurrently and 56-61% reductions when 
administered as a fusion protein (Arumugam et al., 2016). Although both Bm-Ral-2 
and Bm-103 affect adult worm survival, only Bm-Ral-2 had an effect on worm 
fecundity (Arumugam et al., 2016). Using the O. ochengi cattle model, recombinant 
Oo-Ral-2 when in combination with 8 other antigens (including Oo-CPI) induced 
protection, seen as a 42% decrease in dermal Mf following natural infections compared 
to non-vaccinated controls (Makepeace et al., 2009). In endemic areas for 
onchocerciasis 77% of the population had Ov-Ral-2 antibodies, and individuals with 
these antibodies were significantly less likely to develop ocular pathology (Gallin et 
al., 1989). In a separate study, higher quantities of antibodies raised against Ov-103 
were found in endemic normal (naturally protected individuals) compared to infected 
individuals (Johnson et al., 1995). So far, the evidence shows that both Ral-2 and 103 




Another strategy to vaccine candidate discovery, is to use our understanding of filarial 
parasites, to have a targeted approach in the search of vaccine targets. In filarial 
infections, type 2 immune responses are necessary for controlling infection within the 
host, however filarial parasites are able to modulate the host immune system, which 
allows them to survive and evade the host protective immune responses. Therefore, a 
strategy that targets immunomodulators, would offer an attractive approach. 
Identification of potential immunomodulators is achievable through extrapolation of 
known regulators in other organisms (i.e. related species) or because it is known that a 
potential source of immunomodulators are the excretory-secretory proteins (E/S) of 
female worms, these can be investigated. Adult females have been shown to contribute 
to the parasite’s ability to maintain chronic infections, and their ES has been 
hypothesised to contain immunomodulators (Hoffmann et al., 2001). 
One of the most promising vaccine candidates is cysteine protease inhibitor-2 (CPI-2), 
CPI-2 has been characterised in O. volvulus (Lustigman et al., 1992b), B. malayi 
(Manoury et al., 2001), L. sigmodontis (Allen et al., 2000). CPI-2 belongs to the 
cystatin superfamily, which have been described extensively in parasitic nematodes 
(Vray et al., 2002; Gregory, Maizels, 2008), and functions as an immunomodulator 
(Pfaff et al., 2002) by blocking mammalian protease activity in antigen processing 
cells (Manoury et al., 2001). In B. malayi, vaccination with recombinant Bm-CPI-2 
showed no protection in gerbils following subsequent L3 infection, however it did 
induce a significant antibody response and altered worm distribution, resulting in a 
decrease of adult worms in lymphatic tissue (31% of the worms) and increased worm 




mutation in CPI at amino acid position 66 (Asn66 to Lys66), in two independent 
vaccination experiments using either recombinant protein in the B. malayi gerbil model 
(Arumugam et al., 2014b) or using plasmid DNA in L. sigmodontis BALB/c model 
(Babayan et al., 2012), affected female worm fertility and resulted in reduced Mf 
numbers circulating in the blood, proving that targeting immunomodulators and 
allowing the host to mount protection immune response is a feasible strategy for 
vaccination. 
Thioredoxin peroxidase (TPX-2) is a thiol-specific antioxidant detoxification enzyme, 
a critical component in the parasite’s defence against injury caused by oxygen radicals 
and characterised in B. malayi and O. volvulus (Chandrashekar et al., 1998). TPX-2 
shows low protection on its own, however it does induce a strong Th2 immune 
response in mice (Anand et al., 2008); furthermore naturally protected individuals in 
B. malayi endemic areas show strong antibody responses against Bm-TPX-2 (Anand 
et al., 2012). When used in combination with other antigens in multivalent DNA 
vaccines, TPX-2 does induce protection against  B. malayi L3, in a chamber model 
(Anand et al., 2008) and a reduction in circulating Mf in L. sigmodontis model 
(Honglin, 2011), demonstrating that TPX-2 is strongly immunogenic and is a potential 
filarial vaccine but needs to be used in combination with other antigens to confer 
protection. 
A novel antigen Ls-ShK (nLs_04059) was identified in the E/S of L. sigmodontis 
gravid adult female (Armstrong et al., 2014), containing six metridin-like ShK toxin 
domains. These ShK domains have a wide phylogenetic distribution, but the pattern 




O. ochengi, O. volvulus, Acanthocheilonema vitae, Wuchereria bancrofti and Loa loa 
(and Ascaris suum an ascaridid nematode) (Armstrong et al., 2014). Although the exact 
function of Ls-ShK is currently unknown it has been hypothesised to be an 
immunomodulator, as ShK domains can be found in type 1 toxins which are known to 
block voltage-gated potassium channels (Kv1.3 channels). Since ShK proteins inhibit 
Kv1.3 channels, a ShK domain peptide from B. malayi is currently under development 
as therapy for autoimmune diseases, specifically targeting Kv1.3 channels expressed 
by effector memory T-lymphocytes (Chhabra et al., 2014), suggesting that Ls-ShK 
could be modulating acquired immunity by inhibiting memory T cells. In the L. 
sigmodontis model, DNA immunisation with Ls-ShK showed initial promise by 
inducing protection, with no Mf found circulating in the blood compared to controls 
(Duprez. J, MRes Thesis, 2013, University of Edinburgh).  
In human and L. sigmodontis filarial infections, TGF-b has been associated with the 
parasite’s ability to modulate the immune system. Members of the transforming growth 
factor β (TGF-β) family were identified in B. malayi, of particular interest was Tgh-2 
which shows close similarity to human TGF-β. Tgh-2 has been postulated to be a 
immunomodulator, whereby Tgh-2 can ligate to host TGF-β receptors and therefore 
reduce immune responses (Gomez-Escobar et al., 2000). Homologues of Tgh-2 in B. 
malayi, L. sigmodontis and O. volvulus all contain the same conserved C-terminal 
domain, and 9 cysteine residues. Although no vaccination experiments with Tgh-2 
have been done so far, in chronic O. volvulus infections where immune down-




cytokines have a direct role in immunosuppression (Korten et al., 2010), therefore 
Tgh-2 shows potential as a vaccine target against immunomodulatory protein.  
Whether it is as recombinant protein, peptide or DNA vaccines, a problem with many 
vaccine candidates is that they have low immunogenicity, therefore to overcome this, 
adjuvants can be used to enhance their response. DNA vaccine induced immunity can 
be enhanced by the co-delivery of plasmids encoding cytokines, chemokines or any 
co-stimulatory molecule by increasing the magnitude or type of immune responses 
necessary for protection. Co-delivery of interleukin-4 (IL-4) and the macrophage 
inflammatory protein 1 alpha (MIP1a) also known as the chemokine CCL3, were 
demonstrated to enhance DNA vaccine-induced immunity (Honglin, 2011; Babayan et 
al., 2012). Alum is commonly used as an adjuvant in human vaccines, usually in 
combination with peptides or recombinant proteins, and elicits a strong Th2 and 
humoral immune response, primarily mediated by IgG1 in mice (Rubin et al., 1986; 
Beck, Spiegelberg, 1989).  
Another strategy to increase protection and overcome the poor immunogenicity of 
individual peptides is to increase their membrane trafficking, by attaching to the 
peptide a palmitoyl group (derived from pamitic acid) to enhance their hydrophobicity 
(Beekman et al., 1997). However, even with these modifications and as multivalent 
vaccine, there might not be strong enough immune stimulation to trigger an innate 
immune response, which leads to a strong adaptive immune response. Therefore, 
peptide-based vaccines also require adjuvants, such as a peptide containing chimeric 




is able to bind to broad range of MHC II alleles, and has been shown to increase CD4 
memory T cell recall responses and robust antibody production (Fraser et al., 2014).  
Aims of chapter 
• Does Ls-ShK induce protection following immunisation? 
• Can peptides derived from the promising vaccine candidates Ls-102, Ls-Ral-2, 
Ls-CPIm, Ls-ShK and Ls-Tgh-2, induce protection? 
The protective efficacy of vaccine candidates were evaluated in independent 
immunisation time courses, using the permissive L. sigmodontis BALB/c model. In 
these immunisation experiments mice received a challenge infection following 
immunisation. The first experiment involved validating ShK as a vaccine antigen using 
DNA vaccines. Since peptides are an alternative strategy, relying on highly targeted 
immune responses with the potential to avoid allergic responses, peptides derived from 
ShK and the other vaccine candidates were trialled and their protective efficacy 
evaluated. By targeting non-immunomodulatory regions of the antigen or with a 
mutated form of an immunomodulatory peptide, it is hoped that the 
immunomodulation by L. sigmodontis can be overcome, allowing a protective immune 





2.2.1 Ethics statement  
All procedures involving animals were approved by the University of Edinburgh and 
the University of Glasgow ethical review committees, and performed under license 
from the UK Home Office in accordance with the Animals (Scientific Procedures) Act 
1986. Animal experiments were conducted following the ARRIVE (Animal Research: 
Reporting of In Vivo Experiments) guidelines developed by NC3Rs (National Centre 
for the Replacement Refinement & Reduction of Animals in Research) 
(https://www.nc3rs.org.uk/arrive-guidelines), which are intended to maximise 
information published while minimising unnecessary studies  (Kilkenny et al).  
2.2.2 Mice and parasites 
All mice used in the vaccination experiment were female BALB/c mice that were 
obtained from either the Anne Walker Animal unit of the University of Edinburgh or 
purchased from Charles River (UK). Mice were housed in individually ventilated cages 
(IVC) at either the University of Edinburgh or the University of Glasgow and in each 
vaccination experiment the treatment groups were randomly allocated to avoid any 
cage effect. All mice were between 6-8 weeks of age before the start of any procedure. 
The L. sigmodontis life cycle was maintained in gerbils using the mite vector 
Ornithonyssus bacoti by Alison Fulton at the University of Edinburgh. To obtain 
infective third stage larvae (L3) for challenge infections, mites were infected by 




bloodstream. The infected mites were picked from the gerbils and left to incubate for 
12 days at 37°C and 70% humidity, allowing Mf to mature to L3. Infective L3 were 
extracted from those mites (see challenge 2.2.12). 
2.2.3 Preparation of L. sigmodontis cDNA 
Adult female L. sigmodontis worms were harvested from the pleural cavity of infected 
gerbils and washed in sterile phosphate buffered saline (PBS: 137mM NaCl, 2.7nM 
KCL, 10mM Na2HPO4, 1.8mM KH2PO4, pH 7.4).  
RNA was extracted using the RNeasy kit (QIAGEN), by first homogenising 30mg of 
adult worms, in 600µl of RTL buffer, for 30s at 30Hz (using Tissue Lyser II and sterile 
steel balls, QIAGEN). The homogenised worm suspension was centrifuged for 3mins 
at 300 x g at room temperature, then up to 700µl of the supernatant fluid was 
transferred to an RNase free 1.5ml tube (Eppendorf) and 1 volume of 70% ethanol was 
added to it and mixed using a pipette.  
The sample (including the precipitate) was transferred to a RNeasy spin column placed 
in a 2ml collection tube, centrifuged for 15s at ≥8,000 x g and the flow through 
discarded. The column membrane was washed 3 times, first with 700µl Buffer RW1 
(and centrifuged for 15s, at 8,000 x g and flow though discarded), then twice with 
500µl Buffer RPE (centrifuged for 15s the 1st time and 2mins the 2nd time, at 8,000 x 
g and the flow though discarded each time), the 3rd wash step is to ensure no ethanol 
is carried over during RNA elution. To elute the RNA from the column, 30-50µl 




for 1 min at ≥8,000 x g to elute the RNA into a clean collection tube (store RNA at -
80°C).  
Genomic DNA contamination was removed from the RNA sample using Ambion 
DNA-free DNA removal kit (Invitrogen), by adding 0.1 volume of 10x DNase I buffer 
and 1.5µl rDNaseI was added to the RNA and mixed gently, before incubating for 30 
mins at 37 °C. Then 0.1 volume of DNase Inactivation Reagent (making sure it has 
been re-suspended) was added, mixed and incubated for 2mins at room temperature, 
occasionally mixing, before centrifuging at 8,000 x g for 1.5mins. The supernatant 
fluid was transferred to a clean RNase free 1.5ml tube, and the concentration of RNA 
determined using a Nanodrop 2000 spectrophotometer (Thermo Scientific). 
To convert RNA into complementary DNA (cDNA), reverse transcriptase polymerase 
chain reaction (RT-PCR) was used. To do this 1µg of RNA was diluted into of RNase 
free water to get a final concentration of 74.1ng/µl, to which 1µl of oligo(dT) primer 
(Bioscript, Bioline) was added to prime the reverse transcriptase reaction, the mix was 
incubated at 70°C for 5mins. Then 6.5µl of RT-PCR master mix containing: 4µl of 5x 
Reaction Buffer (Bioscript, Bioline); 2µl of 1µM dNTPs (Promega); 0.5µl of Ribosafe 
RNase Inhibitor (Bioscript, Bioline); and 0.25µl of reverse transcriptase enzyme 
(Bioscript, Bioline), was added to the RNA. The RNA mix was placed in a PCR 
machine and incubated at 37°C for 1hr and then 70°C for 10 minutes, and cDNA is 




2.2.4 Preparation of whole L. sigmodontis antigen 
Whole L. sigmodontis antigen was made by homogenising adult worms in 1xPBS 
using a ground-glass homogeniser. The homogenised L. sigmodontis was left on ice 
for 1hr and then centrifuged at 6,000 x g for 10mins. The supernatant fluid was 
collected and filtered using a 0.22µm syringe filter (Millipore). The protein 
concentration was determined using a Bradford assay and stored at -80ºC. 
2.2.5 Amplifying ShK from L. sigmodontis cDNA 
Polymerase chain reaction (PCR) was used to amplify ShK from L. sigmodontis 
cDNA, for either cloning into pcDNA3.1 (Invitrogen) or pET29c (Novagen) plasmid, 
using specific primers (Table 2.1). Each PCR reaction contained: 1x Pfu buffer (from 
10x Pfu buffer: 200mM Tris-HCl pH8.8 at 25°C, 100mM KCl, 100mM NH4SO4, 
20nM MgSO4, 1mg/ml nuclease free BSA and 1% Triton X-100); 2mM of dNTP mix 
(Promega, containing 10mM of dATP, dCTP, dGTP and dTTP in water); 1µM of 
forward primer; 1µM of reverse primer; 1.25u/50µl of Pfu polymerase; 0.1µg of 
cDNA; and nuclease free water to make up the volume needed.  
The PCR programme consisted of an initial denaturation step at 95°C for 2 minutes; 
followed by 35 cycles of: denaturation step at 95°C for 1min, annealing step at a 
temperature according to the Tm of the primers for 30s (Table 2.1), and an extension 





2.2.5.1 Agarose Gel separation and gel extraction 
The PCR products were separated by gel electrophoresis at 100V on a 2% agarose gel 
(Fisher scientific) in 1xTBE buffer (Thermo Fisher scientific) containing 0.5x SYBR 
safe DNA gel stain (Invitrogen), by loading the PCR products with 1x Blue Juice Gel 
Loading Buffer and run alongside a 100bp ladder (Invitrogen). 
The QIAquick gel extraction kit (QIAGEN) was used to extract DNA bands of interest 
(Ls-ShK 808bp). The section of the gel that contained the correct sized band was cut 
out, and placed in 3 volumes of buffer QC for 1 volume of gel, then 1 volume of 
isopropanol was added and mixed. The dissolved gel is samples was then added to a 
QIAquick spin column and centrifuged for 1min at 17,900 x g to bind the DNA to the 
membrane within the column. The flow through was discarded and the DNA washed 
by a 5mins incubation with 750µl of Buffer PE, followed by centrifuging 1min at 
17,900 x g. The flow through was then discarded before re-centrifuging for another 
minute to remove any residual wash buffer. The columns were then placed in clean 
microfuge tubes and DNA eluted by adding 50µl buffer EB to the centre of the 
membrane in each column and left to stand for 1 min before centrifuging for 1min at 
17,900 x g. A spectrophotometer (NanoDrop, Thermo Scientific) was used to quantify 
the concentration of the DNA, at an optical density of 260 nm. 
2.2.5.2 Sanger sequencing 
To verify that the amplified PCR product had the correct sequence, Sanger sequencing 
was used, by following the BigDye Terminator v3.1 Cycle sequencing reaction kit 




another reaction their reverse primer (Table 2.1), each sequencing reaction consisted 
of 2µl of 5x sequencing buffer, 0.32µl of 10µM primer, 3.68µl of nuclease free water, 
2µl of BigDye and 2µl of the sample (200-500ng of DNA). The sequencing samples 
then underwent a PCR program of 25 cycles of 95ºC for 30s, 50ºC for 20s and 60ºC 
for 5mins 15s, when the cycles were over the samples were given to Genepool 




Table 2.1. ShK primers for cloning in either pcDNA3.1 or pET29c 






1 Forward:  
5’-CACCATGTCACCGAGTGTTGAGATTGG-3’ 
47 ºC 













*CACC = sequence needed for cloning into pcDNA3.1; GGATCC = BamHI restriction site; 
AAGCTT = HindIII restriction site 
2.2.6 Cloning of ShK pcDNA3.1 plasmid for DNA vaccine 
Ls-ShK was cloned into a pcDNA3.1 plasmid to be used as DNA vaccines, in the 
vaccination time course experiements. The purified Ls-ShK PCR product was cloned 
into the pcDNA3.1 plasmid using the pcDNA3.1 Directional TOPO Expression Kit 
(Invitrogen). The kit recommended blunt PCR products, hence the use of Pfu 
polymerase, and a 5’CACC sequence for which the primers were designed accordingly 
(Table 2.1). The PCR product were added at 0.52ng/µl to 2.5-3.3ng/µl of Topo vector 
(different ratios of PCR product to vector were tried till an optimal ratio was found), 
in a 1/6 dilution of salt solution (1.2M NaCl, 0.06M MgCl2) provided, the remaining 
volume was made up to 50µl with nuclease free water. The mixture was incubated at 
room temperature for 5mins, and immediately put on ice.  
The plasmids containing the inserts were then transformed into competent Escherichia 




of plasmid to one vial of competent cells, and heat-shocked for 30 seconds at 42ºC. To 
grow up the cells, 250µl of S.O.C media (provided by Invitrogen) was added to the 
cells and left to grow in a shaking incubator for an hour at 37ºC and 2.5 x g. After the 
hour, the cells were plated on Luria Broth (LB) (Fisher Scientific UK Ltd) agar plates 
(LB with 1.5% agar) containing 100µg/ml of ampicillin (Sigma Aldrich), these were 
left overnight in a non-shaking incubator at 37ºC.  
Colonies were picked and grown overnight in 5ml of LB containing ampicillin 
(100µg/ml) at 37ºC in a shaking incubator at 2.5 x g. The next day the cells were 
harvested by spinning 2ml of the overnight cultire at 8,000 x g for 3mins and the 
supernatant fluids removed. Only cells containing the plasmid will have grown. The 
plasmids were extracted and purified from the cells using the QIAprep spin miniprep 
kit (QIAGEN).  
2.2.6.1 TAQ PCR for plasmid validation 
The presence and orientation of the insert in the purified plasmids were checked using 
TAQ PCR (Bioline), using either T7 primer as the forward primers and the inserts 
reverse primer (Table 2.1 & Table 2.2); or the forward primer of the insert (Table 2.1) 
and BGH primer as the reverse primer (Table 2.2). For each 20µl TAQ PCR reaction 
the following master mix was used: 2µl of 10x NH4 Buffer, 0.6µl of 50mM MgCl2, 
0.2µl of 100mM dNTPs, 0.4µl of the 10µM forward primer, 0.4µl of the 10µM reverse 
primer, 0.2µl of BIOTAQ DNA polymerase, 15.2µl of Nuclease-free water (to make 




The PCR program used was: 95°C for 1min as the initial denaturation step; then 35 
cycles of 94°C for 45 seconds for denaturation, 30s at 47°C for annealing, and 72°C 
for 1min for extension, and after the cycles a final extension of 72°C for 10 minutes, 
and stored at 4°C. The PCR products were then run on a 2% agarose gel (Thermo 
Fisher scientific) in 1xTBE buffer (Thermo Fisher scientific) for 45 minutes at 100v. 
The positive colonies that had the insert in the correct direction, were then sequenced 
using sanger sequencing (section 2.2.5.2). If the sequence was correct, the cells that 
contained the correct plasmid were stored in glycerol at -80°C. 
Table 2.2. Primers used to extract and verify insert in pcDNA3.1 plasmids 
Primer Sequence 
T7 5 ́-TAATACGACTCACTATAGGG-3 ́ 
BGH 5 ́-TAGAAGGCACAGTCGAGG-3 ́ 
 
2.2.6.2 Plasmid amplification and purification for vaccination 
experiments 
Every DNA vaccination required 80µg of plasmid DNA, therefore plasmid quantities 
were amplified by growing the cells containing the plasmid of interest overnight. A 
volume of 10µl of the cells (stored at -80°C) were added to 500ml of LB containing 
ampicillin (100µg/ml) and cultured for 12-16hrs in a shaking incubator at 35°C and 
2.5 x g. The bacterial cells where then harvested by centrifuging the culture media for 
20mins at 9,300 x g and 4°C, the supernatant fluid was discarded so that only a 




The HiSpeed Plasmid Maxi Kit (QIAGEN) was used to purify the plasmids from the 
cells. To use the smallest possible volume of DNA vaccine during immunisation, the 
plasmid concentration must be high, therefore in the final step of the kit 500µl of 
elution buffer was used instead of the recommended 1ml. To check the concentration 
of the plasmid DNA samples a NanoDrop was used.  
2.2.7 Cloning and expression of recombinant Ls-ShK for 
ELISA 
The pET system (Novagen) was used for the cloning and expression of recombinant 
Ls-ShK in E. coli. Ls-ShK was cloned into pET29c plasmids, using BamHI and HindIII 
restriction sites. Ls-ShK insert was amplified from adult L. sigmodontis with primers 
spanning the full CDS minus the stop codon and with flanking restriction sites, BamHI 
at the 5’ end and HindIII at the 3’end, following the pfu PCR protocol in section 2.2.5). 
The Ls-ShK insert and the pET29c vector were digested separately in a 20µl reaction 
(all from Promega, Uk): 2µl 10x restriction enzyme buffer E; 0.2µl BSA(10µg/µl); 
0.5µl BamHI (10u/µl); 0.5µl HindIII (10u/µl); 1µg of Ls-ShK insert or pET2c vector; 
and made up to a final volume of 20µl using nuclease free water. The reaction was 
incubated for 1hr at 37°C, followed by 15mins at 65°C to inactivate the enzymes. 
Digested inserts and plasmids were separated on agarose gel and extracted using the 
same method as section 2.2.5.1. The digested insert and plasmid were ligased together 












The T4 DNA ligase reaction (Promega): 100ng of digested vector; 50ng of digested 
insert, 1µl of 10X Ligase Buffer; 0.1-1U T4 DNA ligase; and made up to a final volume 
of 10µl using nuclease free water. The reaction was incubated for 3hrs at room 
temperature (~22°C), followed by 10mins at 70°C to heat inactivate the T4 DNA 
ligase.  
The newly ligated plasmids were transformed into JM109 competent cells (Promega), 
by adding 2µl of ligated plasmids to 30µl of thawed JM109 cells, and incubated for 
20mins on ice. The cells were then heat shocked for 30s at 42°C and transferred on ice 
for 2mins. The transformed cells were then cultured in 100µl of S.O.C media 
(Invitrogen) in a shaking incubator for 1hr at 37°C and 2.5 x g. 30µl of the cultures 
were plated onto a Kanamycin (30µg/ml) agar plates and left to incubate overnight at 
37°C in a non-shaking incubator.  
The following day colonies were picked from the plates, these cells will contain 
plasmid as cells with no plasmid will not have grown. These colonies were further 
grown overnight in 5ml of LB with Kanamycin (30µg/ml), in a shaking incubator at 
2.5 x g at 37ºC. The plasmids were extracted and purified from the cells using the 
QIAprep spin miniprep kit (QIAGEN). The presence and orientation of the insert in 




as the forward primers and the inserts reverse primer (Table 2.2) following the same 
protocol as section 2.2.6.1. 
Plasmids which contained the plasmid with the correct insert, where then transformed 
into BL21 DE3 competent E. coli (Novagen) for recombinant protein expression. 
These were grown overnight at 37°C on Kanamycin (30µg/ml) agar plates. The 
following day colonies were picked from the plates, further grown overnight in 10ml 
of LB with Kanamycin (30µg/ml), in a shaking incubator at 2.5 x g at 37ºC. 
5ml of the overnight culture was added to 500ml of LB with Kanamycin (30µg/ml) 
and cultured at 37°C in a shaking incubator (2.5 x g), when the cell culture reached an 
OD 600 of 0.6, protein expression was induced by adding 1mM of IPTG (Sigma 
Aldrich). 3hrs following induction, cells from the culture were harvested by 
centrifuging the cultures for 20mins at 9,3000 x g, and cell pellets frozen at -20°C (this 
is to facilitate cell shearing).  
First the soluble protein was released from the cells, by thawing the cell pellet and re-
suspending in 30ml of 1x Binding buffer (5mM Imidazole; 0.5M NaCl, 20mM Tris, 
pH7.9), the re-suspended cells were frozen and thawed a second time and sonicated to 
release the protein with 3 times: 30s On, followed by 30s Off. The cells were 
centrifuged for 20mins at 9,300 x g, supernatant fluids containing the soluble protein 
were stored at 4°C. 
To collect the insoluble protein, the cells were the re-suspended in 30ml 1x Binding 
buffer containing 6M of Urea. Similar as for the soluble proteins, the re-suspended 




followed by 30s Off. The cells were then centrifuged for 20mins at 9,300 x g, and 
supernatant fluids stored as insoluble protein stored at 4°C. 
The expression of proteins, was verified using sodium dodecyl sulphate 
polyacrylamide gel electrophoresis (SDS-PAGE) in samples of the un-induced cell 
culture; 1hr, 2hr and 3hr post-induction cell culture; soluble protein; and insoluble 
protein (Figure 2.1). The samples were prepared by adding 75µl of the samples to 25 
µl of 4x loading dye (200mM Tris-Cl pH6.8, 400mM b-mercaptoethanol, 8% sodium 
dodecyl sulphate, 0.4% bromophenol blue, and 40% glycerol), these were boiled at 
100°C for 5minutes, and loaded on the gel (NuPAGE, Novex 4-12% Bis tris gel 
(NP0335BOX)) with a protein ladder (Biolabs, P77115), for 35mins at 200v. To 
develop the gel, add the gel to Coomassie blue (5g Coomassie brilliant blue R-250 
(Sigma B-0630) in 2.5L of 25% methanol and 7.5% acetic acid) for 1hr to stain, and 





Figure 2.1.SDS-PAGE of Ls-ShK at the different stages of expression. 75µl of the samples 
were added to 25µl of 4x loading dye, and loaded into each well. Samples were from insoluble 
proteins released from cells; soluble protein released from cells; sample from cell culture 3hrs 
after induction, 2hrs after induction, and 1hr after induction; and from the un-induced cell 
culture. Most of the Ls-ShK protein was insoluble, with faint bands of soluble protein, that was 
purified and used to measure Ls-ShK specific IgG1 using indirect ELISA. 
Unfortunately, most of the protein was insoluble, therefore the insoluble and soluble 
proteins were isolated separately using His-binding resin columns 1ml Nickel column 
HiTrap chelating (17-0408-01, GE healthcare) using automated AKTAprime 
(Amersham Pharmacia) and purified by dialysis using 3500 MeCo membrane 
(Spectra/Por) in 5L of 1xPBS for soluble proteins or 5L of 1xPBS with 6mM of urea 










The soluble protein was used for indirect ELISA to measure Ls-ShK specific 
antibodies. 
2.2.8 Vaccination timeline 
Two 102-day long vaccination time courses were used to investigate vaccine efficacy. 
For DNA vaccination experiments, two immunisations were given two weeks apart, 
followed by a challenge infection four weeks after the second immunisation (Figure 
2.2).  
For the peptide vaccination experiment, mice received three immunisations, a week 
apart from each other, and a challenge infection four weeks following the 3rd 
immunisation (Figure 2.2).  
The challenge infection for both experiments consisted of a subcutaneous injection 
with 23gauge (G) needle of 40 infective L3. For both vaccination experiments the end 
point was 60-days post challenge infection (D60 p.i) as this coincides with the onset 






Figure 2.2. Vaccine experiment timeline for DNA and Peptide vaccine candidates. All 
mice used were female BALB/c, between 6-8 weeks old at the start of the experiment, mice 
were weighed during the time course before each procedure. For the DNA vaccination 
experiments immunised mice received two DNA immunisation two weeks apart from each 
other, and for the peptide vaccination experiment immunised mice received three peptide 
immunisations a week apart from each other. This was followed by a challenge infection of 40 
infective L3 four weeks after last immunisations, so either after 2nd DNA or 3rd peptide 
immunisation. The experiment was stopped 60-days post challenge infection. During the time 
course, tail bleeds were performed on all mice (for subsequent antibody analysis) the day 
before the challenge (D -1), approximately 20 days (D20) and 40 days (D40) post challenge 
infection. The peptide experiment had extra tail bleeds the day before the peptide immunisation 




2.2.9 DNA vaccine preparation and administration  
DNA vaccines used were a cocktail of pcDNA3.1 plasmid with either candidate 
antigen insert, chemokine or cytokine mouse inserts as adjuvants or empty plasmids as 
controls (Table 2.3). The pCPIm, pTPX, pIL-4 and pMIP1α DNA vaccines were 
previously created by members of the Babayan group (Babayan et al., 2012).  







pCPIm pcDNA3.1 Mutated form of L. sigmodontis CPI-2. 
(Accession; AF229173.1) 
Point mutation of asparagine at position 
66 to lysine  
Vaccine antigen 
pTPX pcDNA3.1 L. sigmodontis TPX  
(WormBase: nLs.2.1.2.g10049) 
Vaccine antigen 




pIL-4 pcDNA3.1 Mus musculus IL-4  
(NCBI Gene ID: 16189) 
Adjuvant 
pMIP1α pcDNA3.1 Mus musculus MIP1α  
(Accession: M73061.1]) 
Adjuvant 
pEmpty pcDNA3.1 - Non-coding plasmid 
control 
 
In these experiments 40 BALB/c mice were split into four groups (n=10). The sample 
size of the treatment groups was calculated based on the vaccine effect on Mf counts 
of the most promising vaccine candidate Ls-CPI (Duprez. J, MRes Thesis, 2013, 
University of Edinburgh). Using the Biomath website (http://www.biomath.info) the 




pEmpty control group as 55.5 Mf and Ls-CPIm vaccination treatment group as 12.8 
Mf; an average standard deviation of 73.6, a power 0.8 and a significant level (alpha) 
of 0.05. This effect size revealed that a sample size of 26 mice per experimental group 
was needed. However, 26 mice per experiment group would have been too large to 
process, therefore this was decreased to 10 mice per experimental group, and the 
immunisation experiment was repeated twice. 
For the immunisation experiments, three groups received DNA vaccines or pEmpty 
control, followed by a challenge infection, whereas the fourth group received neither 
DNA vaccine nor challenge infection (Table 2.3). Since DNA vaccines (purified 
plasmids) were stored at -20°C, the day before vaccination the plasmids were placed 
in a 4°C fridge to allow them to thaw out slowly to avoid any precipitation of DNA. 
On the day of immunisation, the concentration of the plasmids were quantified using 
a NanoDrop, and vaccine cocktails made up to total of 80µg of DNA, with equal 
quantities of each plasmid, this meant that the quantity of each individual plasmid 
decreased as the number of different plasmid were added to a vaccine cocktail (Table 
2.4). The plasmids were delivered in 50µl doses and elution buffer (QIAGEN: 10mM 
Tris-Cl, pH 8.5) was used to make up the volume.  
DNA vaccine cocktails were administered to the tibialis anterior muscle of the left leg 
with a 27G needle, immediately followed by electroporation with an ECM 830 
generator and Tweezertrodes (BTX Harvard Apparatus) using a setting of 8 pulses, 
200 V/cm, 40ms duration with 460ms intervals. During the vaccination process mice 
were under anaesthesia using gas inhalation of isoflurane and placed on heat pads. To 




The treatments were randomised per cage so that each cage had at least one of each of 
the treatment groups. 
Table 2.4. Amount of plasmid added to the different vaccine cocktails in a DNA vaccine 
experiment. 








pCPIm 20µg - - - 
pTPX 20µg - - - 
pShK - 40µg - - 
pIL-4 20µg 20µg 20µg - 
pMIP1α 20µg 20µg 20µg - 
pEmpty - - 40µg - 
Total DNA 80µg 80µg 80µg - 
2.2.10 Peptide vaccine preparation and administration 
All peptides in the peptide vaccination experiment were designed by Dr. Ben 
Makepeace (University of Liverpool) (Table 2.5) and produced JPT Peptide 
Technologies GmbH (Berlin, Germany). These peptides were predicted as being 
immunogenic using a publicly available website 
(http://imed.med.ucm.es/Tools/antigenic.pl), using the Kolaskar and Tongaonkar 
immunogenic scale. This prediction is based on a semi-empirical method, using 
physicochemical properties of amino acid residues and their frequency of occurrence 
in experimentally known segmental epitopes, and can efficiently predict immunogenic 
peptides with about 75% accuracy (Kolaskar, Tongaonkar, 1990). To improve their 
immunogenicity a palmitoyl group (derived from palmitic acid, a fatty acid) is attached 






































The sample size for the peptide vaccination was calculated based on the vaccine effect 
of the same antigens but from DNA vaccines, as this was a pilot study for using peptide 
vaccines in a L. sigmodontis model. Therefore, the same power calculation was used 
as for DNA vaccine experiments. Using the Biomath website 
(http://www.biomath.info) the sample size was calculated using a two-sample t-test, 
with the Mf means from the pEmpty control group as 55.5 Mf and Ls-CPIm 
vaccination treatment group as 12.8 Mf (Duprez. J, MRes Thesis, 2013, University of 
Edinburgh); an average standard deviation of 73.6, a power 0.8 and a significant level 
(alpha) of 0.05. This effect size revealed that a sample size of 26 mice per experimental 
group was needed. However, 26 mice per experiment group would have been too large 
to process, since the maximum number of mice that can be processed per experiment 
is around 40 mice, the number of mice was decreased to 7 mice per experimental group. 
Therefore, for the peptides vaccination experiment 42 mice were used, which were 
split into six groups (n = 7). Four groups of mice received peptide vaccines of either: 
the immunogenic peptides (Vaccine A, Table 2.6); immunomodulatory peptides 
(Vaccine B, Table 2.6); all peptides (Vaccine C, Table 2.6); or just the TpD adjuvant 
as control, which is chimera of universal epitopes from tetanus and diphtheria toxoids 
and is used as an adjuvant (Table 2.6). Two other groups were also present in the 
experiment and consisted of a challenge infection control (Primary infected) and a 
naïve control (no vaccine or challenge infection). 
Peptide cocktails, including the adjuvant control had a total of 100µg of peptide per 
dose, with equimolar quantities of each peptide per cocktail, similar to the DNA 




each peptide. Each peptide cocktail was prepared on the day of vaccination, by mixing 
with 9% aluminium potassium sulfate dodecahydrate (alum) (Sigma-Aldrich), at a 1:1 
ratio, since the final volume per dose per mice was 50µl and there were 7 mice per 
group, therefore 200µl of peptides were mixed with 200µl of alum. Sterile and filtered 
PBS was used to make the peptide cocktails to a final volume of 200µl and the 9% 
alum solution was made in sterile water. Once the peptides and alum solution were 
added together, 35µl of phenol red (Sigma Aldrich) was added to the mix, this was 
used as pH indicator, the solution was initially yellow and sodium hydroxide (1M) was 
added dropwise to the mix (vortexing after each drop) until the solution turned pink. 
The final pink solutions were then turned on the rotator (Stuart SB2) for 30mins at 
room temperature before being centrifuged for 10mins at 6000 x g. The supernatant 
fluid was then discarded and the pellet resuspended in 15ml of sterile PBS. The 
centrifugation step and resuspension step were repeated 3 times, except that on the 3rd 
time the pellets of peptides and alum were resuspended to the final vaccine volume 
with sterile PBS (i.e. 400µl for each peptide cocktail).  
Each vaccinated mouse received a 50µl dose of peptide cocktail, the treatments were 
randomised per cage so that each cage had at least one of each of the treatment groups. 
The doses were injected intramuscularly into the tibialis anterior muscle of the left leg 
using a 27G needle, since no electroporation was needed for this procedure mice were 














Ls-Ral-2 peptides  Ls-Ral-2 peptides  
Ls-103 peptides  Ls-103 peptides  
 Ls-CPIm peptides Ls-CPIm peptides  
 Ls-ShK peptides Ls-ShK peptides  
 Ls-Tgh peptides Ls-Tgh peptides  
TpD TpD TpD TpD 
2.2.11 Tail bleeds 
Tail bleeds were carried out by first placing mice in a heat box at 37°C for 20mins, 
followed by a vein puncture of the tail vein using 27G needle and the blood was 
collected in a BD Microtainer SSTTM Tube containing a gel matrix. These were then 
centrifuged at 6,000 x g for 5mins and stored at -20°C.  
2.2.12  Challenge 
In each vaccination experiment (DNA or peptide), all mice except those in the naïve 
group received a challenge with 40 infective L3, four weeks after the last vaccination. 
On the day of challenge, infected mites were crushed using tweezers in RPMI 1640 
media (Gibco, UK), under a dissection microscope. A glass pipette (with a heat 
elongated tip) was used to collect 40 motile L3, which were then transferred to a glass 
well, where a 1ml syringe with a 23G needle was used to suck up each dose of L3 and 
some extra RPMI 1640 media to make a total dose of 0.2ml. To prevent the L3 




infective L3 doses were then given as a subcutaneous challenge infection over the 
shoulders into the loose skin on the back of their necks. 
2.2.13 Samples collected at the end of experiment 
At the end point of the experiment (D60), mice were sacrificed by exsanguination 
under overdose by receiving 20µg of medetomidine hydrochloride (Domitor, Pfizer) 
and 4mg of ketamine (Vetalar, Boehringer Ingelheim), followed by CO2. Blood was 
collected from the subclavial artery under the axila of the mice for different purposes: 
30µl of it was added to 270µl of FAC’s lysis buffer (BD bioscience) diluted in 1 in 10 
in distilled water and later used for microfilariae count; 300µl of blood was added to 
1.2ml of RNA later (Ambion) for future RNA extractions; and the rest of the blood 
was collected in SSTTM blood tubes (BD) and processed in the same manner as for 
the tail bleeds. 
Before mice could be dissected they were placed in a CO2 chamber to make sure they 
were dead. Firstly, the pleural cavity washes were performed by initially washing the 
pleural cavities of the mice with 2ml of 1x PBS, and then with 8ml of 1xPBS. To 
collect any worms if any present for worm counts and cells and cytokines for future 
analysis. The pleural cavities were checked for any worms that might be left. Then the 
mediastinal and parathymic lymph nodes were harvested (lymph nodes draining the 
pleural cavity) and kept in 5ml RPMI 1640 media (containing HEPES) and 
supplemented with 100 U/ml penicillin-streptomycin (Gibco), 2mM L-glutamine 
(Gibco), 10% Foetal Bovine Serum (FBS) (Invitrogen), from now on referred to as 




2.2.14 Immunological read-outs 
2.2.14.1 Processing of lymph nodes 
The lymph nodes harvested at the end of the vaccination experiment were processed 
on the same day. The lymph nodes were dissociated to obtain a single cell suspension 
by grinding them through a 70µm nylon mesh (Fisher Scientific) using forceps in a 
petri-dish. The single cell suspension was centrifuged at 400 x g for 5mins at 4ºC, the 
supernatant fluid poured off and the remaining cells were re-suspended in 2ml of 
cRPMI. The cell concentration of each sample was determined using a 
haemocytometer, and the cells were made up to a concentration of 106 cells/ml using 
cRPMI, which were then used in re-stimulation assays. 
For the proliferation assay, 100µl of the cell suspension were added in triplicate for 
each treatment to a sterile 96 well round bottom plate. In vitro re-stimulation was 
carried out by adding 100µl of either anti-CD3, L. sigmodontis whole antigen or 
cRPMI as a control to the cell suspensions.  
Anti-CD3 monoclonal antibody (BioLegend) was used to stimulate T lymphocytes, it 
was diluted to 2µg/ml in cRPMI, so that when 100µl was added to the cells the final 
concentration was 1µg/ml. The anti-CD3 cross-links with T-Cell Receptor present on 
all T cells and therefore induces all types of T cell proliferation, which is an indication 
of a healthy cell population. Litomosoides sigmodontis whole antigen was made from 
homogenized worms and made to a concentration of 20µg/ml in cRPMI so that when 




The cells were incubated at 37ºC, 5% CO2 for 24 hours. To measure proliferation, 20µl 
(10% of volume in wells) of alamar blue (AbD Serotec) was added 24hours after 
plating the cells out and then placed back in the incubator. Alamar blue is an indicator 
dye, that quantitatively measures the proliferation of cells, it is an oxidation-reduction 
(REDOX) indicator. Approximately 16hrs after adding alamar blue, proliferation was 
measured by measuring absorbance at 540nm, this was repeated every 2-3 hours until 
saturation (no change in colour). 72hrs after adding the treatment to the cells, the plates 
were centrifuged at 400 x g for 5mins and 150µl of the supernatant fluids were 
removed and stored at 20ºC for cytokine analysis.  
2.2.14.2 Processing of pleural cavity lavages  
From the pleural lavages, 1ml of the initial 2ml lavage was added to clean Falcon tubes 
making sure no worms were transferred over, these were centrifuged at 400 x g for 
5mins and the supernatant fluid aspirated and stored at -80ºC for future cytokine 
analysis. The remaining cells and worms were separated, by aspirating the worms from 
the pleural lavages into a clean falcon tubes and fixing them in 70% ethanol, to be used 
for adult worm counts. 
The remaining cells from pleural lavages were pooled together per sample, and given 
a red blood cells lysis treatment by pelleting the cells at 400 x g for 5mins at 4°C, 
treating them with 2ml of RBC lysis buffer (Sigma Aldrich) for 4mins and stopping 
the treatment with 10ml of cRPMI. The treated cells were centrifuged at 400 x g, 4°C 




then determined using haemocytometer and then made up to 107 cells/ml using cRPMI 
ready for cell analysis using flow cytometry. 
2.2.14.3 Flow cytometry on pleural lavage cells 
Flow cytometry was used to detect cell populations using cell surface markers. Pleural 
lavage cells were stained with a cocktail of markers for T cells, B cells, eosinophils, 
dendritic cells and macrophages using antibodies in Table 2.7. 




Fluorochrome conjugated to antibodies Company 
CD11b Peridinin chlorophyll II protein complex (PerCP) BioLegend 
CD11c allophycocyanin (APC) BD Pharmingen 
CD19 phycoerythrin (PE) BD Pharmingen 
CD3 PE/Cy7 BD Pharmingen 
CD4 fluorescein isothiocyanate (FITC) BD Pharmingen 
F4/80 Alexa Fluor 700 (AF700) BioLegend 
MHC II (I-A/I-E) Violet 500 (V500) BD Horizon 
SiglecF Brilliant Violet 421 BD Horizon 
 
To 106 cells in FACS tubes, non-specific binding was blocked using rat anti-mouse 
CD16/32 (BD Pharmingen) at 5µg/ml in 1/20 mouse serum for 30mins in the dark at 
4°C. These cells were then washed in FACS buffer (PBS with 2% FBS), centrifuged 
at 400 x g for 5mins at 4°C, supernatant fluid discarded and re-suspended before 
adding the staining antibodies for the surface markers, all diluted 1/400. These were 
left for 30mins in the dark at 4°C cells, this was followed by a wash in FACS buffer, 




remaining cells re-suspended in 170µl FACS buffer. Cells were analysed using an LSR 
II (BD Biosciences), running FACSDiva software (BD Biosciences). Some cells were 
left unstained as negative controls and compensation beads (Affymetrix, eBioscience) 
were stained with each individual staining antibody in a 1/400 dilution as the 
compensation control. Analysis of the flow cytometry was performed using Flowjo 
(Tree star).  
2.2.14.4 IgG1 and IgG2a ELISA (Indirect ELISA) 
To measure parasite specific Ig levels in sera collected from the tail bleeds or the D60 
bleeds, indirect enzyme linked immunosorbent assay (ELISA) were used. ELISA flat 
bottom NUNC plates (Thermo Scientific) were coated with 5µg/ml L. sigmodontis 
antigen in bicarbonate buffer (0.45M NaHCO3, 0.18M Na2CO3 (Sigma-Aldrich), 
pH9.6) and left overnight at 4°C.  
Plates were blocked with 200µl of 4% bovine serum albumin (BSA) in PBS and 
incubated for 1hr at 37°C in the dark. Plates were washed 5 times in TBS (50mM Tris-
Cl, 150mM NaCl, pH7.5) containing 0.05% Tween-20 (Sigma-Aldrich). The mouse 
serum was serially diluted (1 in 2 dilution) in PBS with 1% BSA. For detection of 
IgG1, the samples were initially diluted at 1/400 and for IgG2a at 1/200. The serially 
diluted samples were added to the washed ELISA plates (50µl/well), except the last 
column of the plate to which PBS with 1% BSA was added (Blank control). Plates 
were incubated overnight at 4°C in the dark.  
The next day the plates were washed 5 times in TBS and 0.5% Tween-20 and incubated 




IgG1 (1/400 dilution) or IgG2a (1/200 dilution) (Southern Biotechnology Associates) 
in PBS with 1% BSA was added to the washed plates and incubated at 37°C in the 
dark for an hour. Plates were again washed 5 times with TBS and 0.05% Tween-20, 
before adding 50µl/well of TMB-H2O2 (Merk Chemicals) and left to develop in the 
dark at room temperature for 5-10mins until a gradient of blue is seen, the reaction is 
stopped by adding 100µl of H2SO4 (1M). Absorbance was measured at 405nm and 
antibody endpoint titres were determined at the highest O.D. values which exceeded 
three standard deviations above either blank wells or wells belonging to naïve samples 
from the same plate. 
2.2.14.5 Cytokine ELISA (capture ELISA) 
Levels of interleukin 4 (IL-4), IL-5, IL-6, IL-10, IL-12p40, IFNɣ and IL-13 were 
measured by capture ELISA. Flat bottom NUNC plates (Thermo Scientific) were 
coated with 50µl/well of coating antibody, each cytokine had a specific concentration 
and buffer (Table 2.8), and left to incubate overnight in the dark at 4°C.  
The next day plates were washed 4 times with PBS and 0.05% Tween-20 buffer, and 
then blocked with 200µl of 4% BSA in PBS by incubating for 1hr at 37°C in the dark. 
These were then washed four times with PBS and 0.05% Tween-20, and then 50µl/well 
of samples were added to the plate in triplicate and the standards for each cytokines. 
The standards were serially diluted (1 in 2) in their appropriate buffer, starting at the 
appropriate concentration (Table 2.8) and added to the plate (50µl/well), these will be 
used to determine the concentration of the samples. The plates were then incubated 




The next day the plates were washed four times in PBS and 0.05% Tween-20, and 
biotinylated detection antibodies were added to each well (50µl) at the recommended 
concentration and buffer (Table 2.8). These were incubated at 37°C for 1hr in the dark, 
and then washed four times in PBS and 0.05% Tween-20. Then AMDEX streptavidin-
peroxidase (Sigma) was added to each well (50µl) in a 1/6000 dilution made in same 
buffer as for the detection antibodies, the plates were incubated in the dark for 30 
minutes at 37ºC. Once the final incubation was done the plates were washed five times 
in PBS with 0.05% Tween-20. To develop the plates 50µl/well of TMB-H2O2 (Merk 
Chemicals) was added and left to develop in the dark at room temperature for 5-10mins 
until a gradient of blue is seen, the reaction was then stopped by adding 100µl of H2SO4 
(1M). Absorbance was measured at 405nm and the concentration of cytokine levels in 
samples were determined using the standard curve made using the O.D. values of the 




Table 2.8. Concentrations (Conc) and buffers used for the antibodies in the capture 
ELISA.  
Cytokine 
Coating Antibody Standards Detection Antibody 
Conc Buffer Initial Conc Buffer Conc Buffer 







IL-5 1.6µg/ml (1) 1xPBS 10ng/ml (4) 0.17µg/ml (3) 
IL-6 1.0µg/ml (1) 0.1M Na2HPO4 pH12 25ng/ml (4) 0.5µg/ml (1) 
IL-10 4.0µg/ml (2) 0.2M NaHPO4 pH6.5 20ng/ml (4) 0.25µg/ml (2) 
IL-12p40 2µg/ml (1) 0.2M Na2HPO4 pH6.5 50ng/ml (4) 0.5 µg/ml 
IFN-ɣ 1.6µg/ml (3) 0.1M NaHCO3 pH9.6 50ng/ml (4) 1.0 µg/ml (3) 
IL-13 4.0µg/ml (2) 1xPBS 20ng/ml (4) 1% BSA in PBS 1.0 µg/ml 
1% BSA in 
PBS 
For the detection of IL-4, IL-5, IL-6, IL-10, IL-12p40, IFN-ɣ and IL-13 cytokines (1BD 
Pharmingen, 2eBioscience, 3BioLegend, 4Peprotech). 
 
Figure 2.3. Cytokine ELISA Standard curve. An example of a standard curve used to 
calculate cytokine concentration in samples, this was the standard curve for IL-4, and was used 




2.2.15 Parasitological read-outs 
Parasite survival was measured by counting female and male worms that were removed 
from the pleural cavity during the pleural lavages. The fixed worms were poured into 
a petri-dish, counted and sexed under a dissecting microscope. Worm survival was 
calculated as the percentage worms grown to adult stage from the 40 infective L3 







For microfilariae counts, the 30µl (in RBC lysis buffer) blood samples collected at 
D60, were centrifuged at 400 x g for 5mins and 150µl of the supernatant fluid 
discarded. The pellet was re-suspended in the remaining 150µl of supernatant fluid left 
and then spread on a microscope slide. To count microfilariae an optical microscope 
using phase contrast and x40 magnification was used. 
Adult female fertility was assessed by mounting females onto microscope slides with 
40% glycerol and analysed under bright field microscopy. To measure fertility, one 
would start at vulva and follow the uteri back identifying the different embryonic 
stages (Stages 1-3) (Figure 2.4). If within the female uteri there were the elongated Mf 
present then that female was classified as having stage 3 Mf (Figure 2.4). If no 
elongated Mf were seen then pretzel shaped Mf were looked for (Figure 2.4), if present 




shape Mf were present, then the presence of fertilized or non-fertilized eggs were 
looked for, as it was hard to distinguish between the two, they were both classified as 
stage 1 Mf (eggs). 
When the elongated Mf (stage 3) were present, then the density at which they were 
found was recorded, density scores ranged from 1<4. A density of 4 was given if 
elongated Mf were tightly packed and lined up next to each other, as in Figure 2.4, 
whereas a density of 1 would be given if only a few elongated Mf were found, with 







Figure 2.4. Representation of the different embryonic stages found in the female uteri 
under light microscope at x40 magnification. Within the female embryonic stages were 
enumerated. In the pictures above the big pictures represents what can be seen under the 
microscope in the female uteri, when many Mf are close together, whereas the pink pictures 
were taken from Ziewer et al (2012) and represent the different life stages on their own, once 
removed from the females. Stage 1 represents fertilised eggs, although sometime hard to 
distinguish between fertilized and non-fertilised so both were classified at stage 1. Stage 2 
represented the developing Mf, sometimes referred to as a pretzel shaped Mf. Stage 3 
represented the developed Mf (/elongated Mf), these are sometimes hard to identify as the line 
up next to each other in the uteri as seen in the picture, the pink picture represents on its own. 
(Ziewer et al., 2012).  
2.2.16 RNA isolation and RT2 profiler PCR array 
Blood collected at ~Day 60 post vaccination was stored in RNA later. Total RNA was 




recommendations. Briefly cells were collected by centrifuging the blood in RNA later 
for 3mins at 8000 x g and the supernatant fluid discarded. The pelleted cells were re-
suspended in 2ml of lysis buffer (provided by Ambion, with 1% b mercaptoethanol), 
once re-suspended 200µl of sodium acetate (3M, Ambion) was added and mixed, this 
was then made up to 3.8ml by adding more lysis solution. Once cells are lysed and all 
clots dissolved, RNA was extracted by adding 1.5mL of acid-phenol:chloroform 
(Sigma) and shaking vigorously for 30s. The mix was left for 5 mins and centrifuged 
for 10mins at 16,000 x g and the aqueous phase was recovered. To recover total RNA 
from the aqueous phase, 0.5 volume of 100% ethanol (Sigma) was added and vortexed 
for 10s, which can then be purified using Ambion filter cartridges. To elute the purified 
RNA from the cartridges, 50µl nuclease free water was used.  
RNA quality and quantity was determined using a Tape Station (Agilent Technologies) 
and a NanoDrop, samples with a RIN values between 7-10 and a A260/280 ratio 
between 1.8-2.1 were determined as having passed quality control. Therefore 0.5-1µg 
of QC passed RNA samples were send to Tepnel Pharma Services (Manchester, UK), 
for processing and quantitative RT-PCR. Briefly Tepnel reverse-transcribed each 
sample using the RT2 First Strand kit (Qiagen) mixed with RT2 qPCR Master Mix 
containing SYBR Green (Qiagen), to then be added to a customised Mouse Innate & 
Adaptive Immune Responses RT² Profiler™ PCR Array CAPM13455 (QIAGEN). 
Each array measured the expression of 84 genes (Appendix A: Table S1); five 
housekeeping genes (β-actin (Actb); β-2-microglobulin (B2m); glyceraldehyde-3-
phosphate dehydrogenase (Gapdh); glucuronidase beta (Gusb); and heat shock protein 




first strand synthesis (RTC) and real-time PCR efficiency (PPC). Quantitative RT-PCR 
was performed using the ABI 7900HT Fast System (Life Technologies), the data was 
obtained as threshold cycles (Ct), these values denote the cycle number at which the 
increasing fluorescence signal of target DNA crosses the threshold set in the 
logarithmic phase of amplification, therefore lower Ct values indicate greater 
concentration of target DNA. Genes with low expression (Ct <35) were removed and 
relative gene expression to Actb were calculated to use to compare changes in 
expression between vaccinated treatment groups. Actb was used, as this was the only 
housekeeping gene not to have a statistically significant relationship between treatment 
and expression (Ct values). 
Relative genei expression = Actb Ct – genei Ct  
2.2.17 Statistics 
Generalised linear models were used to assess the differences between the vaccination 
groups and the parasitological and immunological readouts. Worm counts were 
modelled with a Poisson distribution, and Mf counts were log transformed and then 
modelled with a negative binomial distribution. Differences in gene expression 
between vaccination groups measured by qPCR arrays was assessed using GLM. Since 
84 genes were measured, multiple testing was accounted for using Bonferroni 
correction. Residuals were tested for normality using Shapiro test and results with a P-
value lower than 0.05 were considered statistically significant. All statistical analysis 
and graphs were done on Rstudio v0.97.318 statistical software, and graphs were 





2.3.1 Validating Ls-ShK antigen in DNA plasmid vaccination 
experiments 
Initial vaccination with Ls-ShK p.c.DNA3.1 plasmid showed protection, with a 
decrease in worm burdens in the pleural cavity and numbers of microfilariae found 
circulating in the blood (Figure 2.5 ShK Vacc Exp 1, from Duprez. J, MRes Thesis, 
2013, University of Edinburgh). This initial vaccination experiment showed that Ls-
ShK was significantly protective, by decreasing Mf numbers when used on its own, 
but when combined to CPIm which is a promising vaccine candidate, the protective 
effect was abolished. Therefore, vaccination experiments using ShK were repeated and 
compared to different vaccine combinations. In these experiments 40 BALB/c mice 
were split into four groups (n=10), with three groups receiving two intra-muscular 
injections with plasmid DNA containing the antigen inserts of interest two weeks apart 
from each other, this was then followed by a challenge infection of 40 infective L3 
four weeks after the last immunisation. The three immunised groups were: 
• CPIm_TPX (Adj) – These mice received a cocktail of pcDNA3.1 plasmids 
containing the CPIm and TPX antigens, with IL-4 and MIP1a as adjuvant 
plasmids. This was used as a control for a protective vaccination, as it has been 
previously shown to be a promising vaccination cocktail (Honglin, 2011). 
• ShK (Adj) – These mice received a cocktail of ShK pcDNA3.1 plasmid, with 




• pEmpty (Adj) – These mice receive pcDNA3.1 plasmid with no antigen insert, 
as well as the IL-4 and MIP1a as adjuvant plasmids. This was to control for the 
effect of the plasmid backbone and adjuvants. 
The fourth group were mice that received no vaccination nor challenge infection and 
termed naïves. 
To assess the protective effect and immunogenicity of the ShK plasmid vaccine, blood 
was collected at day 60 post challenge for microfilariae counts and antibody levels in 
the serum; and the pleural cavity of mice were washed to collect adult worms to 
determine worm survival. However, the repeated ShK vaccination experiments (ShK 
Vacc Exp 2 and ShK Vacc Exp 3), showed no sign of protection with similar 
percentages of worm survival between the ShK and the pEmpty control (Figure 2.5. 
A), similarly no decrease in Mf numbers was seen in vaccinated groups in the repeat 
ShK experiments (Figure 2.5. B), contrary to what seen in the first ShK experiment.  
Antibodies raised to L. sigmodontis antigen were found in challenged mice, with 
significantly increased levels of IgG1 (Figure 2.6. A) in infected mice compared to 
naïve controls, although no differences were seen between the immunised groups. 
IgG2a which is normally found in low levels in L. sigmodontis infections, were raised 
in infected groups in the third ShK experiment compared to Naïve controls, suggesting 
a Th1 response was raised (Figure 2.6. B, ShK Vacc Exp 3). 
To determine if the ShK plasmid used in the repeat DNA vaccinations experiments 
still had the correct antigen insert, the plasmids were amplified using PCR, and the 




suggesting that the change in protection is not due to the absence of the vaccine antigen 





Figure 2.5 Percentage worm survival and microfilariae counts from three independent 
ShK vaccination experiments. Mice were vaccinated using different combinations of DNA 
plasmids, using pEmpty as the vaccination control. 4 weeks after the last vaccination mice 
were challenged using 40 L3, and then at day 60 post-challenge infection (p.i.) mice were 
sacrificed and 30µl of blood was collected for B) Mf counts, these were counted under a phase 
contrast microscope. Pleural lavages were performed to collect the worms from the pleural 
cavity, these were counted under a dissection microscope, and A) worm survival was 
calculated as the percentage of worms present at day 60 p.i. from the 40 L3 used in challenge 
infection. ShK Vacc Exp 1 data was collected in a previous study (Duprez. J, MRes Thesis, 
2013, University of Edinburgh) and differs in terms of vaccination groups compared to the 
ShK Vacc Exp 2 and ShK Vacc Exp 3. After the ShK Vacc Exp 1 vaccination experiment, the 
CPIm_ShK with adjuvant and CPIm with adjuvant groups were replaced with CPIm_TPX 
with adjuvant, and was intended to be used as a positive control for vaccination. Dots represent 
individual mice (N=5 per treatment group for 1st experiment, N=9-10 for the 2nd and 3rd 
experiment), and bars represent the mean per treatment group with error bars as the standard 
error of the mean. GLM’s were used to analyse the statistical difference between the pEmpty 
group and the vaccinated groups, since the Naïve group was not infected it omitted from 





Figure 2.6. Levels of IgG1 and IgG2a specific to L. sigmodontis whole antigen, 
represented as titres in blood serum at day 60 p.i. in three independent ShK vaccination 
experiments. Serum from blood collected at day 60 p.i. were analysed for L. sigmodontis 
antigen (Ls-Ag) specific to A) IgG1 and B) IgG2a in three independent ShK vaccination 
experiments. Antibody levels were measured using an indirect ELISA and are represented as 
titres. Each dot represents individual mice, split into their vaccination groups (N=3-5 per group 
for ShK Vacc Exp 1, N=9-10 for the ShK Vacc Exp 2 and ShK Vacc Exp 3), and bars represent 
the mean per treatment group with error bars as the standard error of the mean. GLM’s were 
used to analyse the statistical difference between the näive group and the other vaccinated 
groups, as no difference was seen between infected groups (* P-value <0.05, ** P-value <0.01, 





Figure 2.7. Gel of PCR products of ShK plasmid. To determine if the ShK pcDNA3.1 
plasmid used in the vaccination experiments still contained the antigen insert, a PCR using a 
ShK primer and a T7/BGH primer (Table 2.2) was done on four different ShK plasmids batch 
that were used to make up the vaccine cocktails. The PCR product show a band of the correct 
size representing the ShK antigen (808bp), each band on the gel marker corresponds to 100bp. 
 
2.3.1.1 Measuring changes in gene expression at day 60 post 
infection 
Blood samples were collected for RNA extraction at the end of the DNA vaccination 
experiments (day 60 post challenge infection), to identify changes in gene expression 
that might correlate with protection, with hope to use these as markers of protection. 
RNA was extracted from the blood and the quality of the samples were analysed before 
being send to Tepnel Pharma Services (Manchester, UK) for qPCR array analysis, to 
measure the expression of 84 genes involved in immune pathways. Not all samples 
passed the quality control and of those that did, only 6 mice were classified as protected 
showing no signs of Mf in the blood following immunisation. Of the 6 protected mice 
two mice were from antigen immunised groups (ShK or CPIm_TPX immunisations) 




investigate changes in gene expression associated with protection induced by different 
vaccine candidates.  
Changes in gene expression were therefore compared to Mf numbers in the blood 
(regardless of immunisation), and genes involved in interferon (IFN) signalling (Irf7, 
Stat1, Jak2, Tyk2) or downstream effects of IFN (Ccl5) were found to be significantly 
positively correlated with Mf numbers (Figure 2.9), as well as H2-T23 and Myd88 
(Figure 2.10). H2-T23 is a MHC class I presentation gene and Myd88 is an adaptor 
protein involved in most toll like receptor signalling (except TLR3). 
It was not possible to determine whether changes in gene expression was associated 
with vaccine-induced protection (only 2 samples from immunised mice had 0 Mf). 
However, Ccr4 and Cd80 were found to have higher expression in vaccinated mice 
compared to primary infections, but there was no correlation with Mf or worm numbers 
(Figure 2.11).  Ccr4 (C-C chemokine receptor type 4) encodes a protein which is a 
receptor for various CC chemokines known to regulate cell trafficking of various types 
of leukocytes and aid the interaction of antigen primed T cells and DC (Wu et al., 
2001). Furthermore, Cd80 encodes a protein for a co-stimulatory molecule found on 
dendritic cells and activated B cells, and is necessary for T cell activation, this possibly 
indicates that in vaccinated mice there was an increase in DC and T cell interaction 





Figure 2.8. Percentage worm survival and microfilariae counts from three independent 
DNA vaccination experiments, used in the qPCR array. Worm survival and log 
transformed Mf numbers found circulating in the blood at day 60, in three independent DNA 
vaccination experiments from which RNA was extracted from blood at day 60 for qPCR 
analysis. The vaccination groups were: Ls-CPIm and Ls-TPX with adjuvants (n=8); Ls-CPIm 
with adjuvants (n=5); Ls-Shk with adjuvants (n=7); empty pcDNA3.1 control (n=12), these all 
received a challenge infection. The primary infected group received no vaccine and were only 
challenged infected (n=5), and the naïve group received neither vaccine nor challenge infection 





Figure 2.9. IFN signalling genes were found to have a significant association with 
microfilariae numbers in the blood. RNA was extracted from blood at day 60 post challenge 
infection. and qPCR arrays were used to measure changes gene expression between 
vaccination groups. Relative expression of genes to Actb were calculated and expression of 
genes involved in IFN signalling (Irf7, Stat1, Jak2 and Ccl5) were found to have a positive 
correlation with Mf numbers in the blood (represented as log transformed Mf data). These 






Figure 2.10. H2-T23 and Myd88 gene expressions were significantly associated with 
microfilariae numbers in the blood. RNA was extracted from blood at day 60 p.i. and qPCR 
arrays were used to measure changes gene expression between vaccination groups. Relative 
expressions of genes to Actb were calculated and expression of H2-T23 and Myd88 were 
found to have a positive correlation with Mf numbers in the blood (represented as log 
transformed Mf data). H2.T23 is a component of MHC-class II molecules and Myd88 is an 
adaptor connecting proteins that receive signals from outside the cell to the proteins that relay 






Figure 2.11. Relative expression of Ccr4 and Cd80 across treatment groups. RNA was 
extracted from blood at day 60 p.i. and qPCR arrays were used to measure changes gene 
expression between vaccination groups. Relative expression genes to Actb were calculated, 
Ccr4 and Cd80 were the only genes in which there was a difference in expression between 
vaccinated groups and primary infections. Ccr4 is a receptor for the CC chemokines MIP-1, 
RANTES, TARC and MCP-1. Cd80 is a receptor found on dendritic cells, activated B cells 
and monocytes, and induces T cell proliferation and cytokine production. Each dot represents 
individual mice split into their vaccination groups (n=5-12 per treatment) and error bars 
represent standard error of the mean. GLM’s were used to assess the statistical difference 
between the vaccinated groups and the primary infection. *** P-value <0.001, ** P-value 





2.3.2 Vaccination with peptide antigens 
Peptides derived from the vaccine candidates Ls-Ral2, Ls-103, Ls-CPIm, Ls-ShK and 
Ls-Tgh2, were predicted to be immunogenic using the Kolaskar and Tongaonkar 
antigenicity scale (Kolaskar, Tongaonkar, 1990). This prediction algorithm makes use 
of physicochemical properties of amino acid residues and their frequencies of 
occurrence in experimentally known epitopes, to predict potential antigenic epitopes 
in protein sequences. Application of this method to a large number of proteins was 
shown to predict antigenic determinants with 75% accuracy which is higher than most 
known methods (Kolaskar, Tongaonkar, 1990).  
The vaccine candidates can be split into two groups based on their known function (or 
hypothesised function), peptides derived from proteins such as CPI, ShK and Tgh2 
which are known to have immunomodulatory properties were grouped together, 
whereas Ral2 and 103 functions remain unknown but show to be immunogenic and 
induce protection in various vaccination experiments formed the second group (Table 
2.5).  
For the immunomodulatory proteins, six peptides were derived from Ls-CPI, whereas 
Ls-ShK (nLs_04059) had 19 immunogenic peptides predicted, however only the 
peptide that corresponded to the putative active C-terminal domain was used, and this 
amino acid sequence was mutated to remove the active site, by replacing both Lys-528 
and Tyr-529 with Ala. The rationale behind the mutation is similar to the mutation of 
CPI by Babayan et al (2012), in which mutating the active site of the molecules would 




avoid immunising with a potential functional molecule, but also the antibodies raised 
against the molecule following immunisation would have the ability to neutralise the 
native molecule in the following infection and hence prevent potential future immune 
regulation, allowing the immune response to mount a protective response.  
As for Ls-Tgh2 (nLs.2.1.2.g04798), which is highly conserved with mammalian TGF-
b especially in the region of the active domain in the C-terminal portion, two peptides 
were predicted within that region and synthesised.  
For the second group of peptides, Ls-RAL2 (nLs_01747) had four peptides predicted, 
however one of them was too long to synthesise (50 amino acid long) and was therefore 
broken down into three, whereas Ls-103 (nLs_03356) had five antigenic peptides 
predicted and were all synthesised.  
All peptides had a palmitoyl group added to the N-terminal of the peptide, to increase 
their immunogenicity by increasing their membrane trafficking. To increase the 
immune responses to the peptides, a chimera of universal epitopes from tetanus and 
diphtheria toxoids (TpD) was co-administered.  
Since there were 20 peptides predicted from the antigens of interest, assessing the 
immunogenicity and protection of individual peptide would not only be pointless as 
one peptide on its own is not likely to be immunogenic enough, but also logistically it 
would require too many mice. Therefore, peptides were grouped by their functional 
role and vaccination experiments immunising BALB/c mice against groups of peptides 




were given three intra muscular injections a week apart from each other with either a 
cocktail of:  
• Ral2_103_TpD: A combination of highly immunogenic Ls-Ral-2 and Ls-103 
peptides with the TpD adjuvant in alum (total of 11 peptides). 
• CPI_ShK_Tgh2_TpD:  A combination of immunomodulatory Ls-CPI, Ls-ShK 
and Ls-Tgh2 peptides with the TpD adjuvant in alum (total of 10 peptides). 
• All_peptides: A combination of all the 19 peptides including TpD adjuvant in 
alum (a total of 20 peptides). 
• TpD: The chimera of universal epitopes from tetanus and diphtheria toxoids 
(TpD) was give on its own in alum, to measure its effect as a control. 
Four weeks after the last immunisation, the immunised groups and a fifth group which 
had not received an immunisation (Primary infection), received a challenge infection 
with 40 infective L3. The sixth remaining group did not receive any immunisation nor 
a challenge infection, and was termed naïve control.  
2.3.2.1 No change in adult worm survival but a trend towards 
decreased Mf in peptide immunised mice 
To assess protection efficacy of the peptide vaccines, worm survival was calculated as 
the percentage of adult worm’s present in the pleural cavity out of the 40 infective L3 
used in the challenge. Overall around 20% of the worms survived and matured into 
adults, for all the challenged (/infected) groups showing no difference between the 




Numbers of microfilariae were counted from 30µl of blood collected at the end of the 
vaccination experiment. Groups vaccinated with Ral2_103_TpD and 
CPI_ShK_Tgh2_TpD showed a slight decrease in Mf numbers compared to primary 
infection (Figure 2.12. B), but this small effect is abolished when all peptides are 
combined. 
 
Figure 2.12. Worm survival and microfilariae count at day 60 post-challenge infection. 
At day 60 post-challenge infection (p.i.) mice were sacrificed and 30µl of blood was collected 
for B) Mf counts, these were counted under a phase contrast microscope. Pleural lavages were 
performed to collect the worms from the pleural cavity, these were counted under a dissection 
microscope, and A) worm survival was calculated as the percentage of worm’s present at day 
60 post infection from the 40 L3 used in challenge infection. Dots represent individual mice 
(N=7 per treatment group), and bars represent the mean per treatment group with error bars as 
the standard error of the mean. GLM’s were used to analyse the statistical difference between 
the challenged groups (Naïve group was omitted from the analysis since it was not challenged), 
but no significance was found. 
To further investigate the impact of the peptide vaccinations on the fertility of female 
worms, the female uteri of each worms were looked at under a microscope and a score 
was given depending on the Mf development stage present in its uteri: oocyte or 




2.4). Empty females or females that were too degraded to measure were excluded from 
the analysis, leaving 76% of females to be analysed.  
When comparing the effect of the different immunisations, on the development of Mf 
found within worms, mice immunised with CPIm_ShK_TpD had a greater percentage 
of female worms with only eggs (stage 1) present within their uteri (i.e. missing the 
fully developed Mf). All other groups had a greater percentage of female worms with 
mature Mf.  
When mature Mf were present in the uteri of female worms, the density at which they 
were found was also recorded, as in some worms where mature Mf were present, these 
were found in low numbers with lots of dead eggs or dead “pretzel” Mf stages. The 
density of mature Mf was given as a score (1-4), where 1 is given when few mature 
Mf are present with lots of dead eggs or pretzel shaped Mf, and 4 when the majority 
of the Mf present were mature Mf.  
Immunisation with Ral2_103_TpD had no effect on the development of Mf (Figure 
2.13A), however this peptide vaccine did reduce the density at which the Mf were 
produced (P-value<0.05), with more dead eggs and debris found in these female 
worms, compared to primary infections (Figure 2.13.B).  
In conclusion, CPIm_ShK_TpD immunisation is affecting the development of Mf 
within the uteri. Ral2_103_TpD immunisation does not impair the ability of females 
worms to produce mature Mf, but the density at which they are produced is reduced, 
compared to those found in the worms recovered from mice that had not been 




analysis of adult female uteri revealed that only stages 1-2 were present (no fully 
mature Mf). Therefore, immunisation with either immunogenic or immunomodulatory 
peptides is affecting the fecundity of female worms, hence why there was a slight 
decrease in circulating Mf in those vaccinated mice. 
 
Figure 2.13. Embryonic stages in female uteri between treatment groups. The uteri of 
adult females from the vaccination experiments were analysed under an inverted microscope 
and the worms were scored from 1 to 3 depending on the developmental stage of Mf present. 
Stage 1, Fertilised egg; Stage 2, Pretzel shaped Mf; and Stage 3, Elongated Mf (mature Mf). 
A) represents the percentage of females harbouring the different life stages, between the 
different treatment groups. B) When the fully mature Mf were found in the female uteri, the 
density (1<4) at which they were found was also recorded, the low density of 1 is when lots of 
dead fertilised eggs or pretzel shaped Mf were present with the elongated Mf, and the higher 
density (4) is when Mf were tightly packed together. Therefore, the graph above represent the 
average density per immunisation group. Density of elongated Mf were compared between the 




2.3.2.2 Ral2 and 103 peptide combination raises a Th2-type 
response 
To assess the immunogenicity of the peptides, blood was collected from mice at days 
14, 42 and 60 post challenge infection to measure antibody levels. The kinetics of IgG1 
was assessed by measuring IgG1 levels throughout the infection, showing that IgG1 
levels specific to L. sigmodontis antigen (Ls-Ag) significantly increased over time, 
with a 5-fold increase in antibody titre at each time point in infected mice (Figure 
2.14A). By day 60 post infection levels of IgG1 titers were higher in immunised groups 
compared to primary infection with only Ral2_103_TpD vaccination being 
significantly increased (P-value < 0.01, Figure 2.14B), whereas IgG2a responses were 
low, with only a few mice in the CPI_Shk_Tgh2_TpD and TpD groups having 
increased levels of IgG2a (Figure 2.14C). 
IgG1 antibodies specific to CPI were only slightly raised in mice vaccinated with the 
CPIm, suggesting some cross-reactivity with other peptides (Figure 2.15A). ShK 
specific IgG1 was significantly increased in the CPI_Shk_Tgh2_TpD vaccinated 
(Figure 2.15B), however since ShK specific antibodies were only measured in the 
primary infection, CPI_Shk_Tgh2_TpD and naïve group it is impossible to tell if there 






Figure 2.14. IgG1 specific to L. sigmodontis whole antigen in blood serum at day 14 and 
day 42 post infection. A) Kinetics of IgG1 specific to L. sigmodontis antigen levels in blood 
serum at days 14, 42 and 60 post challenge infection, these responses were measured using 
indirect ELISA and are shown as the O.D. values (450nm) for the 1/800 dilution. B) Ls-Ag 
specific IgG1 titers at day 60 p.i. for which all challenged groups had significantly higher IgG1 
compared to naïve controls (P-value <0.05), and vaccination with RAL-2_103_TpD peptides 
induced significantly IgG1 compared to the non-vaccinated primary infection control (** P-
value <0.01, *** P-value <0.005). C) Ls-Ag specific to IgG2a titres, only the 
CPI_ShK_Tgh2_TpD and TpD control vaccination had increased IgG2a compare to naïve 
controls (P-value <0.05), but none of the vaccinated groups had any statistical difference with 
primary infection. Each dot represents individual mice, split into their vaccination groups 
(N=3-7 mice per group, some mice did not have enough blood for the ELISA), and error bars 
represent standard error of the mean. GLM’s were used to assess the statistical difference 





Figure 2.15. IgG1 titres specific to Ls-CPI and Ls-ShK in blood serum at day 60 p.i. Serum 
from blood collected at day 60 p.i. were analysed for IgG1 antibodies specific A) Ls-CPI and 
B) Ls-ShK by indirect ELISA and are represented as titres, however only the 
CPI_ShK_Tgh2_TpD, primary infection and naïve control groups were measured for Ls-ShK 
specific IgG1, and showed that the CPI_ShK_Tgh2_TpD mice had increased IgG1 compared 
to the primary infection (** P-value <0.005) and naïve control (P-value <0.05). Each dot 
represents individual mice, split into their vaccination groups (N= 7 mice per group), and error 
bars represent standard error of the mean. GLM’s were used to assess the statistical difference 
between the treatment groups. 
2.3.2.3 Lower numbers of macrophages, eosinophils and DC 
recruited to pleural cavity after peptide vaccination 
compared to infected controls 
To determine what cells were being recruited to the pleural cavity. Cells were collected 
at the end of the vaccination experiment (day 60 p.i.) by pleural lavages with PBS. 
Overall infected mice had greater number of cells present in the pleural cavity 
compared to naïve controls (Figure 2.16A), analysis of the cell population with flow 
cytometry showed that eosinophils are the predominant cell population found in 




(CD11c+ MHC+ cells) were found in lower numbers in peptide vaccinated mice 
compared to primary infected, especially when vaccinated with all peptides and the 
TpD control (Figure 2.16. B, C and D). For the number of lymphocytes, B cells showed 
little difference between the groups even compared to non-infected naïve mice, 
suggesting that B cells have little role in infection in the pleural cavity (Figure 2.16E), 
whereas CD4+ T cells numbers were increased in infected mice with higher numbers 





Figure 2.16. Cell recruitment to pleural cavity at day 60 p.i. At day 60 p.i. mice were 
sacrificed and their pleural cavity washed to recover cells, A) represent the total number of 
pleural cells harvested from the pleural cavity, showing that challenged mice irrespective of 
vaccination or not had a significant increase in cells present in the pleural cavity compared to 
naïve controls (*** P-value <0.001 compared to primary infection, but all challenged groups 
have significantly higher number of cells compared to naïve, P-value <0.05). Flow cytometry 
was used to differentiate between cell populations found in the pleural lavages, B) 




SiglecF+CD11c-, D) activated dendritic cells (DC) as CD11c+MHCII+, E) B cells as CD3-
CD19+ and F) CD4+ T as CD3+CD4+ cells. Asterisks denotes significant difference between 
primary infection and the other groups (*** P-value <0.001, ** P-value <0.01, * P-value 
<0.05). Each dot represents individual mice, split into their vaccination groups (N= 7 mice per 
group), and error bars represent standard error of the mean. GLM’s were used to assess the 
statistical difference between the treatment groups. 
2.3.2.4 No change in cytokine responses in the pleural cavity with 
peptide vaccinations 
No change in cytokine levels were measured in the pleural cavity of mice at day 60 
between the different peptide vaccination groups and the primary infected. Using 
capture ELISA, Th2 cytokines IL-4, IL-5, IL10 (Figure 2.17. A, B and C) and Th1 
cytokines IFNg (Figure 2.17.D) were measured. Only changes in IL-4 and IFNg levels 
were detected compared to naïve controls, but overall low levels of cytokines were 





Figure 2.17. Cytokine concentrations found in the pleural cavity at day 60 p.i. At day 60 
p.i. mice were sacrificed and their pleural cavity washed to analyse cytokine concentrations of 
A) IL-4, B) IL-5, C) IL-10 and D) IFNg concentrations in the pleural cavity. These were 
measured using capture ELISA, and each dot represents the mean of triplicated samples per 
individual mice, and each treatment group (N=7) is represented as the mean with error bars 
representing the standard error of the mean. Asterisks denotes significant difference between 
primary infection and the other treatment groups (* P-value <0.05). GLM’s were used to assess 
the statistical difference between the treatment groups. 
2.3.2.5 No difference in lymph node cell proliferation between 
vaccinated mice 
To investigate the immune responses within the draining lymph nodes of the pleural 
cavity, the mediastinal and parathymic lymph nodes were harvested at day 60 post 
infection and used in re-stimulations assays. Lymph node cells from infected mice had 




with either Ls-Antigen, anti-CD3 (to stimulate T cells) or left unstimulated with media 
control (Figure 2.18. A, B and C). There was no striking difference in proliferation 
between the immunised groups and with the primary infection control. 
 
Figure 2.18. Proliferation of re-stimulated lymph node cells. The mediastinal and 
parathymic lymph nodes were harvested at day 60 post challenge infection, and their cells were 
re-stimulated with either A) L. sigmodontis whole antigen to stimulate proliferation of Ls-Ag 
specific cells, with B) anti-CD3 to stimulate T cell proliferation and with C) RPMI 1640 as the 
media control. Proliferation is represented as O.D. values as 540nm, the higher the value the 
more cells have proliferated. Each dot represents individual mice, split into their vaccination 
groups (N= 7 mice per group), and error bars represent standard error of the mean. GLM’s 
were used to assess the statistical difference between the treatment groups, where asterisks 





2.3.2.6 Decreased IL-4 production by re-stimulated lymph nodes 
after vaccination with CPIm, ShK, Tgh2 peptides 
Levels of cytokines produced by re-stimulated lymph nodes were assessed using a 
capture ELISA. Overall, lymph nodes re-stimulated with either Ls-Ag or anti-CD3 
lymph nodes had an increased production of IL-4 (Figure 2.19. A and C) and IL-5 
(Figure 2.19. B and D) in infected mice compared to naïve controls. However, 
induction of IL-4 production was significantly lower in mice vaccinated with the 
CPI_ShK_Tgh2 peptides, which are known to be immunomodulatory. No change in 








Figure 2.19. IL-4 and IL-5 production by re-stimulated lymph node cells. Cells from 
lymph nodes harvested at day 60 p.i. were stimulated with either L. sigmodontis whole antigen, 
anti-CD3 or RPMI 1640 as a media control for 72 hours and supernatant fluids were collected 
to measure cytokine productions by re-stimulated cells using capture ELISA. The graphs show 
concentrations of IL-4 (ng/ml) after re-stimulation with either A) Ls-Antigen, C) anti-CD3 or 
E) media; and show concentrations of IL-5 (ng/ml) after re-stimulation with either B) Ls-
Antigen, D) anti-CD3 or F) media. Asterisks denote significant difference between primary 
infection and the other treatment groups (*** P-value <0.001, ** P-value <0.01, * P-value 
<0.05). Each dot represents individual mice, split into their vaccination groups (N= 7 mice per 
group), and error bars represent standard error of the mean. GLM’s were used to assess the 





Figure 2.20. IL-10 and IFNg production by re-stimulated lymph node cells. Cells from 
lymph nodes harvested at day 60 p.i. were stimulated with either L. sigmodontis whole antigen, 
anti-CD3 or RPMI 1640 as a media control for 72 hours and supernatant fluids were collected 
to measure cytokine productions by re-stimulated cells using capture ELISA. The graphs show 
concentrations of IL-10 (ng/ml) after re-stimulation with either A) Ls-Antigen, C) anti-CD3 
or E) media; and show concentrations of IFNg (ng/ml) after re-stimulation with either B) Ls-
Antigen, D) anti-CD3 or F) media. Each dot represents individual mice, split into their 
vaccination groups (N= 7 mice per group), and error bars represent standard error of the mean. 
GLM’s were used to assess the statistical difference between the treatment groups, but no 





Vaccine induced immunity against filarial parasites was shown to be possible using 
live attenuated vaccines, such as immunisation with irradiated L3 or Mf (Le Goff et 
al., 2000; Ziewer et al., 2012), these induce antigen-specific responses that protect the 
host against subsequent infection. Although they provide proof that vaccination is 
possible for filarial diseases, due to constraints with production and ethical issues, it is 
unfeasible to use them in humans, therefore the use of DNA plasmids or peptides of 
filarial antigens as vaccines is proposed. 
Several potential vaccine candidates have already been identified and can demonstrate 
protection and/or immunogenicity in various filarial animal models, and novel ones 
are continuously being identified. A relatively novel vaccine candidate in filarial 
research is Ls-ShK. It was identified in the E/S (secretome) of L. sigmodontis gravid 
females (Armstrong et al., 2014), and although it was moderately abundant in the 
female E/S, it was present in the E/S of all mammalian derived stages. Homologues to 
Ls-ShK, such as ones found in B. malayi have been hypothesised to be 
immunomodulators, by modulating memory T cells (Chhabra et al., 2014), therefore 
Ls-ShK stood out as being a potential immunomodulator vaccine candidate.  
In initial DNA vaccination experiment, Ls-ShK showed promise (Duprez. J, MRes 
Thesis, 2013, University of Edinburgh) inducing protection seen as reduction in Mf 
numbers, however in repeat experiments this failed to show any protective response. 
Since Ls-ShK is hypothesised to be an immunomodulator, the lack of protective 




its immunomodulatory properties reduced its efficacy as vaccine candidate 
(Arumugam et al., 2014a). With CPI-2, when modified to remove its 
immunomodulatory sequence protective immunity was achieved (Babayan et al., 
2012; Arumugam et al., 2014b), therefore in a subsequent vaccination experiments 
ShK was modified to removed its putative immunomodulatory side, in hopes that this 
would allow the vaccinated mice immune system to mount a protective response 
following challenge infection. Overall DNA vaccines (Ls-CPIm_TPX and Ls-ShK) 
showed low immunogenicity and protection even with the control immunisation (Ls-
CPIm_TPX), therefore another approach to vaccination was used. 
Peptide vaccines have several advantages over live attenuated, DNA or recombinant 
protein vaccines. Peptides are relatively inexpensive, due to the ease of production and 
simple composition, these can also be safer by avoiding the inclusion of unnecessary 
components possessing high reactogenicity to the host. Therefore, the efficacy of 
peptides derived from Ls-ShK, Ls-CPI, Ls-103, Ls-Ral2 and Ls-Tgh2, were 
investigated using the L. sigmodontis model. These peptides were split into two 
groups; peptides derived from Ls-Ral2 and Ls-103 were termed highly immunogenic 
peptides, as these antigens in recombinant form have induced protection against B. 
malayi in gerbils (Arumugam et al., 2016), O. volvulus using the chamber model (Hess 
et al., 2014) and O. ochengi in cattle model with natural infections (Makepeace et al., 
2009). The second group of peptides were derived from known immunomodulatory 
proteins: Ls-CPI, which has been shown to induce protection, especially when 
modified (Babayan et al., 2012; Arumugam et al., 2014b; Hess et al., 2014); and two 




Immunisation with different combinations of peptides induced a reduction in Mf 
number but did not inhibit L3 development, as worm burdens did not differ. This is 
not so surprising, as immunisation with the antigens CPIm, Ral2, 103 have previously 
been shown to affect Mf numbers but not worm burdens (Babayan et al., 2012; Hess 
et al., 2014; Arumugam et al., 2016). Although not significant, there was a reduction 
in Mf observed in the blood in mice that were immunised with either a combination of 
Ls-Ral3 and Ls-103 peptides (highly immunogenic); or Ls-CPI, Ls-ShK and Ls-Tgh2 
peptides (immunomodulatory), but not when all peptides were used together. This 
decrease in Mf was linked to an intrauterine inhibition of embryogenesis, as female 
worms derived from the mice vaccinated with either the immunogenic or 
immunomodulatory peptides, either had no viable Mf found in the uteri of the female 
worms (these correlated with no Mf found in blood) or had low viable Mf density with 
lots of fertilised eggs or pretzels shaped Mf found in the uteri alongside with the 
elongated Mf. This vaccine induced reduction in fecundity has been demonstrated 
several times in the L. sigmodontis models (Babayan et al., 2012; Ziewer et al., 2012), 
B. malayi in gerbils (Arumugam et al., 2014b) and with an ES vaccine in Brugia 
pahangi gerbil model (Zipperer et al., 2013).  
Immunisations with immunogenic or immunomodulatory groups of peptides showed 
some signs of protection, however when all peptides were combined, all protective 
effect was abolished. There are two possible reasons why immunisations with a 
combination of all peptides may not to have worked; either the combinations of 




immunisation dose was controlled for, the group with all peptides had less of each 
individual peptide and not enough to induce an effective response. 
Filarial parasites are complex infections triggering different cellular and humoral 
responses, as well as inducing a suppressive mechanism, with different life stages 
varying in both antigenic make-up and tissue location, therefore pinpointing effector 
mechanisms of protection has been difficult and the exact mechanisms remain 
unknown. Early research using passive transfer experiments of serum from B. pahangi 
infected cats, suggested that serum antibodies could mediate Mf killing (Medeiros et 
al., 1996). The role of antibodies in in vivo killing of Mf, was later confirmed using 
mice deficient in B cells, where Mf-specific antibodies were indeed necessary to clear 
B. malayi Mf in mice (Gray, Lawrence, 2002). However, in the permissive L. 
sigmodontis model of infection, there are contrasting results depending on the B cell 
deficiency. Mice with a µMT mutation, which lack mature B cells were 
amicrofilariamic (Mf-ve) (Martin et al., 2001), whereas mice lacking B1 cells in 
BALB/c Xid mice had a higher microfilaremia compared to wild types (Al-Qaoud et 
al., 1998), but great care needs to be taken in interpretation of knockout mice as often 
mutations can induce important modification. Antibodies have been implicated in 
antibody-dependent de-granulation of eosinophils in irradiated L3 immunisation in the 
L. sigmodontis model, responsible for the death of incoming L3 following challenge 
infection (Martin et al., 2001), but since murine eosinophils do not express receptors 
that bind IgE, the antibody responsible is most likely IgG as murine eosinophils do 





In a study by Ziewer et al, where mice were immunised with L. sigmodontis Mf, Mf-
specific IgG1 and IgG2a antibodies were present throughout the infection (Ziewer et 
al., 2012), in this study it was suggested that protection was mediated by Mf-specific 
IgG entering the female worm uterus or interfering with developing stages of Mf, 
hence why adult female where intact despite low Mf numbers found circulating in the 
blood (Ziewer et al., 2012). Although it is impossible to say that this is what is 
happening with the peptides immunisation, since no significant protection was 
achieved with any of the vaccines combinations, there are some similarities.  
Using flow cytometry the number of B cells were found to be similar between the 
immunised groups and the primary infection. Further, when measuring adult L. 
sigmodontis specific antibodies, IgG1 was found elevated in the mice vaccinated with 
the Ls-Ral2 and Ls-103 peptides (these mice had low densities of elongated Mf). This 
difference in IgG1 was only detected at day 60 (patency) and no differences between 
the infected mice whether immunised or not were seen at day 14 and day 42 post-
challenge suggesting a cumulative increase. However, in the future it would be 
necessary to measure Mf-specific antibodies, as well as using immunohistochemistry, 
to establish if antibodies are binding to the embryonic stages. 
Cytokine profiles during infections can give an indication of the type of immune 
responses being triggered. Th-2 cytokines, IL-4 and IL-5 in L. sigmodontis infections 
are necessary for parasite containment (Al-Qaoud et al., 2000; Volkmann et al., 2001; 
Le Goff et al., 2002; Volkmann et al., 2003), as well as the Th-1 cytokine IFN-g 
(Lawrence et al., 2000; Saeftel et al., 2003). Whereas IL-10, which was initially 




cells and is now mostly associated with immunomodulation and parasite survival 
(Specht et al., 2004; Haben et al., 2013; Hartmann et al., 2015). Therefore, levels of 
IL-4, IL-5, IFN-g and IL-10 were measured in the lavages of the pleural cavity, but no 
changes were detected between the different immunisation groups.  
Cytokines produced by lymph node cells re-stimulated with either L. sigmodontis 
antigen, anti-CD3 to stimulate T cells or culture media were also measured, with only 
cells from mice immunised with immunomodulatory peptides showing a change in IL-
4 production, producing lower levels of IL-4 compared to other immunised groups and 
the primary infection group. Although cytokines and cells present in the pleural cavity 
and lymphoid system were collected at the time of necropsy, earlier time points would 
be more informative, during the migration of larval parasites which are the likely major 
targets of the protective immune response and that by day 60 immune responses have 
returned to baseline levels. 
The evidence so far shows that the peptide vaccines are targeting female fertility and 
not the circulating Mf, and in onchocerciasis, dermal and ocular pathology is 
associated with innate immune responses to Wolbachia released from dying Mf in the 
skin and eyes (Hise et al., 2003; Tamarozzi et al., 2011). Therefore, a vaccine against 
the Mf stage would be beneficial to the affected population, not only to decrease 
transmission but also to ameliorate pathology. However, because immunity to filarial 
parasites is mostly associated with Th2-type responses, there may be a risk that a 
vaccine might induce strong eosinophil and IgE mediated responses which could lead 
to induction of pathology (Babu, Nutman, 2012). Therefore, vaccine candidates tested 




et al., 2012; Hotez et al., 2013), especially since in the L. sigmodontis model mice do 
not exhibit pathology. 
Hypersensitivity (allergic reactions) following vaccination are a cause for concern. 
Phase I trials of the hookworm (Necator americanus) vaccine, against the 
ancylostoma-secreted protein 2 (Na-ASP-2), resulted in generalised urticarial 
(allergic) reactions in volunteers and the suspension of the trial. This reaction was 
associated with pre-existing Na-ASP-2 specific IgE, most likely from previous 
hookworm infections, as negligible levels of Na-ASP-2 IgE were found in hookworm 
naïve-adults living in non-endemic areas (Diemert et al., 2012). Surveys in hookworm 
endemic foci in Brazil showed that a significant percentage of the population had 
increased levels of IgE to Na-ASP-2. This has caused serious concern and has 
implications for the development of vaccines against helminths (Diemert et al., 
2012).Therefore, one way to prevent this from happening in onchocerciasis vaccine 
trials, is firstly to test the potential vaccine antigens against serum from individuals 
living in endemic foci, to make sure the antigens are not recognised by IgE antibodies. 
Since one of the strategies to identify vaccine candidate has been to target 
immunomodulators, this decreases the risk of having IgE specific antibodies prior to 
vaccination. 
The use of a peptide vaccine is an attractive vaccine strategy against filarial disease, 
firstly because of the ease of production and secondly because specific antigen 
epitopes can be chosen and easily modified, so that they do not elicit to IgE. However, 
because they usually only contain one antigenic epitope, these would need to be 




combining an immunogenic peptide with an immunomodulatory peptide (Babayan et 
al., 2012). The duration of protection elicited by any vaccine would also need to 
investigated, as this was modelled to have a long-term impact in vaccination 
campaigns (Turner et al., 2015). 
Protection in vaccination experiments are measured around day 60 post challenge 
infection, as this is the point at which adult worms are known to be present and Mf are 
being produced. Although immunological readouts can be informative of what type of 
immune responses are being triggered, at day 60 immunological readouts may not be 
always indicative of protection. Quantitative RT-PCR arrays were used to measure 
changes in gene expression in vaccinated mice, to determine if gene signatures at the 
end of vaccination experiments could be more informative than antibody, cytokine and 
cellular measures. However, most gene signatures identified were associated with a 
response to parasites burden and not predictive of protection.  
Review of the data obtained and published results of other studies suggest that 
investigative associations at day 60 may be too late to measure changes associated with 
vaccination, and events at the onset of infection may determine infection outcome 
(Taylor et al., 2009). Identifying gene signatures or biomarkers predictive of vaccine 
efficacy or immunogenicity would greatly aid vaccine trials, by reducing costs if a 
vaccine shows signs of not being protective early on (Mastelic et al., 2013; Hagan et 
al., 2015). Therefore, one would need to look at changes in gene signature throughout 






• Immunisation with Ls-ShK using DNA vaccines in the L. sigmodontis model 
does not confer protection. 
• Immunisation with peptides derived from immunogenic antigens (Ls-Ral2 and 
Ls-103) and from immunomodulatory antigens (Ls-CPI, Ls-ShK and Ls-Tgh2), 
affects adult female fecundity. 
• Immunisations with a combination of peptides derived from all vaccine antigens 
shows no protection. 
• Peptides have potential as vaccines but correct formulation needs to be 
determined. 
• Measuring gene signatures potentially associated with protection at the end of a 




Chapter 3. Using machine learning techniques 
to dissect gene expression patterns in filarial 
infection from whole blood data 
3.1 Background 
The possibility of vaccination against filarial infections such as onchocerciasis is based 
on the evidence that protective immunity is observed both in humans and animals 
naturally exposed to filarial infections, and the ability to induce partial protection in 
multiple laboratory models of filarial infection. In humans, protective immunity is seen 
in a small proportion of the population living in hyper-endemic areas which show no 
clinical or parasitological signs of infection even though they have had a life-long 
exposure (Hoerauf, Brattig, 2002).  
In the Litomosoides sigmodontis mouse model, such apparent natural 
immunity/resistance is host strain-dependent, e.g. BALB/c mice are susceptible to the 
full development of adults and production of blood-circulating microfilariae (Mf), 
while C75BL/6 mice, termed resistant, eliminate the parasite within 40 days of 
infection, i.e. before the onset of patency (Petit et al., 1992; Marechal et al., 1996; 
Babayan et al., 2003). Furthermore, in BALB/c mice, protective immunity can be 
induced by vaccination with the infectious stage (L3) larvae or the transmissible filarial 
offspring (microfilariae, Mf) (Le Goff et al., 2000; Ziewer et al., 2012). Protection 
induced by vaccination in the L. sigmodontis models is determined as a decrease in 
parasite burden, either in adult worm number seen in the pleural cavity, or in the 






Identifying markers of early immune responses to immunisation that are predictive of 
vaccine efficacy, would provide a surrogate endpoint to vaccine trials, but could also 
ultimately help predict the efficacy of a vaccine in humans. Because mice differ from 
humans, with respect to the development and activation of innate and adaptive immune 
response (Mestas, Hughes, 2004; Seok et al., 2013), successful translation of any 
vaccine from murine models to clinical application is not always straightforward, and 
vaccines that showed promise in murine models, have had a lack of efficacy in humans 
(Gray et al., 2011; Tameris et al., 2013; Kaufmann et al., 2014) or sometimes raise 
safety concerns during early human clinical trials (Diemert et al., 2012). However, the 
use of an animal model cannot be bypassed for evaluating vaccines, and based on 
common ancestry and relatively high conservation of genes and their expression 
profiles (Mestas, Hughes, 2004), immune mechanisms that take place in vivo following 
vaccination with L3 or Mf in mice could help identify the “immune signatures” that 
are necessary to trigger protection, and see if there is overlap with human makers of 
natural protection. 
Until recently studying these immune responses to infection would have been 
performed in a highly focused manner, by either investigating antibody responses, 
abundance of certain cells types, or cytokines. These methods have provided 
tremendous insight as to how and what type of the immune responses are being 
triggered, however the immune system is complex with considerable in-built 
redundancy, and consequently a focused approach can be limited when it comes to 





The introduction of high-throughput technology such as microarrays, has opened a 
broader approach to the analysis of immune responses, in which expression levels of 
tens of thousands of genes can be measured simultaneously (Weiner et al., 2015). One 
of the aims of the work described in this chapter was to investigate whether markers 
(predictors) of immunity can be detected in the blood, and whether commonalities 
could be identified between mouse and human expression profiles during filarial 
infection. Whole blood was chosen as the sample tissue, as not only is it the least 
invasive sampling method (compared to tissue biopsies) and often the only practical 
option, but also filarial infections elicit a systemic response, which is best captured by 
analysing the blood during an infection. 
The use of microarray technology for studying helminth infection is relatively 
uncommon compared to other parasites and pathogens (Kwarteng, Ahuno, 2016), with 
most studies investigating the host responses to helminths such as schistosomiases and 
Nippostrongylus brasiliensis (a helminth closely related to human hookworms) (Zhou 
et al., 2016), with even fewer studies on filarial nematodes (Kwarteng, Ahuno, 2016). 
In most of the helminth studies, changes in gene expression were measured in tissue 
samples (i.e. not readily applicable as a non-invasive approach) or isolated responses 
in filtered cell populations, instead of whole blood. However, in other pathogen 
infections such as bacteria (Schoolnik, 2002), viruses (Gaucher et al., 2008; 
Slobedman, Cheung, 2008; Querec et al., 2008) and malaria (Vahey et al., 2010), 
microarray analysis of whole blood samples has proved useful in identifying disease 
or vaccine associated biomarkers and underlying immune responses. Therefore, whole 





infections. There are some drawbacks to using blood, as RNA isolated from whole 
blood has been associated with increased noise and reduced gene expression levels, 
but it does prevent problematic artefacts caused by cell separation which activates 
cells, and therefore biases the results (Feezor et al., 2004).  
Another issue is that microarrays leads to very high dimensional datasets (i.e. many 
variables are measured), often compounded by a relatively low number of samples, 
which are sometimes allocated to multiple treatment groups (i.e. non-immunised, 
control immunisation vs antigen immunised), a problem termed the "curse of 
dimensionality". Thus, to overcome the low signal to noise ratio and the curse of 
dimensionality, sophisticated analytical approaches are needed. 
Classical statistical methods, typically compare fold changes in gene expression levels 
between genes in treated/infected samples compared to control samples, and a 
threshold level based on the test statistic (P-value) is used to identify genes with a 
significant fold change (differentially expressed genes). This approach is simple, fast, 
and easy to interpret, but faces several constraints when it comes to analysing high 
dimensional data (Table 3.1) (Butte, 2002). 
In high dimensional datasets, the expression of thousands of genes are measured 
simultaneously, this therefore becomes a multiple testing/hypothesis problem, because 
of this, simply selecting a significance of P < 0.05, can result in many false positive 
discoveries. Several solutions have been proposed, but by controlling for the false 
discovery rate, it can cause many false negatives, and many genes that might be 





identify genes that provide a significant amount information in isolation to other genes. 
In reality, the regulation and activation of most functional pathways and networks is 
achieved through small incremental changes. The lack of sensitivity of the “fold 
change” approach combined with considerable variation found in blood derived 
samples reduces the possibility of identifying significant pathways and discriminating 
gene expression profiles (Huynh-Thu et al., 2012).  
An alternative approach such as Weighted Gene Correlation Network Analysis 
(WGCNA) (Langfelder, Horvath, 2008), recognises that gene expression data is more 
complex than a list of differentially expressed genes, and instead considers the 
correlation of genes expression levels across samples. This method uses gene 
correlation networks, which finds highly correlated genes (genes with similar 
expression levels) and groups them into large clusters (co-expression clusters). The 
gene expression patterns can be summarised within a cluster to a “module eigengene” 
(ME), this is a weighed summary of gene expression within a cluster (similar to a 
principal component). If a cluster ME has a particular behaviour, then it is likely most 
of the genes in that particular cluster also have a similar behaviour. This ME is then 
used to measure associations between the clustered genes and the sample traits.  
Although this method has been used extensively and provided insight into 
pathogenesis of autoimmune diseases (Sundarrajan, Arumugam, 2016), neurological 
disorders (Mina, 2016) and cancer (Yepes et al., 2016), it cannot be used to investigate 
the relationship of gene expression in multi-categorical data (such as multiple 





to the analysis of the top 1000-5000 most varying genes or differentially expressed 
genes.  
To obtain maximal information from the high dimensional (greater number of genes 
measured compared to samples), multi-categorical (multiple experimental groups) 
microarray data, which contains complex interaction between genes, biomedical 
research is now increasingly turning to machine learning to identify “informative” 
genes (genes important in infection/vaccination) (Molla et al., 2004). In this study a 
series of publicly available machine learning methods were put together in a “pipeline” 
to identify genes associated with protection either in vaccinated mice or humans living 
in endemic areas. There is no gold-standard methodology for comparative studies in 
machine learning. However, WGCNA, is a popular approach in biomedical sciences 
(Langfelder, Horvath, 2008). Therefore, WGCNA was conducted on a subset of the 
data and results were used to validate results produced by the pipeline. 
Table 3.1. Microarray analysis methods. 
Methods Advantages Disadvantages 
Differential 
fold change 
Simple, fast, and their output is 
easy to interpret. 
Accounting for multiple-testing reduces 
the sensitivity of the test when many 
genes are measured simultaneously 
(such as in high dimensional data) and 
struggles with multi-categorical data, 
therefore, this potentially misses out 
informative genes that have a small 




More robust with complex data 
set and at finding important 
genes within noisy data. 
Cannot deal with high dimensional data 




Good at analysing high 
dimensional, multi-labelled 
microarray data, which 
contains complex interaction 
between genes. 
Can sometimes be complicated to 






• To determine if changes in gene expression can be detected in whole blood, 
collected from mice vaccinated with infective L3 or Mf from L. sigmodontis 
using a machine learning pipeline. 
• To determine if changes in gene expression associated with protection in humans 
exposed to O. volvulus can be measured in whole blood using a machine learning 
pipeline. 
• To determine if mechanisms that are important for protection in mice and 





3.2 Introduction to machine learning concepts 
Machine learning is a branch of computer science that utilises algorithms that “learn” 
from data to build models capable of predicting properties of unknown or new data. 
These can be split into two broad categories, supervised and unsupervised methods 
(Libbrecht, Noble, 2015) (Figure 3.1).  
• Supervised methods are trained on labelled data, with labels equivalent to 
response variables (i.e. experimental group the samples belong to), and then used 
to make predictions on unlabelled data (i.e. new or unknown data). For example, 
when using genomic data, a supervised learning algorithm may build a model on 
a subset of the gene expression data for which sample information is known (i.e. 
experimental group to which it belongs, or whether a patient is or is not infected); 
this is known as the “training” dataset. Then the “trained” model is subsequently 
used to predict the characteristics of the remaining data. 
• Unsupervised methods find internal structure or relationships within the data 
without any prior knowledge of the sample labels. These methods do not try to 
predict the sample label.  
Another categorisation of machine leaning methods which mostly applies to the 
supervised method is based on the type of output data. When the sample labels are 
categorical (i.e. different experimental groups, immunised/non immunised) this 
becomes a classification problem, however when sample labels are continuous (i.e. 
parasite counts) this is then regression. Some approaches are amenable to both 





To find the genes that best differentiate between the samples, depending on their 
experimental group (immunised/non-immunised control) or susceptibility to infection 
in humans (infected/endemic normal), several supervised algorithms exist, each with 




Figure 3.1. Overview of machine learning categorisation. Machine learning can be broadly 
split into two categories supervised and unsupervised algorithms. Supervised algorithms build 
models on samples were the response variable is known, and are often used to predict the 
response of new data. Whereas, unsupervised algorithms find internal structure or relationships 
within the data without any prior knowledge on the sample labels. Supervised algorithms can 
be further classified into classification or regression algorithms, although some supervised 
algorithms can do both regression and classification. Classification is done, when the responses 






Table 3.2. Common classification machine learning methods, used to identify 
differentially expressed genes in microarray data. 
Methods Advantages  Disadvantages 
Naïve Bayes 
(a type of 
Bayesian 
classifier) 
Fast and easy to implement, allows for 
missing values; only requires a small 
training dataset to estimate the 
parameters. 
It assumes variables are independent of 
each other; and highly dimensional data 




Can handle heterogeneous data; works 
well with complex interactions among 
variables (genes), easily interpretable 
results, that are ranked in order of 
importance, can handle missing data. 
Algorithms are unstable, with high bias and 
therefore prone to overfitting. 
Random 
Forest 
Can handle heterogeneous data, works 
well with complex interactions among 
variables (genes), easily interpretable 
results, that are ranked in order of 
importance, performs well with high 
dimensional data, resistant to 
overfitting. 
Does not allow missing data, loses stability 




Robust to noise, performs well with 
small sample size, fast to compute. 
Input variables need to be numerical and 
scaled, works better when there are no 
interactions between variables, sensitive to 
parameter choice, output of model is not 
easily interpretable. 
K – nearest 
neighbours 
Simple model to build, you do not 
need to have any prior knowledge of 
the data. 
Severely affected by noisy or irrelevant 
variables, sensitive to parameter choice, 
there are large variations in prediction 
performance every time the model is run, it 




Can be used to model complex 
relationships between inputs and 
outputs and find patterns in data, can 
handle noisy data. 
Input variables need to be numerical and 
scaled; output of model is not easily 






3.2.1 Generalisation error 
Machine learning works by building a model on a subset of the data available, this is 
called the “training” dataset, and the remaining data is used to evaluate the model, and 
this is termed the “testing” dataset. One of the main considerations when building the 
“learning” algorithm is how generalisable the model is, in other words how good is the 
learned model at predicting unknown data (Haury et al., 2011). 
• Generalisation error – is a measure of how accurately a model can predict the 
labels (response variable) of new data or previously unseen data, such as which 
treatment group the samples belong to. 
For example, if gene expression is to be used to predict the vaccine efficacy in patients, 
a model would be built on a training dataset, in which the vaccine efficacy in patients 
is known (i.e. whether the vaccine successfully induced protection). The model is then 
used to predict vaccine efficacy in new patients (the testing set), and the difference 
between what the model predicts and reality, is the generalisation error. Therefore, a 
model with low generalisation error would be good at predicting vaccine efficacy in 
new patients.  
Having a low generalisation error in classification means that the model is good at 
classifying new samples into their correct experimental group, it is simply a measure 
of how good the model is, and this can be used to compare different machine learning 





3.2.2 Variance and bias trade-off 
The generalisation error contains two sources of error, bias and variance. There is an 
inherent trade-off between bias and variance, and they prevent supervised learning 
methods to be used beyond their original training dataset.  
• Bias - The error between what the model predicts and what the outcome is, 
therefore high bias, suggests that the model is too simplistic and is missing the 
relevant relationships between variables (genes) and sample outcomes (vaccine 
efficacy).  
• Variance – Applies to the stability of the model in the face of “noise”. If the 
model is built again on a different subset of the data, would the model produce 
the same outcome? If the model has high variance, then the model is fitting 
(being built) on the noise in the data and not finding the underlying relationship 
between the variables (genes), this is termed overfitting.  
Since there is a trade-off between variance and bias, it is not always easy to minimise 
both simultaneously, however there are certain concepts / techniques that are utilised 
by machine learning methods, to minimise these errors. 
3.2.3 Techniques used to improve bias and variance errors 
There are some techniques that can be used to improve bias and variance, such as: 
• Dimensionality reduction – This reduces the number of variables (genes) the 





et al., 2015). If the number of variables (which in machine learning terminology 
are called features, and in context of this study are genes), are much larger than 
the number of samples this gives a highly dimensional dataset, and some models 
are better at handling this than others. If the dataset is too highly dimensional, a 
step can be added to identify variables of importance and discard the unwanted 
variables, which creates a lower dimensional space on which to run the 
supervised learning algorithm. Alternatively, variables can be grouped together 
and transformed or summarised into a new feature, therefore reducing the total 
number of variables (genes).  
• Ensemble of learning algorithms – This consists of using the same learning 
algorithm multiple times on the same dataset or subset thereof, the principle is 
to combine a group of “weak learners” to form a “strong learner” (Dietterich, 
2000). There are different ways of doing this, with the most common methods 
being: 
I. Bagging (portmanteau of “bootstrap aggregating”), this is when a 
machine learning model is built on a random subset of the data, drawn 
with replacement from the original dataset. This is repeated multiple 
times, with each time a new subset of data drawn. This produces a series 
of weak models that are combined to boost performance. Bagging 






II.  Boosting, in the current context, uses a series of a “weak” learners, or 
model, which are weighted according to their performance and 
combined into a strong learner to boost their performance. The 
difference with bagging is that the subset selection is not random and 
depends on the performance of the previous models. Boosting tends to 
improve the accuracy (bias) of the model, but it is prone to overfitting1. 
• Inbuilt parameters – Learning algorithms also have tuneable parameters that 
control bias and variance  
3.2.4 Characteristics of the data to consider 
Different machine learning methods exist, and some are better suited to certain 
datasets, therefore there are several considerations to make before choosing an 
algorithm, such as: 
• Does the data contain lots of noise (irrelevant genes)? – In the case of this study, 
whole blood was used to measure changes in gene expression data, and may 
contain a lot of noise, therefore choosing an algorithm with high accuracy and 
low stability is preferred.  
• Does the data contain variables of the same type (count / continuous / discrete 
data)? – Some algorithms will work better if only one data type is present, 
                                                






whereas some have no issue using different types. In this study, only gene 
expression data will be investigated so this problem does not arise, although it 
could become an issue if non-continuous variables/factors are added to the 
analysis. 
• Are there interactions between the variables or are they independent? – Genes 
are known to interact and regulate each other, and therefore have complex 
interactions, therefore algorithms such as decision trees, random forest and 






3.3 Methods in Machine Learning commonly used for 
microarray data analysis 
For microarray data, machine learning techniques such as Bayesian classifiers, 
Decision Trees, Random Forest (RF), Support Vector Machines (SVM) and Artificial 
Neural Network (ANN) have extensively been compared to one another (Pirooznia et 
al., 2008; Swan et al., 2013; Hemphill et al., 2014; Karimpour-Fard et al., 2015). When 
considering which algorithm to use the issues mentioned above need to be considered, 
as microarrays are notoriously highly dimensional (large number of genes), small 
numbers of samples, contain uninformative genes with regards to the processes of 
interest, and genes not only interact with each other but their expression is often 
correlated. 
A few different machine learning algorithms have been applied to microarray data, 
with the most popular being SVM and RF, which have been used or modified for a 
wide variety of tasks from identifying cancer subtypes (Anaissi et al., 2013) to 
predicting patients responses to treatments (Gim et al., 2016). 
3.3.1 Support Vector Machine 
Support Vector Machines (SVM) is a machine learning method used for both 
classification and regression tasks, and was first conceived by Cortes and Vapnik 
(Cortes, Vapnik, 1995). The simplest type of SVM, tries to draw a straight line 
(hyperplane) that best separates the data, so that data points belonging to one 
group/category are on one side of the line, and the data points in another category are 





how close they are to the line drawn, and these weights can be used to compute a 
variable ranking score.  
 
Figure 3.2. Schematic representation of Support Vector Machine in two dimensions. 
SVM is a supervised learning methods that draws a line (line in 2D, plane in 3D and hyperplane 
in higher dimensions) that separate two classes (red / blue data points). In theory, infinite 
numbers of lines could be drawn to separate the data, but SVM calculates the straight line that 
best separates the two classes of points with largest distance to the nearest data points 
(maximum margin). In other words, SVM draws an optimal line perfectly in the middle of two 
classes, so that points in the red class are on one side of the line and the points in the blue class 
are on the other side of the line. When the two classes of the data are not linearly separable, 
the points are projected into a higher dimensional space where linear separation may be 
possible. Support vectors are the data points that lie closest to the line (filled red and blue 
circles). Because these are the most difficult points to classify, these are important for 






3.3.1.1 SVM with Recursive Feature Elimination 
Guyon et al modified SVM, by using it in a backward elimination procedure for gene 
selection (Guyon et al., 2002). For this, a SVM is initially fitted on all the genes in the 
dataset, this assigns a weight to the variables (genes) which is used to compute a gene 
coefficient, that can be ranked so that genes with the smallest coefficients are 
eliminated. Then a new SVM is built on the remaining genes, and a new gene 
coefficient is calculated and again the genes with smallest coefficients are removed, 
this is repeated until a final number of genes are met. The number of genes to remove 
at each iteration, and the final number of gene to retain, are the set of parameters that 
can be optimised to get an accurate final classifier. 
Removing variables (genes) each time a SVM model is built is termed recursive 
feature elimination (RFE). Support vector machine with recursive feature elimination 
(SVM-RFE) was initially created for cancer classification using gene expression data 
(Guyon et al., 2002), and is continuously being improved, such as using an ensemble 
approach (multiple SVM-RFE built), which uses subsamples of the original data to 
create multiple SVM-RFE (Duan et al., 2005).  
A limitation of SVM-RFE is that it can only handle binary classification. Therefore, to 
extend the application of SVM-RFE to multi-class (i.e. multiple treatment groups) 
problems Zhang et al (2015) proposed that a multi-class dataset could be split into 
multiple binary problems (one versus all method). These models were applied to 





compared to other SVM-RFE methods (Zhang, Xiaojuan Huang, 2015). However, like 
most of these algorithms they are not easily incorporated into statistical software. 
3.3.2 Random Forest 
Random forest (RF) is a robust classification algorithms (Breiman, 2001), and has 
many characteristics that makes it well suited for gene expression data (Chen, 
Ishwaran, 2012): 
• it is well adapted to handle high dimensional data that can often be noisy, 
•  it can accommodate categorical (classification) and continuous (regression) 
data, 
• it handles imbalanced multiclass data, 
• it is less prone to overfitting compared to other machine learning techniques,  
• it has a fewer parameters to fine-tune making it easier to optimise, 
• it provides measures of feature (gene) importance.  
For classification problems, RF has been extensively compared to other machine 
learning algorithms on microarray datasets, and has been found to be the most efficient 
method on the datasets that were tested (Lee et al., 2005; Díaz-Uriarte, Alvarez de 
Andrés, 2006; McKinney et al., 2006; Heidema et al., 2006; Jeong, Soni, 2015).  
RF is an ensemble of classification trees (decision trees), which uses different subsets 





bagging2 technique, each tree is independently built using a bootstrap sample of the 
data (subsample of the dataset which is replaced after being used to fit a tree), each 
tree is recorded and combined at the end. 
The goal of a decision tree, is to create a model that can predict the value of unknown 
variables (classify new samples), based on the input variables. For example, can the 
experimental group of samples be predicted based on their gene expression? 
Decision trees start with a parent node, these are then split into two daughter nodes in 
a recursive way (i.e. the daughter node in turn becomes parent node, and is 
subsequently split into two daughter nodes) (Figure 3.3). At the parent node, the 
decision tree algorithm chooses the variables at that level, that best separates the data 
into “pure” classes, i.e. the gene that best separates the samples into either immunised 
or non-immunised mice. For example, if gene A is found by the algorithm to be the 
most discriminative gene, this means that if gene A has an expression over defined 
level (x), those samples are associated with immunised mice, whereas an expression 
level below x, that sample will be more likely to be from non-immunised mice. 
At each parent node, the algorithm searches for a variable (present at that node) that 
best separates the data, this process is applied to each parent node, and as the tree grows 
less and less variables (gene) are present, till either a homogenous tree (where samples 
                                                
2 Bagging – Bootstrap aggregating, when classifiers are built on different subsets of 
the dataset, each subset is replaced after classifier is built, by sampling with 





cannot be split anymore as they all belong to one treatment group) or non-homogenous 
terminal (the end of the tree is reached and no more genes are left to split) (Figure 3.3). 
 
Figure 3.3. Decision Tree. The diagram represents an example of a decision tree using gene 
expression data. Decision trees work by finding genes that best discriminate between the 
experimental groups, in the example above, immunised or non-immunised. At each node of 
the tree (rectangles), the algorithms finds the gene which is the best at splitting samples into 
experimental treatment groups. The node at which the split is happening is termed the parent 
node, at the this point the data separated into two sister nodes depending on the expression 
level. For example, “gene A” is chosen by the algorithm to be best gene at splitting the data 
into experimental groups, and splits the samples into two daughter nodes depending on 
expression level of “gene A”, i.e. samples, in which “gene A” has an expression level above 
splitting criteria (x) will go to one sister node, and the samples with expression levels of “gene 
A” below the splitting criteria will go to the other sister node. These sister nodes then in turn 
become parent nodes, and the algorithm then finds another gene that best splits the data, this 
happens recursively until the tree is fully grown, either till perfect classification is reach, so 
when all the samples in that node belong to one treatment group (full circles) or till there is no 
more gene to split the data (semi-circles and represent the percentage of predicted treatment). 





3.3.2.1 Optimising random forest parameters 
Random forest has two main parameters to optimise:  
• The number of trees to construct – RF uses bootstrap aggregation (sampling 
with replacement) to sub-sample the dataset and trees are grown from those sub-
samples. This allows RF to construct multiple trees on different samples of the 
dataset, therefore the optimal number of trees to grow (subsamples to take from 
the dataset) needs to be optimised, as this can affect the model accuracy.  
• The number of variables to consider when splitting a node – RF selects the 
variable that best splits the node, from a random subset of variables, compared 
to other decision trees that look at all variables when considering the split. 
Therefore, the number of random variables to consider when looking for the best 
split is the second parameter that needs to be optimised. This allows random 
forest to build many trees with low correlation (unlikely to comprise identical 
trees). For example, if one or a few genes are strong predictors of the response 
variable, these gene will be selected in many trees, causing many of the trees in 
a random forest to look alike (correlated), and this will affect the accuracy and 
stability of the model. 
To achieve a RF model with the lowest generalisation error, the two parameters 
mentioned above need to be optimised. To do this, RF has an internal estimation of 





• The OOB score – is calculated for each tree grown, by setting aside one third of 
the samples before building the tree, this becomes the OOB data. The OOB data 
is then used to measure the accuracy of the tree built. The OOB score is 
calculated for each tree constructed, and then averaged to become the OOB error 
score for the random forest.  
To optimise the RF model, a procedure called k-fold cross-validation is used. This 
builds a random forest on a percentage of the data using different combinations of 
parameters, and for each combination the model is evaluating itself using the samples 
that were left out when building the model, this avoids the risk of overfitting. The best 
practice is to use k=10 (10-fold cross-validation), this means that 10 RF models are 
built on each combination of parameters, the OOB error score for the 10 RF models 
are calculated and then averaged out. This is repeated for each combination of 
parameters, and the combination of parameters that gives the lowest OOB score are 
then used to train a final RF classifier. 
3.3.2.2 RF ability to rank variables in order of importance 
Advantages of RF over other supervised methods is that it provides a measure of 
variable importance (gene importance in our case). For classification problems, RF 
computes a measure of variable importance, by calculating a mean decrease in Gini 
for each variable, which can then be ranked, to find which variables (genes) are the 





• Mean decrease in Gini – A measure of how each variable (gene) contributes to 
the homogeneity of the nodes (if nodes contain the majority of the samples of 
one experimental group).  
For example, if a variable is important, it will split the data, which has samples 
belonging to different experimental groups, into pure samples groups (all coming from 
the same experimental group). Therefore, each time a variable (gene) is used to split a 
node, the Gini coefficient for the child node is calculated (based on how pure the node 
is) and compared to that of the parent node, giving a decrease in Gini value for that 
variable.  
Since random forest builds many trees and variables can be used in more than one tree, 
the decrease in Gini coefficient for each variable is calculated across all trees and 
averaged out, giving the mean decrease in Gini for that variable. The greater the mean 
decrease in Gini is, the more important the variable (Breiman, 2001). 
3.3.2.3 RF issues with stability 
Because of the intrinsic randomness of random forest, there can be instability in the 
variable importance ranking (Somorjai et al., 2003; Michiels et al., 2005; Kursa, 2014; 
Wang et al., 2016). That is, in repeated runs of RF on the same data using the same 
parameters, there can be a different order of variable importance ranking. The issue of 
stability in importance rankings is increasingly receiving attention. Strobl et al (2008) 
showed that instability in variable ranking in RF was due to highly correlated variables, 





3.3.2.4 Dealing with correlated variables 
Due to the nature of gene expression data, it is very likely that there are many correlated 
genes. There are a several ways to deal with correlated variables, such as: increasing 
the number of trees grown (Haury et al., 2011); grouping correlated genes together 
(clustering) (Tolosi, Lengauer, 2011); or backward elimination strategies such as 
recursive feature elimination (removing the least important variables every time a 
model is build) based on the rankings of the variables in the previous RF models.  
Adding a recursive feature elimination (RFE) to random forest works by first fitting 
an RF model to the whole training dataset; this model ranks variables in order of 
importance. A defined percentage of variables with the lowest rankings are removed. 
A new RF model is built on the remaining variables and the ranking of the new set of 
variables are re-calculated, and again a percentage of variables with the lowest ranking 
are removed. This is repeated till the set of variables that gives the smallest OOB error 
rate are left (Díaz-Uriarte, Alvarez de Andrés, 2006; Genuer et al., 2010).  
This method of recursive feature elimination combined with random forest when tested 
on correlated datasets was found to reduce the effect of correlation on the variable 
importance measure and produces stable models (same rankings were obtained if 





3.3.3 Performance metrics 
To measure the stability of the variable selection and to evaluate the accuracy3 of the 
classification models built, several metrics can be used.  
3.3.3.1 Accuracy measures 
A common approach of evaluating the performance of classification models, 
sometimes referred to as model accuracy, is to use cross-validation (Kohavi, 1995). In 
cross validation, a percentage of the samples are held out and the classifier is built on 
the remaining data. The classifier is then used to predict the labels (experimental 
group/response variable) of the held-out data. If the predicted labels match the true set 
of labels then the accuracy is 1. This is repeated multiple times and the average 
accuracy score is given.  
A simple way of representing this is using a confusion matrix. Figure 3.5 shows an 
example of a confusion matrix for a multiclass problem (more than two experimental 
groups). It shows the number of samples that the model accurately predicted per label. 
Since there is more than one label involved, the overall accuracy is the fraction of 
correctly classified samples over the total numbers of predictions.  
If the datasets are unbalanced (not equal numbers of samples in each experimental 
group), it can lead to misleading results, therefore other metrics such as precision and 
                                                





recall are used. For multiclass problems precision and recall are computed for each of 
the class labels and averaged out. 
• Precision – Measures how accurate the classification model is at predicting each 
class (experimental groups), in a new dataset (Figure 3.4). 
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• Recall – Measures how good the classifier is at finding all the correct labels per 
class (experimental group). This is the same as sensitivity (Figure 3.4). 
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For example, if a model produced both high precision and recall, this would mean that 
the model has accurate predictions (precision) and is also good at finding all the 
samples that belong to that class (recall). A model with high precision and low recall, 
means the model predicts few results per class but most of them are accurate 
predictions. Low precision and high recall is the opposite; the model produces lots of 
predictions per class but a lot of them are incorrect. Ideally both high precision and 






Figure 3.4. Precision and recall. Precision is the fraction of predicted points that are correct 
among all the predicted outcomes. Whereas recall (also called sensitivity), is the fraction of 
correct points that were predicted over the total number of correct points. Precision is true 








Figure 3.5 Confusion Matrix. This confusion matrix was constructed from a RF model built 
on a dataset from this study. An RF model was built on a subset of the data (training data), and 
then used to predict the samples labels from remaining data (test data - not used to build the 
model). In this case, there were 6 samples in the test dataset belong to the experimental groups 
(Labels): Immunised, Naïve or Mock. These were then compared with the labels the RF model 
predicted. In this example, the model was able to accurately identify two out of three samples 
as belonging to immunised mice (the third was misclassified as mock). The model also 
correctly identified a naïve mice, second sample was misclassified as immunised. The model 
was unable to predict any of the mock samples. Precision and recall is also calculated to 
evaluate Machine Learning models, and when models are built on multi-class problems 
(multiple experimental groups), precision and recall is calculated for each experiment group 
and a mean is calculated. In the confusion matrix above, for the immunised group precision 
was defined by the ratio of predicted samples to known immunised samples. In example above, 
2 samples were correctly predicted out of 4 predictions. Recall was defined as the fraction of 
immunised samples it can retrieve and in this example, 2 immunised samples were identified 





3.3.3.2 Stability measures 
The stability of the model is measured as the robustness of variable rankings, that is 
produced by the classification model over repeated runs (can also be called variance). 
Measuring stability requires a similarity measure, for this the Jaccard index was used 
(Wang, 2015; Wang et al., 2016) to evaluate stability of the top ranked variables over 
repeated run, the closer the index is to 1 the more similar the gene rankings are between 
each other. 
3.4  Machine Learning Pipeline for Gene Selection 
Despite some of the drawbacks RF faces when dealing with microarray data, it remains 
one of the most robust classification algorithms available. Therefore, a gene selection 
“pipeline” was put together using publicly available machine learning algorithms 
including RF, to identify genes that explain the differences seen in protection in 
vaccinated mice and humans living in endemic areas, from microarray data obtained 
from blood samples. Before the Machine Learning (ML) pipeline can be applied, the 
raw gene expression data from the Illumina microarrays were pre-processed to account 
for the variability that arises from microarray processing, such as RNA hybridisation 
to plates, scanning and image analysis (details in section 3.5.5). This pipeline combines 
a clustering algorithm with multiple RF classifications to identify genes of interest, 
and consists of 4 steps (Figure 3.6):  
• Step 1: Dimensionality reduction - The first step uses a clustering method, to group 





expressions within those gene clusters are summarised (mean expression). This was 
done for two purposes:  
I. To remove noisy genes. This is on the assumption that genes which 
are functionally relevant and work together are more likely to have 
similar expression levels and therefore cluster together (Heyer et al., 
1999). The advantage of the clustering method used in this pipeline, 
over others is that it does not force all data points into a cluster and 
some genes remain unclustered. For this study, the unclustered genes 
are deemed as noise; these genes might be part of an activated 
pathway but the clustering algorithm is unable to detect it.  
II. Clustering is used for dimensionality reduction. This is when the 
original data is summarised into a smaller dimension (smaller 
numbers of genes), by reducing all the genes within a cluster to a 
single variable, this results in a smaller set of uncorrelated variables 
(genes). This dimensionality reduction is a necessary step since 
microarray data is highly dimensional (more genes compared to 
samples), and therefore reducing the dimensionality of the data helps 
improve the stability and accuracy of the subsequent classifier.  
• Step 2: Random forest for feature selection (RF-FS) – This next step of the 
pipeline, which is known as feature selection, involves the use of random forest 
(RF), as a classifier to rank the summarised gene clusters in order of importance, 
according to which gene cluster best classified the data into experimental groups 





iterations and the gene clusters that are consistently top-ranked over the 10 
iterations are deemed the most informative gene clusters. 
• Step 3: Random forest for quality control of gene selection (RF-QC) – The 
top ranked gene clusters are then used to build a second set of RF models, this is 
to see if these gene clusters can accurately predict the experimental groups the 
samples came from (i.e. if they came from immunised or non-immunised mice / 
whether they were from naturally protected or infected humans). 
• Step 4: Functional analysis – The genes that belong to the top gene clusters, 
are then subsequently used in a pathway enrichment analysis to identify what 








Figure 3.6 Machine Learning (ML) Pipeline for Gene Selection. The input data for the 
pipeline was pre-processed Illumina microarray data, the pre-processing involved background 
correction, between-array quantile normalisation and log2 transformation (see pre-processing 





a density-based algorithm called HDBSCAN, it finds genes that have similar gene expression 
levels and groups them together, but does not force all points into a cluster, and therefore some 
genes remain unclustered. The gene clusters are summarised by calculating the average (the 
mean) expression of the genes within that cluster, this forms a new variable that is piped to the 
next step. Step 2, is termed the feature selection step, as informative features (variables and in 
this case gene clusters) are detected. This step uses Random Forest to rank the gene cluster, on 
how good they are at classifying the samples into the different experimental groups 
(immunised group / infection status). There are four parts to selecting the gene clusters: 1) 
when building a RF model two parameters need to be optimised, this was done by building 
models with different combinations of parameters, and the pair of parameters that gave the 
highest accuracy score was chosen. 2) Then a RF classifier was built with the gene clusters 
using the best set of parameters. 3) The optimised RF ranks the gene clusters in order of 
importance, and the ranking is saved. Step 1-3 are then repeated 10 times (this is because RF 
can be unstable in ranking variables). 4) The gene clusters that were consistently ranked in the 
top 20% over the 10 iteration, were chosen as the most informative gene clusters. Step 3 in the 
pipeline, involved doing a quality check on the gene clusters chosen in step 2 as being 
informative, for this a second set of RF classifier are built using only the informative gene 
clusters. The accuracy of the models are measured, to see if indeed they are good at classifying 
the samples into their experimental group. Step 4, once the gene clusters have passed the 
quality check, the genes within the clusters are extracted, and functional analysis performed 
on them to find their function or what pathways they belonged to. 
3.4.1 Step 1: Dimensionality reduction 
For dimensionality reduction, a density based clustering algorithm called Hierarchical 
Density-Based Spatial Clustering Applications with Noise (HDBSCAN) was used. 
HDBSCAN was developed by Campello, Moulavi, Zimek and Sander (2013) by 
improving the density based clustering algorithm DBSCAN, to allow the identification 





HDBSCAN works by finding density-connected regions (densely connected genes) in 
the data, which are then defined as clusters, whereas points that do not belong to any 
density-connected regions are labelled as noise (Figure 3.8). 
Advantages of HDBSCAN are that: 
• It does not force all data points (genes) into a cluster, unlike other clustering 
algorithms, such as K-means, which does. 
•  It can find clusters of varying densities, unlike the original density based 
clustering (DBSCAN) algorithm. 
• It is more robust to parameter selection, since it only requires one input 
parameter to be fine-tuned, minimum cluster size which is the minimum number 
of samples in that group to be considered a cluster, any groups smaller then this 
will be considered noise. 
• It is stable, producing the same clusters when the algorithm is used again. 
•  HDBSCAN was implemented into a python package by Leland McInnes, 
making it simple to apply to the data (McInnes, 2015). 
Before clustering could be applied, the data was standardised by removing the mean 
and scaling to unit variance. In practice this means that each gene measured, had a 
mean of 0 and a variance of 1.  
HDBSCAN has one parameter that needs to be selected, this is the minimum cluster 





a cluster. Normally, when the minimum cluster size increases, the number of clusters 
identified by HDSCAN decreases (Figure 3.7.A). However, this was not the case in 
some of the datasets used in this study and no uniform decrease in cluster numbers 
were observed when the minimum cluster size is increased, possibly due to small 
sample size. However, when several datasets were merged (increasing the sample 
size), HDBSCAN produced a constant decrease in cluster numbers as the minimum 
cluster size increased. Therefore, for the purpose of this study the minimum cluster 
size, was chosen as the smallest number, which produced the largest number of 
clusters, for example in Figure 3.7.B, minimum cluster size was chosen as 4, as this 








Figure 3.7 Selecting minimum cluster size for HDBSCAN clustering. Minimum cluster size 
is the parameter that needs to be chosen, for HDBSCAN clustering. Minimum cluster size is 
the minimum number of samples that are needed to consider a group of samples as a cluster. 
A) HDBSCAN clustering over a range of minimum cluster size (min_clust_size: 3-20), on a 
dataset with 66 samples (this is from merging samples from different time points in an 
immunisation time course), this produced a constant decrease in number of clusters produced. 
B) Whereas when HDBSCAN was applied to a single time point in the immunisation time 
course, with 21 samples (all time points in the mice immunisation time course had samples 
ranging from 20-24 samples), there was not a constant decrease in numbers of clusters 
produced. Therefore, for the purpose of this study, the minimum cluster size was chosen as the 
smallest number that produced the greatest number of clusters. For example in B), a minimum 





HDBSCAN assigns a number to each gene according to which cluster it belongs to, 
and assigns a -1 to genes that are unclustered (noise) (Figure 3.8). Once genes have 
been clustered, the expression of genes within a cluster can be summarised (one new 
data point is created for that cluster, instead of multiple genes), so that the 
dimensionality (number of genes) can be reduced. Therefore, for each cluster (genes 
labelled ≥ 0), the mean expression of the genes within that cluster was calculated, this 
groups correlated genes together to form a smaller set of gene clusters. Genes that were 
not clustered, were removed from the analysis.  
 
 
Figure 3.8. HDBSCAN clustering. A representation of HDBSCAN clustering. For simplicity 
only two dimensions (2 samples) are shown, but in reality there are multiple dimensions (equal 
to the number of samples). Each point represents a scaled gene, the colours represent different 
clusters and the grey points are the unclustered genes (noise) that are filtered out using 
HDBSCAN. As this is a multi-dimensional dataset, it is difficult to differentiate between the 




3.4.2 Step 2: Random forest for feature selection (RF-FS) 
Random forest was used for feature selection, this means that random forest was used 
to find the gene clusters (produced by HDBSCAN), that best describes the difference 
between the experimental groups. For this, the summarised gene clusters were used to 
build a RF model, which then ranks them in order of importance, on how good they 
were at differentiating between the different labels (experimental groups). Because 
random forest struggles with stability in variable ranking, 10 random forest models 
were built, and the genes constantly ranked in the top 20% across the 10 iterations were 
chosen as being informative. The process of feature selection (gene selection) using 
random forest consist of five steps. 
1) Optimisation of the random forest classifier parameters – Random forest has 
two parameters that needs to be optimised, the number of trees grown from a subset 
(bootstrapped sample) of the data (n_estimators parameter in Scikit-learn, Python, 
(Pedregosa et al., 2011)) and the number of variables to consider when looking for 
the best split of a node (max_features parameter in Scikit-learn), RF does not look 
at all samples at a node to split the data like with decision trees. A range of values 
were chosen for each parameter and different combinations were tested out using a 
method called cross-validation, which trains a RF model on 80% of the samples and 
the remaining 20% are used to validate the model. In python there is a function called 
Stratified_Shuffle_Split (Scikit-learn, Python), which facilitates cross-validation and 
ensuring that there is at least one sample from each experimental group in the 
validation (test) dataset. To ensure that each sample is present in the validation set 





combination of parameters that gave the highest OOB_score scores (i.e. gives the 
most generalisable model), were chosen and used to train the RF classifier. 
• n_estimators parameter – The number of trees grown were chosen 
from a range of 1000-2000, even though Figure 3.9 shows that the 
number trees grown after 500 has no effect on the accuracy of the 
model (OOB score), but the greater the number of trees the better the 
stability of feature ranking (Genuer et al., 2010; Haury et al., 2011).  
• max_features parameter – The number of variables to consider when 
looking for the best split was either the square root of all the features 
(variables/ genes), 10%, or 40% of all the features.  
2) Fitting random forest model to the data using the optimised parameters – A 
random forest model was built on the data using the parameters optimised in step 1. 
Similar to the optimisation step, the accuracy of the RF model (built with the 
optimised parameter), was measured using 10-fold cross-validation. For this 20% of 
the data was held out when building the RF model, and then used to measure how 
accurate the model was at predicting the held-out data. 
3) Ranking variables (genes clusters) – The RF model ranks the gene clusters in 
order of importance using the Gini index. Although other metrics can be used, the 
Gini index was chosen because it is less affected by correlated data than other 
importance measures (Strobl et al., 2008). The Gini index is prone to give higher 





a concern, as the data in this study are all gene expression data and are therefore 
continuous data. 
4) Selecting the top ranked gene clusters – Random forest can suffer from instability 
when ranking variables in order of importance, especially if these variables are 
correlated. Therefore, step 1 to 3 were repeated 10 times, and the gene clusters that 
were consistently ranked in the top 20% of the 10 iterations, were considered as the 
informative gene clusters. Twenty percent was used as the cut-off value, for two 
reasons: 
• The top 20% ranked gene clusters over the ten iterations gave a high 
stability index across the datasets.  
• The number of genes that belonged to those gene clusters were enough 
to perform pathway analysis.  
5) Measuring accuracy and stability of the random forest models built for feature 
selection – The accuracy, precision and recall of the RF models built on gene 
clusters, were measured for each of the 10 RF models and the averages out, the closer 
the values were to 1, the more accurate the models were. Stability was measured 
using the Jaccard index, which quantifies how similar the ranking of the gene 
clusters were in the top 20% rankings. The closer the Jaccard index was to 1, the 







Figure 3.9 OOB_score cross-validation. In RF models, there are two parameters that are 
important to optimise. The OOB_score is used to choose the best set of parameters, and the 
closer the value is to 1, the more accurate the model build using that set of parameter. Above 
is an example of how the OOB_score changes for varying values of: n_estimators, which the 
number of trees to grown from each bootstrap subsamples of the data; and max_features, which 
is the number of variables to consider when looking for the best split of a node. Random Forest 
models were built using range of n_estimators (2-2000) with either the square root, 10%, or 
40% of the variables as the max_features value. In the machine learning pipeline n_estimators 
was chosen from a range of 1000-2000, although this range is higher than required according 
to the graph above, a higher value for n_estimators provides a more stable feature ranking. 
3.4.3 Step 3: Random forest for quality control of gene 
selection (RF-QC) 
This section of the pipeline was used to evaluate the accuracy (quality) of the gene 
clusters selected by the random forest above. This was done by measuring the gene 
clusters ability to differentiate the samples by experimental group (in mice models) or 
parasitological presentation (in human data), by building a second round of random 
forest models, only using the informative gene clusters (top 20% gene clusters). This 





the model can be built. The accuracy, precision and recall was measured for this second 
random forest used for quality control (RF-QC). This was done to verify that the gene 
clusters were indeed good at predicting the experimental groups from which they were 
derived. It is also another way of confirming that the selected genes are important in 
relation to immunisation (mouse studies) or infection (in human datasets).  
3.4.4 Step 4: Functional and pathway analysis  
Once the gene clusters were identified as “important”, using the second round of RF 
models, the genes within these clusters were analysed. To do this functional pathway 
analysis was conducted, using in clusterProfiler (Yu et al., 2012) in R. This finds the 
biological functions and pathways that are over-represented in a list of genes.  
Two databases were used to identify the over-represented pathways or biological 
functions: 
•  The Gene Ontology (GO) project – To categorise genes based on their 
Biological Processes (BP) (Ashburner et al., 2000). 
• The Reactome database – To find pathways and larger processes the genes 
belong to (Croft et al., 2011).  
The degree of over-representation was calculated using cumulative hypergeometric 
distributions, which is the probability of finding genes belonging to a functional GO 
category or Reactome pathway within the gene list. A P-value was calculated for each 
of the pathway or processes using the Benjamini-Hochberg method to correct for 





chosen as an adjusted P-value ³0.05. Furthermore, at least five genes from the input 
list were needed for a term or pathway to be classified as over-represented, and the 
reference background was all the genes present on the microarray. The comparison 






To investigate and compare human and murine protective immune responses to filarial 
infections, the machine learning pipeline was applied to four microarray datasets 
collected by E PIAF4 partners.  
Two of these datasets were created from the mouse model of human filarial infection, 
Litomosoides sigmodontis in BALB/c mice. Protective immunity in this model can be 
achieved through vaccination by inoculating mice with either irradiated infective 
larvae (L3) (Le Goff et al., 2000) or microfilariae (Ziewer et al., 2012).  
The other two datasets are from human samples, these were collected in Ghana, in foci 
where either onchocerciasis (O. volvulus) or lymphatic filariasis (Wuchereria 
bancrofti) is endemic. Within these populations, a small percentage of individuals are 
naturally protected showing no signs of infection (no pathology, parasites nor 
circulating filarial antigen) even though they are constantly exposed, these individuals 
are termed endemic normal (EN). To make a fair comparison between mice and human 
responses whole blood was chosen instead of measuring responses in specific tissues. 
3.5.1 L3 Vaccination dataset 
To investigate the changes induced by immunisation with L. sigmodontis infective L3, 
mice were split into four groups of 6. Three of these groups were immunised with 
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either: infective L. sigmodontis L3 (Unirradiated); irradiated L. sigmodontis L3 
(Irradiated); or a mock dose of RPMI 1640 (Gibco) (Mock). The immunisations 
occurred 28, 21 and 14 days before the challenge inoculation with infective L3 (non-
irradiated). The last group was left as the naïve control (no immunisation nor 
challenge). For each mouse whole blood samples were collected: 6 hours after the 1stt 
immunisation, 6 hours after the challenge and 10 days after the challenge (Figure 3.10). 
Day 10 was chosen as the end point of this experiment because most of the parasite 
killing happens within two days of challenge. This vaccination targets the incoming 
L3 mostly at the site of inoculation, and protection is achieved because less L3 are 
reach the pleural cavity, therefore less maturing to adults compared to non-vaccinated 
controls. Therefore, to minimise cost the experiment was stopped at day 10 which is 
enough time to see any changes in gene expression. 
The blood samples and RNA extractions were done by E PIAF partners, Dr Sabine 
Specht (University Hospital Bonn, Germany and Institute of Laboratory Animal 
Science, Vetsuisse Faculty, University of Zurich, Switzerland) and Dr Coralie Martin 
(Museum National d’Histoire Naturelle, France). All experimental procedures: 
labelling, array hybridization to Illumina MouseWG-6 BeadChip arrays 
(MouseWG6_V2_0_R3_11278593_A, Illumina) and array scanning was performed 
by Fios Genomics, Edinburgh. Fios Genomics also conducted the quality control of 
the arrays, for which 4 samples failed QC control. In addition, a 5th sample was found 
to incompletely hybridise to the array, and a 6th sample was missing altogether. As a 





Initial analysis of the data, showed that the RF pipeline could not distinguish between 
irradiated and unirradiated groups, a closer look at the parasite survival at day 10 post 
challenge shows very little differences in parasite burden between these two groups 
(Figure 3.11A). Therefore, the two L3 immunised groups were merged as one and 
named “Immunised”. The new immunised group had a lower parasite burden 
compared to the control immunisation (Figure 3.11), demonstrating that immunisation 
with L3 induces protection in these datasets. Table 3.3 summarises the characteristics 
of the L3 immunisation dataset taken forward for analysis. 
 
Figure 3.10 L3 immunisation time course. 24 BALB/c mice were split into four groups, 
three of these groups received subcutaneous immunisation of either: 40 infective L. 
sigmodontis L3 (Unirradiated); 40 irradiated L. sigmodontis L3 (Irradiated); or a mock dose of 
RPMI 1640 (Gibco) (Mock). The immunisations occurred at 28, 21 and 14 days before a 
challenge inoculation of 40 L3. The remaining group was the naïve control, which received no 
immunisation nor challenge.  For every mouse in the immunisation time course whole blood 
was collected: 6 hours after the 1st immunisation (Day -28), 6 hours after the challenge (Day 






Figure 3.11 L4 Worm Counts. A) Shows L. sigmodontis L4 number in the pleural cavity at 
day 10 post challenge of mice either immunised with Irradiated L3, Unirradiated L3 or a Mock 
immunisation with RPMI. Naïve mice were never challenged or immunised, therefore have no 
parasite burden. B) Shows the L. sigmodontis L4 number when the Irradiated and Unirradiated 
treatment group are merged together.  
Table 3.3. Characteristic of L3 vaccination dataset. Showing the number of samples, 
number of different treatment groups (classes), number of genes measured for each 
sample. 
Time point No of Samples No. Classes No. Probes 
Day -28 20 3 45281 
Day 0 22 3 45281 






3.5.2  Mf Vaccination dataset 
To investigate the changes induced by microfilariae immunisation, mice were split into 
four groups, three of which received immunisation of either: Microfilariae and Alum 
(MfA); Microfilariae (Mf); or an Alum control (Alum). The immunisation occurred 
28, 21 and 14 days before the challenge, where the three immunised groups and the 
fourth control group (Control) were subcutaneously challenged with 40 infective L3. 
Whole blood samples were collected for each mouse: 6 hours after each of the three 
immunisations; 6 hours after the challenge; at day 49 (adults worms are present) post 
challenge; and day 67 post challenge (blood circulating Mf are seen) (Figure 3.12).  
The whole blood samples were collected and RNA was extracted by E PIAF partners, 
Dr Sabine Specht (University Hospital Bonn, Germany and Institute of Laboratory 
Animal Science, Vetsuisse Faculty, University of Zurich, Switzerland) and Dr Coralie 
Martin (Museum National d’Histoire Naturelle, France). RNA hybridisation to 
Illumina MouseWG-6 BeadChip arrays (Mouse WG6_V2_0_R3_11278593_A, 
Illumina) was done by Fios Genomics, Edinburgh, who also conducted the quality 
control. In this time course 15 samples were missing and 7 arrays failed the quality 
control, therefore 22 samples were removed from the subsequent analyses, 
unfortunately this meant that at the day -28 (6 hours after 1st immunisation) time point, 
the Control group was missing and therefore day -28 was removed from analysis 
(Table 3.4). Parasitological readouts of worm numbers in the pleural cavity (Figure 
3.13A) and microfilariae circulating in 30µl of blood (Figure 3.13B) were collected on 
Day 67. Table 3.4 summarises the characteristics of the Mf immunisation dataset taken 






Figure 3.12 Mf vaccination time course. 24 BALB/c mice were split into four groups, three 
of which were immunised three times with either: 105 Microfilariae and Alum (MfA); 105 
Microfilariae alone (Mf); or Alum on its own as a control (Alum). The immunisations occurred 
28, 21 and 14 before the challenge with 40 infective L3, the fourth group only received a 
challenge (Control). For each mice whole blood was collected 6 hours after each immunisation 
(Day -28, Day -21 and Day -14), 6 hours after the challenge (Day 0), 49 days post challenge 
(Day 49) adults from the challenge should have developed, and 67 days post challenge (Day 
67) when circulating microfilariae would be present. 
 
 
Figure 3.13. Parasite Counts. A) shows the number of adult worm found in the pleural cavity 
and B) Shows the number of microfilariae found in the 30µl of blood at day 67 post challenge 






Table 3.4. Characteristic of Mf vaccination dataset. Showing the number of samples, 
number of different treatment groups (classes), number of genes measured for each 
sample. 
Time point No. of Samples No. of Classes No. of probes 
Day -21 20 4 45281 
Day -14 23 4 45281 
Day 0 22 4 45281 
Day 49 21 4 45281 
Day 67 22 4 45281 
 
3.5.3 Wuchereria bancrofti endemic area dataset 
Whole blood samples were collected from patients living in a Wuchereria bancrofti 
endemic area in the western regions of Ghana (Ahanta West and Nzema East districts) 
by E PIAF partners, Dr Sabine Specht (University Hospital Bonn, Germany and 
Institute of Laboratory Animal Science, Vetsuisse Faculty, University of Zurich, 
Switzerland), Prof Achim Hoerauf (University Hospital Bonn, Germany), Dr Alex 
Debrah (Kwame Nkrumah University, Ghana), Dr Laura Layland (University Hospital 
Bonn, Germany), Gnatoulma Katataw (University Hospital Bonn, Germany, and 
University of Lome, Togo) and Alexander Kwarteng (Kwame Nkrumah University, 
Ghana). 
A total of 184 whole blood human samples were collected and RNA extracted by the 
E PIAF collaborators from the Kwame Nkrumah University of Science and 
Technology (Kumasi, Ghana). The RNA samples were hybridised to Illumina 





Genomics, Edinburgh who also conducted quality control on the samples, of which 12 
arrays (samples) failed the quality control and were therefore removed from the 
dataset. A summary of the characteristics of the data are found in Table 3.5. All the 
samples also had clinical information associated with them, such as: 
• Phenotype of patients: Circulating filarial antigen (CFA) and Mf positive for W. 
bancrofti was measured, with 118 patients being CFA positive with of which 48 
were Mf positive.  For the purpose of this analysis patients with who were CFA 
positive with or without Mf were classified as infected, and patients with CFA 
negative and no Mf were classified as endemic normals (EN). 
• Coinfection with other filarial nematodes, although no coinfections with O. 
volvulus or L. loa were present 
• Whether the patients had other helminth infections: 9 patients were infected with 
Ascaris, 9 with hookworm infections, 1 patient had both Ascaris and 
hookworms, 1 sample with schistosomiasis and 2 had trichuriasis. 
• Whether they had protozoan infections: 4 patients had Plasmodium falciparum 
and 1 with P. vivax; 4 patients also had Giardia. 
• How many rounds of Ivermectin treatment the patients received; although not all 
patients received Ivermectin, 66 patients received 1 round and 12 received 2 
rounds. 






3.5.4 Onchocerca volvulus endemic area dataset 
Whole blood samples were collected from patients living in Ghana in an 
onchocerciasis endemic area, by the E PIAF partners, Dr Sabine Specht (University 
Hospital Bonn, Germany and Institute of Laboratory Animal Science, Vetsuisse 
Faculty, University of Zurich, Switzerland), Prof Achim Hoerauf (University Hospital 
Bonn, Germany), Dr Alex Debrah (Kwame Nkrumah University, Ghana), Dr Laura 
Layland (University Hospital Bonn, Germany), Gnatoulma Katataw (University 
Hospital Bonn, Germany, and University of Lome, Togo) and Alexander Kwarteng 
(Kwame Nkrumah University, Ghana). 
A total of 167 whole blood human samples were collected and RNA extracted by the 
E PIAF collaborators from the Kwame Nkrumah University of Science and 
Technology (Kumasi, Ghana). The RNA samples were hybridised to Illumina 
HumanHT12 BeadChip arrays (HumanHT12_V4_0_R2_15002873_B) by FIOS 
Genomics, Edinburgh who also conducted quality control on the samples, of which 5 
samples failed the quality control and were therefore removed from the dataset. A 
summary of the characteristics of the dataset is found in Table 3.5. All the samples 
also had clinical information associated with them, such as: 
• Whether patients were O. volvulus microfilariae positive; these were classified 
as infected. If no microfilariae were found in skin snips, then patients were 
classified as endemic normals (EN), in total 109 patients were classified as 





• Whether patients received treatment; 63 patients received one round of 
Ivermectin, 1 patient received 6 round of Ivermectin and no patients received 
doxycycline. 
• Infection with other parasites; 23 patients also had P. falciparum infections. 
• Also present is information on patients, age, weight, sex (73 Females, 89 Males) 
and what village they live in. 
The human datasets are highly variable (in contrast to data from animal experiments) 
as a consequence of many confounding factors, such as whether patients have co-
infections and/or received Ivermectin treatment. Therefore, as an initial analysis 
samples from patients that had other infections, either other helminths (i.e. hookworms 
or Ascaris), or protozoan infections (malaria or Giardia); and patients who had 
received Ivermectin treatment were removed from the analysis. Removing the 
confounding factors helped with the interpretability of the results, and therefore for the 
purpose of this study only cleaner samples were looked at. 
Table 3.5 Characteristic of human dataset. Showing the number of samples, number of 
different treatment groups (classes), number of genes measured for each sample. 
Dataset No. of Samples No. of Classes No. of probes 
Wuchereria 
bancrofti 
All samples 172 2 (Infected / EN) 46698 
Pure samples 71 2 (Infected / EN) 46698 
Onchocerca 
volvulus 
All samples 162 2 (Infected / EN) 46698 





3.5.5 Pre-processing of Illumina microarray data 
The raw microarray data was imported into R programming language (R Development 
Core Team,, n.d.), using the lumi Bioconductor package (Du et al., 2008). The raw 
data was pre-processed using, the neqc function in the limma Bioconductor package 
(Ritchie et al., 2015) to:   
1) background correction, using Normal-exponential convolution, which uses 
negative controls (Ding et al., 2008; Xie et al., 2009), 
2) between-array quantile normalisation, 
3) log2 transformation. 
This package was found to be the best pre-processing strategy, giving the highest 
precision for a given bias (Shi et al., 2010).  
To find the genes associated with the probes on the Illumina microarrays, the Illumina 
probe identifiers were matched to nuID annotation (a unique identifier) using the lumi 
package (Du et al., 2008), and then corresponding Entrez Id were extracted, as these 
are needed for functional analysis using the ClusterProfiler package. All the machine 






3.6  Evaluation of pipeline performance 
As this area of research is getting significant attention, more alternative algorithms are 
emerging, however there is still a lack of gold-standard methods or datasets to compare 
it to. Therefore, to evaluate the pipeline’s performance, its accuracy at predicting 
withheld data for each dataset was measured and compared to the accuracy of other 
machine learning methods (SVM-RFE, RF-RFE) often used on gene expression data. 
The machine learning results were further compared to a non-machine learning method 
of analysing gene expression which has been popular in biomedical sciences, WGCNA 
(Langfelder, Horvath, 2008). 
3.6.1  Pipeline performance on the murine and human 
datasets. 
The pipeline works by initially clustering genes, and summarising the expression of 
the genes within each cluster. These gene clusters are then ranked in order of 
importance using random forest (RF). This step uses random forest (RF) to select 
informative genes and is therefore named random forest for feature selection (RF-FS) 
for the purpose of this study. During the RF-FS step, RF models were built using the 
summarised gene clusters and ranks the gene clusters in order of importance. These 
RF models were built 10 times on the same dataset, to see how repeatable the gene 
rankings were (how stable it is). The gene clusters that were consistently ranked in the 
top 20% over the ten iterations of RF were classified as the most informative gene 
clusters (Table 3.6). These are termed informative as these gene clusters best describe 





The informative gene clusters are then used to build a second RF model, used as a 
quality control step, termed random forest for quality control (RF-QC). RF-QC was 
done to make sure that the gene clusters selected by the first RF were truly important. 
Different metrics were used to evaluate the model throughout the pipeline. The 
stability of the feature selection RF (RF-FS) model was evaluated using a Jaccard 
index, and then the accuracy of the two sets of random forest models (RF-FS and RF-
QC) were assessed (Table 3.6). 
3.6.1.1 Stability measures 
In an ideal scenario, RF ranks the gene clusters in the same order of importance every 
time a RF model is built on the same dataset, using the same parameters. However, 
this is not always the case, therefore a similarity index (Jaccard index) is used to 
measure how similar the rankings are between the 10 RF iterations. The closer the 
Jaccard index is to 1, the more similar the rankings are. Across the datasets (both 
murine and human datasets), the pipeline’s ability to rank variables in order of 
importance was relatively stable, with high index measures all above 0.8, except for 
the W. bancrofti dataset which gave an index of 0.77 (Table 3.6).  
3.6.1.2 Accuracy measures 
Another important measure is how accurate the pipeline is at classifying data, RF 
works by choosing variables (genes) which best classify the samples into their 
respective experimental groups, so that when to new data is used the RF model is able 
to predict the experimental group of the samples. Therefore, how well RF predicts the 





was measured in the form of precision5, recall6 and 10 fold cross-validation accuracy 
(Table 3.6). These were calculated for both: 
• The random forest used for feature selection (RF-FS) – Accuracy of the 
random forest models used for feature selection (selecting the informative gene 
clusters) was measured. Since 10 RF models were built on the same data, the 
average accuracy, precision and recall were calculated. 
•  The random forest used for quality control (RF-QC) – The accuracy of the 
random forest models used for quality control, was also measured. This was to 
make sure that the gene clusters identified by the random forest feature selection 
step were indeed good at classifying the data into their respective experimental 
groups.  
In all datasets the accuracy of the RF models improves when they are built on the gene 
clusters previously identified as being important by the first set of RF models (RF-FS). 
This signifies that the genes selected by the random forest models (in the feature 
selection step) are indeed good at classifying the data into the experimental groups. 
In the L3 vaccination dataset, the ML pipeline was able to identify gene clusters that 
were informative for each time point, as the accuracy of the random forest for quality 
control at day -28, day 0 and day 10, was 0.95, 0.86 and 0.88 respectively. Figure 3.14 
represents a confusion matrix for the Day -28 time point in the L3 vaccination dataset, 
which shows the difference between the RF ability to predict unknown data when 
trained on all gene clusters (Figure 3.14, RF-FS), or on gene clusters identified as 





In the Mf vaccination experiment, the pipeline identified gene clusters at day -21, day 
-14 and day 0, that gave a high accuracy score of 0.70, 0.82 and 0.88 respectively, 
suggesting that those genes are good at identifying the different immunisation groups. 
However, by days 49 and 67 post challenge, the accuracy was lower, with an accuracy 





Table 3.6. Performance of pipeline. The Jaccard index represents how similar the top 20% 
ranking of the gene cluster, over 10 iterations of RF. The accuracy, precision5 and recall6 are 
measured by 10-fold cross-validation (data is split into a testing and validation set 10 times, 
and the results are represented as averages and with standard errors in parantheses, the closer 
the measure is to 1 the more accurate the classifier is). Random Forest for Feature Selection 
(RF-FS) is the RF models used to selected informative gene clusters. Random Forest for 




Accuracy Precision Recall 

























































































































































                                                
5 Precision – The fraction of true positives identified out of all the predictions. (P = 
Tp/(Tp +Fp)) 








Figure 3.14. Confusion Matrix. Confusion matrix illustrating the classification accuracy 
between A) the random forest built on all gene clusters, i.e. random forest for feature selection 
(RF-FS), and B) the random forest built on gene clusters selected as being important by RF-
FS, this is the random forest used for the quality control of the gene clusters selected (RF-QC). 
The confusion matrix above are based on random forest models built on the data from the Day 
-28 time point in the L3 immunity dataset, this corresponds to 6 hours following the first 
immunisation. Labels are the experimental groups the samples belong to: Immunised group 
signifies mice received a dose of either irradiated or non-irradiated L3; mice in the mock group 
received a dose of RPMI media as a mock immunisation; and naïve mice received no 
immunisation. The confusion matrix in B) shows that the RF built on informative gene, was 
able to predict the experimental group the samples belong to, whereas in A), the RF model 
built on all the gene, shows that there are some samples that are misclassified. Suggesting that 
genes selected are indeed good at differentiating between experimental group the samples 
belong, and are therefore informative on what is happening in vivo in blood following 
immunisation. 
3.6.1.3 Stability and accuracy of unclustered genes 
The importance of the clustering step (dimensionality reduction) in the machine 
learning pipeline was evaluated by building RF models of un-clustered genes and 





vaccination dataset using the pre-processed gene expression data (without the 
clustering step). 10 RF models were built at each time point (Day -28, day 0 and day 
10), and the stability and accuracy of the RF models were measured (Table 3.7). The 
clustering step (dimensionality reduction) was necessary to increase the accuracy of 
RF, which is much lower without clustering (Table 3.7). 
Clustering also increases the stability of the RF models. Thus, when RF models are 
built on all the genes (no clustering), a Jaccard index of 0.14-0.26 was recorded, but 
when clustered, Jaccard index of between 0.95 and 0.86 was obtained (Table 3.7). 
Using gene clusters, the RF model is able to consistently rank the clusters in a similar 
order of importance. 
Table 3.7. Performance of pipeline without the clustering step on L3 vaccination dataset. 
The machine learning pipeline was applied to the L3 vaccination without the clustering step 
and compared to the pipeline with clustering step in terms of model accuracy and stability. The 
Jaccard index represents how similar the gene rankings were in the top 20% ranked (closer to 
1 the more similar the ranking, so more stable the pipeline), the accuracy was measured by 10-
fold cross-validation. 
Time points 








































3.6.2 Comparison with alternative machine learning methods 
The pipelines accuracy was compared to two other machine learning algorithms, 
Support Vector Machine with Recursive Feature Elimination (SVM-RFE, (Zhang, 
Xiaojuan Huang, 2015) and Random Forest with Recursive Feature Elimination (RF-
RFE, (Díaz-Uriarte, Alvarez de Andrés, 2006). These alternative machine learning 
methods were applied to the L3 vaccination dataset. Using a 10 fold cross-validation, 
these alternative machine learning methods were optimised to output the number of 
variables (genes) that gave the highest accuracy. 
The machine learning (ML) pipeline used in this study gave a higher classification 
accuracy scores compared to SVM-RFE and RF-RFE (Table 3.8). However, only a 
few genes were found to overlap between the gene list produced by SVM-RFE and 
RF-RFE and the ML pipeline (Table 3.8). Furthermore, the running time of the ML 
pipeline is much faster than both SVM-RFE and RF-RFE, and ML pipeline in this 
study is easier to optimise and allows for more flexibility in choosing the number of 
features (genes/clusters) to take forward for further analysis. SVM-RFE and RF-RFE, 
identifies the genes that are important, but the number of genes that one is left with at 
the end of the analysis, that are classified as important cannot be chosen. Whereas, 
with the ML pipeline, the percentage of the top ranked genes can be changed depending 





Table 3.8.Accuracy of SVM-RFE and RF-RFE, on the L3 vaccination dataset, measured by 
10-fold cross-validation (splits the data into a testing and validation set 10 times, the results 
are averages and standard error of each classification), the genes classified as important by the 
SVM-RFE and RF-RFE methods were compared to the genes extracted from the clustered 
classified as important the pipeline in this study, by measuring the overlap in gene (% overlap). 
Time 
points 





Overlap Accuracy No. 
genes 
Overlap 






9 0 % 0.60 
(± 0.24) 
31 30% 





















3.6.3  Comparison with a non-machine learning method used 
in the microarray literature 
A popular non-machine learning method for the analysis of gene expression data is 
Weighted Gene Correlation Network Analysis (WGCNA), which works by finding 
highly correlated groups of co-expressed genes (these have similar gene expressions 
across the samples). In this study, WGCNA was used to identify groups of genes that 
were associated with immunisation. The genes identified by WGCNA were then 
compared to the genes identified by the ML pipeline.  
However, WGCNA cannot analyse multiclass data and struggles with large 
dimensional data (i.e would not be able to analyse the 46,000 genes measured by 
microarrays). For this reason, comparison was restricted to data from the Mf 
vaccinated mice and genes involved in immune responses identified using the 
Reactome database (R-MMU-168256.1) and Gene Ontology database (GO:0002376), 
a total of 2,568 genes. The Mf immunisation dataset has a measure of Mf counts at 
Day 67 and this provides the simplest way to split mice into a binary outcome of 
presence or absence of Mf. 
WGCNA essentially clusters genes based on their expression, and a principal 
component is calculated for each cluster. The first component of the clusters are then 
correlated with presence or absence of Mf, to see if there is an association between the 
gene clusters and presence or absence of the parasite. WGCNA was conducted in R 
using the parameters recommended the WGCNA guidelines (Langfelder, Horvath, 





At each time points a different number of clusters were produced, with varying 
numbers of genes in each (Table 3.9). The cluster first principal component was 
calculated (a way of summarising the cluster) and correlated with a binary outcome of 
presence or absence of Mf seen at Day 67. The clusters found to be significantly 
associated with the presence or absence of Mf were further investigated using pathway 
analysis to determine any association with parasite numbers. Pathway analysis was the 
same as that used by the machine learning pipeline, except genes associated with 
immune responses where used as the reference background. 
Table 3.9. WGCNA per time point: The number of clusters (groups of genes) identified at 
each time point; the average number genes per cluster; and number of clusters significantly 
associated with protection. 
Time point Number of clusters 
Average size of 
clusters (genes) 
Number of clusters 
associated with protection* 
Day -21 127 20 6 (263 genes) 
Day -14 66 39 1 (158 genes) 
Day 0 24 108 4 (232 genes) 
Day 49 90 29 5 (125 genes) 
Day 67 105 25 3 (122 genes) 
*Clusters significantly correlated with presence/absence of Mf at day 67, with a P-value <0.05 (T-test) 
 
The pathways identified by WGCNA were compared to the pathways identified by the 
machine learning pipeline. For the post immunisation time points (Day -21 and Day -
14) both methods identified similar pathways being triggered by the Mf immunisation 
(Table 3.10) such as: negative regulation of T cell receptor signalling (TCR and PD-1 
signalling); interferon signalling (IFN-g and IFN-b); antigen processing and cross-





MAP Kinases involved in the activation Toll Like Receptor (TLR) cascades (Table 
3.10).  
Pathways identified by WGCNA following the challenge infection (Day 0) or 49 days 
later (Day 49) are not particularly informative (Table 3.10). At Day 0 genes involved 
in nucleus organisation were identified. At Day 49 genes associated with response to 
external stimulus (GO:0009605) were identified: this is a broad category of processes 
that involves any change of activity of a cell, in terms of movement, secretion, enzyme 
production, gene expression due to an external stimulus.  
Interestingly at Day 67 WGCNA successfully identified pathways associated with 
interferon signalling (IFN-g and IFN-β), antigen presentation and regulation of 
immune responses (Table 3.10), the same as after immunisation. The genes involved 
with these processes are more highly expressed in mice with microfilariae circulating 
in their blood, suggesting that WGCNA can detect the immune responses to Mf being 
produced by the adult worms and which is not possible using ML pipeline. However, 
this observation may also be explained by the fact, that for the WGCNA the data was 
split into presence and absence of Mf, which was not done in the ML pipeline as the 
focus was on the effect of immunisations. 
Although there may not be complete overlap of results from the new ML pipeline and 
the popular WGCNA method, the ML pipeline successfully identifies the same 
biologically relevant pathways as WGCNA. Moreover, since it is not restricted to 
candidate genes (immune genes) and two groups, it is able to identify greater number 





Table 3.10. Summary of processes/pathways found as being important by WGCNA and 
the ML pipeline, using the GO database and Reactome database for each time point. (Full list 
Supplementary Table S2 and Table S3) 
Time  
Point 
Summarised processes / pathways 
 identified by WGCNA 
Overlap with pathways 
identified by the ML 
pipeline 
Day -21 
TCR signalling  
PD-1 signalling  
Antigen processing and presentation  
Antigen cross-presentation  
Interferon signalling (IFN-g and IFN-b)   
Regulation of immune responses  
Regulation of ERK (a MAPK) involved in TLR cascades  
Day -14 Interferon signalling (IFN-g and IFN-b)  
Day 0 Nucleus organization  
Day 49 Response to external stimulus  
Day 67 
Defence response to other organisms  
Interferon signalling (IFN-g and IFN-b)  
Regulation of immune responses  






3.7  Biological relevance of results from machine 
learning pipeline 
3.7.1  Changes in gene expression after vaccination in murine 
models 
Functional analysis was performed on the genes selected by the machine learning 
pipeline to investigate the biological significance of the genes; overlap between time 
points within a dataset; and to uncover any overlap in protective immunity between 
the L. sigmodontis mouse models and human filarial infections (O. volvulus and W. 
bancrofti).  
It was determined that concentrating on pathways or processes with which specific 
genes are associated to may give more insight into the overall responses being 
triggered during the vaccination time course, and determine if there is any overlap with 
human immune responses. As little overlap between the different time points was 
observed when comparing the genes selected by the ML Pipeline throughout a 
vaccination time course (Figure 3.15A). However, when comparing the functional 
pathways those genes belonged to between the time points, these showed greater 
overlap (Figure 3.15B). This implies that similar pathways are being triggered 






Figure 3.15 Venn diagrams of genes and their corresponding pathways selected by the 
pipeline for the L3 vaccination dataset. Venn diagrams showing overlap between time points 
in L3 vaccination dataset of A) genes from the clusters selected by the pipeline and B) 
“immune system process” (GO:0045087) those genes are involved in. 
Over-represented pathways were identified in each of the gene lists produced by the 
ML pipeline. The degree of over-representation was calculated using cumulative 
hypergeometric distributions, which is the probability of finding genes belonging to a 
functional Gene Ontology (GO) category or Reactome pathway within the gene list. A 
P-value was calculated for each of the pathway or processes using the Benjamini-
Hochberg method to correct for multiple testing (Benjamini, Hochberg, 1995).  
Different numbers of GO terms associated with Biological Process (BP) were found at 
each time point, and different pathways were identified using the Reactome database 
(Table 3.11). Because there are some discrepancies between the pathways found 
between the two databases, both databases were used in order to obtain the best 
overview of what is biologically happening at each time point.  
Overall the list of genes identified by the ML pipeline at the time points after 





This analysis suggests, that the early events in infection are important in determining 
the outcome to infection and this fits with what is known from the L. sigmodontis 
literature (Babayan et al., 2003), especially in terms of initial CD4+ T cells responses, 
which are crucial in determining immunity to later stages of infection (Taylor et al., 
2009).  
The conclusion is that a vaccine would need to skew the immune system to a protective 
phenotype from the onset of infection, as once the infection is established it is hard to 
reverse the immune-regulatory pathways triggered, and hence why in these vaccination 
experiments more pathways were found over-represented at the earlier time points and 
not once infection has established itself. 
Table 3.11. Over-represented terms and pathways across the murine datasets. The 
number of genes selected by the pipeline for each time point; the number of genes annotated; 
number of over-represented pathways using the Gene Ontology (GO) database looking at 
Biological Processes (BP) and Reactome database 
Datasets & Time 
points 
No of Genes 
selected by 
the pipeline 
No of genes 
annotated  
Terms/Pathways using: 
GO BP Terms Reactome 
L3 
Vaccination 
Day -28 421 309 3 0 
Day 0 218 177 0 0 
Day 10 268 191 0 2 
Mf 
Vaccination 
Day -21 216 146 59 41 
Day -14 128 92 35 14 
Day 0 218 158 0 0 
Day 49 144 113 2 0 






3.7.1.1 Informative genes and pathways in L3 immunised mice 
Among the genes identified from the L3 vaccination dataset by the pipeline, biological 
processes were significantly over-represented at day -28 and were involved with 
neutrophil movement (Chemotaxis: GO:0030593; Migration: GO:1990266) (Figure 
3.16A). The genes involved in these processes have increased expression in the 
immunised group after the 1st immunisation (day -28), followed by increased 
expression in the mock group after challenge (day 0), and by day 10 expression across 
the groups is relatively similar (Figure 3.17). This suggests that the machine learning 
pipeline is detecting the innate response to incoming L3 and that such responses have 
been demonstrated to have a major role in controlling the early stages of filarial 
infection in the skin (Pionnier et al., 2016). 
Interestingly, over-represented pathways associated with regulation of interferon (IFN) 
α signalling (Reactome: 5992081) were found at Day 10 (Figure 3.16). Both IFN-α 
and IFN-b are type I interferons, which exert multiple functions in the immune system 
and have various stimulatory and suppressive effects on dendritic cells (DC), 
macrophages, natural killer (NK) cells, T and B lymphocytes. While mostly associated 
with viral infections, they have recently been shown to be induced by bacteria or 
bacterial products, protozoa such as Leishmania spp and Plasmodium spp, and in 
helminths by Schistosoma mansoni eggs (Bogdan et al., 2004). Both IFN-α and IFN-
b  have been shown to have immunomodulatory properties and are therefore used as a 





Four genes from the IFN-α regulation pathway were selected by the ML pipeline; two 
genes encoding IFN-α, Ifna5 and Ifna9; and two genes involved in the regulation of 
cytokine signalling Socs1 (negative feedback loops) and Ptpn11 (Sh2). However, the 
precise role of IFN-α and its regulation in L. sigmodontis infection remains unclear 
(Figure 3.18).  
 
Figure 3.16 Over-represented terms found in the genes identified by the ML pipeline, in 
mice immunised with L3. A) Biological processes using the Gene Ontology database were 
found over-represented at Day -28 (6 hours post 1st immunisation) in the L3 vaccination time 
course, these were associated with neutrophil movement (Chemotaxis: GO:0030593; 
Migration: GO:1990266). B) Using the Reactome database, pathways involved in IFN-α 
signalling were found over-represented at Day 10. Each process or pathway is represented as 
an over-representation score, the –log10 of the adjusted P-value (which accounts for multiple 
testing using the Benjamini-Hochberg method) and denotes the significance of the terms over-
represented, the higher the value the more significant the GO term was. An adjusted P-value 






Figure 3.17 Gene expression of genes involved in neutrophil pathways across the 
different time points. Log2 of expression intensity of Cxcr2 and Csf3r on day -28 (6hr after 
1st immunisation), day 0 (6hrs after challenged) and day 10 time points (L. sigmodontis worms 
from challenge, that have survived would have matured to L4 stage and some will have reached 
the immature adult stage). Cxcr2 is a receptor for IL-8 and mediates neutrophil migration. 
Csf3r is a receptor for Csf3 which is a cytokine that controls the production, differentiation 
and function of granulocytes. Both of these genes are involved in pathways associated with 







Figure 3.18. Gene expression of genes involved in IFN-α pathway across the different 





involved in the regulation of cytokine signalling (C) Ptpn11 and (D) Socs1, on Day -28 (6hr 
after 1st immunisation), Day 0 (6hrs after challenged) and Day 10 time points. Ifna5 is a gene 
that encodes IFN-a5, and Ifna9 is a gene that encodes IFN-a9. Ptpn1 is a member of the 
protein tyrosine phosphate family, these catalyze the hydrolysis of the phosphate monoesters 
specifically on tyrosine residues, and are known to be signalling molecules that regulate a 
variety of cellular processes. Socs1 is a member of the STAT-induces STAT inhibitor and are 
known to suppress cytokine signalling. Altogether these genes are associated with pathways 
involved in the regulation of IFN-α signalling and were selected by the ML pipeline at day 10 
as being informative. 
3.7.1.2 Informative genes and pathways in Mf immunised mice 
Similar to that seen following L3 vaccination, time points 6 hours after Mf vaccination 
were the most informative with over-represented biological processes found at day-21 
and day -14 (Table 3.11).  
Since large numbers of GO terms were found over-represented at day -21 and day -14, 
only the top 20 significant BP GO terms are represented in Figure 3.19, with some 
overlap seen between the time points (Figure 3.20). At day 0 (6 hours post L3 
challenge) the ML pipeline did not identify any biological process as being 
differentially expressed between the treatment groups. This could be that there is little 
difference in response to incoming L3 between Mf immunised and the controls, and 
that the changes in gene expression that determine the outcome of infection happen 
early on after immunisation, and again once the worms have matured, since it’s known 
that the Mf vaccine affects adult worms fertility and not the incoming L3 (Ziewer et 
al., 2012). The full list of significantly over-represented GO categories for Biological 





The main biological processes found by the pipeline for day -21 were processes 
involved in the response to IFN with an emphasis in IFN-b and IFN-P; antigen 
processing and presentation with processes triggering lymphocyte activation and 
adaptive immune responses; homotypic cell to cell adhesion of immune cells such as 
T cells including their activation and aggregation; and defence responses to single cell 
organisms such as bacteria and protozoa.  
At day -14 processes such as response to IFN-b and IFN-P; antigen processing and 
presentation, and defence responses to protozoan and bacteria were found over-
represented. The difference between the two immunisation time points is that day -14 
also had over-representation of processes involved in regulation of gene expression 
(epigenetics).  
In addition, Day 49 had GO terms over-represented in processes involved in regulation 
of gene expression through epigenetic changes and chromatin silencing. Day 49 








Figure 3.19. Gene Ontology Terms of biological processes in the Mf immunity dataset. 
Time point Day -21, Day -14 and Day 49 in the Mf immunity dataset had significantly over-
represented GO terms. The over-representation score is the –log10 of the adjusted P-value 
(which accounts for multiple testing using the Benjamini-Hochberg method) and denotes the 
significance of the GO terms, the higher the value the more significant the GO term is. The 







Figure 3.20. Overlap of over-represented Gene Ontology Terms for biological processes 
in the Mf immunity dataset. There is overlap between terms at Day -28 and Day -14; and 
then between Day -14 and Day 49. The data is presented as enrichment scores, which is the –
log10 of the adjusted P-value (accounting for multiple testing using the Benjamini-Hochberg 
method) and denotes the significance of the GO terms within a gene list, the higher the value 
the more significant the GO term is. A GO term was classified as significantly over-
represented, if the term had an adjusted P-value < 0.05 and a Q-value < 0.2. 
Pathway analysis based on the Reactome database also revealed significantly over 
represented pathways at time points directly after immunisation, the majority of which 
were related to the immune system. The over-represented pathways following 
immunisation were mostly associated with genes involved in the initiation of adaptive 
immune response, in terms of antigen processing and antigen presentation (MHC I 
mediated); and interferon signalling, with an emphasis on IFN-P. Furthermore, at day 





cell co-stimulation signalling through receptors of the CD28 family (including PD-1 
which is a negative regulator of TCR signalling and leads to the dephosphorylation of 
CD3 zeta chains) were over-represented (Figure 3.21).  
 
 
Figure 3.21. Pathway over-represented using Reactome database. Using the Reactome 
database over-represented pathways were found in the gene lists extracted for day -21 and day 
-14 of the Mf immune dataset. The data is presented as enrichment scores, which is the –log10 
of the adjusted P-value (accounting for multiple testing using the Benjamini-Hochberg 
method) and denotes the significance of the GO terms within a gene list, the higher the value 
the more significant the GO term is. The analysis accounted for multiple testing using the 
Benjamini-Hochberg method, and each process was over-represented with a P-adjusted-value 
< 0.05 and a q-value < 0.2. 
All together the GO and Reactome pathways found over-represented highlight the fact 





consequently to the outcome of infection. Therefore, measuring changes in gene 
expression at the end of a vaccination time course would not be as informative as was 
seen in chapter 2. Despite there being some discrepancies between the pathways 
identified between the two databases (GO and Reactome), there are common themes.  
Responses to IFN seemingly play an important role at the earlier time points, as genes 
involved in these processes have a similar expression across the time point, showing a 
response to Mf, with higher expression after immunisation with Mf and again at Day 
67 in groups that have higher Mf burdens (Figure 3.23). This has been demonstrated 
in vivo, where single stage infection with Mf in mice induces the production of IFN-ɣ 
(Lawrence et al., 2000). Genes involved in IFN-β pathways were also detected; 
although commonly associated with antiviral immunity IFN-β has been shown to have 
immunomodulatory properties in bacterial infections, whereby DC produce IFN-b 
upon activation by LPS, leading to induction of T cell tolerance by enhancing PD-1 
binding and therefore facilitating Treg generation (Wang et al., 2014), or where 
Schistosoma mansoni eggs induce myeloid DC to produce IFN-b as a potential 
immune evasion strategy (Trottein et al., 2004), but there is no documented role of 
IFN-b in filarial infections. Another possible explanation is that there is a lot of overlap 
between the genes involved in interferon signalling pathways (IFN-b, IFN-g and IFN-
a), and because the genes selected by the pipeline are involved in both and are not 
specific to either pathways, they are shown as over-represented. Comparing the gene 
assigned to each pathway shows that indeed they are very similar genes and are shared 





responses, with a possible novel role of IFN-b but further in vivo experiments would 
need to be done to confirm this. 
Pathways involved in initiation of the adaptive immune responses were also 
upregulated after immunisation. These include antigen processing and presentation, 
and T cell recruitment and activation. Although most of the genes are associated with 
antigen presentation are genes that form the MHC class I molecules (H2 class I genes, 
orthologue for HLA-A genes in humans), all had greater expression when Mf were 
present (Figure 3.24), suggesting that Mf antigens are being cross-presented to CD8+ 
T cells, and that these might play a larger role in innate (initial immune) response to 
Mf, which has been suggest to be the case for modulation of infection in chronically 
infected Loa loa (Steel et al., 2012). 
 
Figure 3.22. Timeline of Mf immunisation time course. Day -28, -21 and -14 before the 
challenge infection, mice received immunisation, with either Mf on their own, Mf in alum, 
alum alone as a control, or media as a second control. At day 0, mice received a challenge 
infection with L3. By day 49 adult worms should be present in the pleural cavity of the mice 







Figure 3.23. Expression of Ifitm3 and Irf1 genes throughout the Mf vaccination time 
course. Interferon regulatory factor 1 (Irf1) is a gene that encodes a transcription factor and 
interferon-induces transmembrane protein 3 (Ifitm3) encodes a gene that is an interferon 
induced membrane protein that is most known to be involved in immunity to virus. Both genes 
are involved in pathways responsible for responses to IFN-g and IFN-b (IFN-g: Gene Ontology 
GO:0034341, Reactome: R-MMU-913531.1; and IFN-b GO:0035456). Other genes were 
selected by ML pipeline that were involved in these pathways (B2m, Cdc37, Gbp2b, Gbp2, 
Gbp3, H2-D1, H2-Q8, H2-T23, Ifitm3, Irf1, Irf7, Sp100) and all follow a similar pattern of 
expression, with higher expression when Mf are present such as after immunisation and again 






Figure 3.24. Expression of B2m and H2-D1 genes throughout the Mf vaccination time 
course. Beta-2 microglobulin (B2m) is a gene encoding a component of MHC class I 
molecules and histocompatibility 2, D region locus 1 (H2-D1) is a gene encoding is a 
component of MHC class I molecules. Both genes are involved in pathways associated with 
antigen processing and presentation, and T cell activation, this is because these genes form 
part of the MHC class I structure, other genes were also selected by the pipeline that form this 
complex (B2m, H2-K1, H2-Q6, H2-Q8, H3-T23), and all follow a similar pattern of 
expression, with higher expression when Mf are present such as after immunisation and again 





3.7.2  Human Filariasis 
To find pathways associated with protection in human onchocerciasis and lymphatic 
filariasis, the ML pipeline was used initially on all 162 and 172 samples from the O. 
volvulus and W. bancrofti datasets respectively, however no significantly over-
represented pathways where found in W. bancrofti dataset, and only pathways 
associated with cell cycle were identified in O. volvulus. 
Clinical data from human samples is inherently noisier than data collected from 
controlled experiments (e.g. mice vaccination experiments). Samples from patient with 
co-infections, either from other helminths (i.e. hookworms or Ascaris), or protozoa 
infections (malaria or Giardia); and patients who had received Ivermectin treatment 
were removed from the analysis. This left 85 and 71 samples for the O. volvulus and 
W. bancrofti dataset respectively (Table 3.12). When the pipeline was applied to these 
“cleaner” samples, a higher classification accuracy and stability was achieved. Over-
represented pathways were found in the genes identified as being associated with 







Table 3.12. Number of genes identified as important in distinguishing infected and 
protected individuals in O. volvulus and W. bancrofti endemic areas. The number of genes 
selected by the pipeline for each human datasets; number of annotated genes; number of over-
represented pathways/process in the gene list produced by the ML pipeline, using Gene 
Ontology Biological Process and Reactome database.  
Human 
Datasets 
No Genes selected 





BP GO Terms Reactome 
O. volvulus   275 198 53 12 
W. bancrofti 195 128 0 4 
 
Onchocerca volvulus endemic area dataset 
Overall 53 GO terms were found over-represented in the gene list produced by the 
pipeline from O. volvulus dataset, and 12 using the reactome database (Figure 3.25). 
These terms were summarised based on their function to get an overview of processes 
important in onchocerciasis infections: 
• Killing of cells of other organisms (GO:0031640):  
_ Defence responses to fungus (GO: 0050832) and Gram-positive 
bacterium (GO:0050830)  
_ Modification of morphology or physiology of other organism 
(GO:0035821), these are process that are involved in killing a 
variety of organisms 
_ Innate immune responses in mucosa (GO: 0002227)  





_ Negative regulation of growth of symbiont involved in interaction 
with host (GO:0044146) 
• Humoral immune response (GO:0006959): 
_ Organ or tissue specific immune response (GO:0002251) – an 
immune response happening in an organ or tissue, such as liver, 
brain, mucosa or nervous system 
_ Leukocyte mediated immunity (GO:0002443) -including DC 
• DNA-dependent DNA replication (GO:0006261): 
_ Anaphase-promoting complex-dependent proteasomal ubiquitin-
dependent protein catabolic process (GO: 0031145) - chemical 
reactions and pathways resulting in the breakdown of a protein or 
peptide by hydrolysis of its peptide bond. 
• DNA conformational change (GO:0071103) 
• Chromosome segregation (GO:0007059) 
• G1/S transition of mitotic cell cycle (GO:0000082) 
• Cell killing (GO:0001906) 






Wuchereria bancrofti endemic area dataset 
In the lymphatic filariasis dataset, no GO terms and 4 pathways using Reactome 
database were found significantly over-represented, all associated with T cell receptor 
signalling (Figure 3.25). The genes involved in these processes (HLA-DP and HLA-
DR) had higher expression in infected individuals compared to endemic normal 
(Figure 3.26). These genes are part of the MHC class II cell surface receptors, which 
is the ligand for CD4 T cell receptors and therefore associated with T cell receptor 







Figure 3.25. Over-represented pathways were detected in both Onchocerciasis and 
Lymphatic Filariasis datasets. Using the reactome database over-represented pathways were 
detected in the gene list produced by the ML pipeline for both the onchocerciasis and lymphatic 
filariasis datasets, (these were gene expression for individuals living in O. volvulus or W. 
bancrofti endemic areas respectively). The data is presented as over-representation scores, the 
–log10 of the adjusted P-value (accounting for multiple testing using the Benjamini-Hochberg 
method) and denotes the significance of the GO terms within a gene list, the higher the value 
the more significant the GO term is. The analysis accounted for multiple testing using the 
Benjamini-Hochberg method, and significance defined as a P-adjusted-value < 0.05 and a q-






Figure 3.26. Gene expression of HLA-DPA1 and HLA-DRA in individuals living in W. 
bancrofti endemic area of Ghana. Both of these genes are associated with T cell receptor 
signalling and are in fact part of the MHC class II molecule. Both HLA-DPA1 and HLA-DRA 
have increased expression in individuals infected with W. bancrofti compared to endemic 
normal. GLM’s were used to fins statistical differences between the groups, but no statistical 
difference was found. 
3.7.3  Overlap between mice and human protective immunity 
As one of the aims of this study was to investigate if there was any overlap in protection 
in humans living in endemic areas and immunised mice, pathways associated with 
protection were compared between both systems. Pathways associated with Mf 
immunity, such as defence against bacteria were found to be associated with protection 
in individuals living in O. volvulus endemic areas, these pathways could be being 
triggered by Wolbachia found in L. sigmodontis Mf and O. volvulus. By contrast T cell 
receptor signalling pathways were found to be important for protection in both 
individuals living in W. bancrofti endemic areas and in L. sigmodontis Mf 






Figure 3.27. Representation of overlap in pathways between human datasets (W. 
bancrofti and O. volvulus endemic areas) and Mf vaccination dataset. Overlap in GO terms 
and reactome pathways that are identical matches between human datasets and mice datasets, 
only the Mf vaccination out of both murine models had an identical match. Genes involved in 
cell killing mostly associated with bacteria killing were over-represented in both O. volvulus 
and the immunization time points of the Mf vaccination dataset, and genes involved in T cell 
receptor signalling were found over-represented in both W. bancrofti and the immunization 






3.8 Conclusions and future uses 
Microarray array technology has become an important tool to dissect the complex 
mechanisms involved in diseases, in this study microarrays were used to identify the 
underlying pathways associated with protection, induced in vaccination experiments 
in L. sigmodontis a murine model of filariasis, and in humans living in either an 
onchocerciasis or lymphatic filariasis endemic area. Gene expression was measured in 
whole blood as this is the most convenient sampling method for both humans and 
murine studies. The disadvantage of starting with whole blood is that the “background 
noise” is relatively high. Lower backgrounds can be obtained if isolated cell 
populations are used (Bondar et al., 2014) however, this is not a realistic proposition 
in the context of either the murine or human studies described here, and systemic 
responses would be overlooked. 
To analyse the microarray data, machine learning techniques were used to create a 
pipeline to identify informative gene expression in murine and human datasets that 
may differentiate between protected or infected individuals. The advantages of a 
machine learning pipeline over traditional and popular methods such as differential 
fold changes or gene co-expression networks, is that the pipeline can incorporate 
samples with multiple experimental groups and is not restricted to comparing two 
groups or disease states. In addition, this approach can handle large multi-dimensional 
data sets and is robust at detecting small changes in gene expression. 
The ML Pipeline uses publicly available algorithms including a density based 
clustering algorithm to overcome the problem of dimensionality that afflicts 





and identifies genes that do not cluster. The genes within a cluster were “summarised” 
so that a new variable can represent the expression of many genes within a cluster. The 
summarised gene clusters were then used to build a random forest model that ranks the 
gene clusters in order of importance, i.e. by how well they discriminate between the 
experimental groups in mice (immunised, mock or naïve) or infection status in humans 
(infected or EN). Random forest was repeated over several iterations and the gene 
clusters that routinely fell into the top 20% at each iteration were selected as being 
“informative” gene clusters. The function of the individual genes within the 
informative clusters were determined using pathway analysis. Compared to other 
machine learning, the ML Pipeline provides greater accuracy and is more flexible than 
recursive methods such as RF-RFE and SVM-RFE.  
Biologically relevant genes were successfully identified from whole blood gene 
expression data from mice vaccinated with either live attenuated infective L3 larval 
stage or microfilariae. Furthermore, it was shown that these different vaccination 
protocols elicited protection through different mechanisms. Thus, in the case of L3 
vaccination, protection was associated with neutrophil recruitment and migration. 
Such a response has also been demonstrated by Pionnier et al (2016) who showed that 
subcutaneous delivery of L3 resulted in an increase in neutrophils in the skin and which 
is essential for the early control of infection (Pionnier et al., 2016). In contrast, 
protection associated with Mf immunisation involved IFN signalling and IFN 
responses which corresponds to what is seen in vivo where mice immunised with Mf 





RNA levels in re-stimulated splenocytes were increased after the onset of patency in 
L. sigmodontis infected BALB/c (Taubert, Zahner, 2001).  
The results presented in this study clearly show that genes identified by the ML 
pipeline are biologically relevant to filarial infections and the use of whole blood 
provides a convenient and workable starting point for additional studies. 
The ML pipeline also demonstrated that adaptive immune responses are being 
triggered 6-hours post immunisation. Following the final (3rd) immunisation (Day -
14), antibody production by B cells is triggered (GO:0002822, somatic recombination 
of receptors). The results also may suggest that Th1 responses such as IFN-a/β and 
MHC I antigen cross-presentation might play a greater role in filarial immunity than 
has been reported in the literature, at least during the initial stages of exposure and 
infection.  
A comparison of human and murine datasets showed that protective responses evoked 
in mice by immunisation with microfilariae most closely resembled protective 
pathways induced in human through infection with either O. volvulus or W. bancrofti 
infections. This is not to say that protective responses evoked by L3 vaccination in 
mice may not be mirrored in humans. To investigate this possibility would however be 
difficult because it would require collecting blood shortly after an initial exposure and 
in practice, this would mean taking samples from very young children. This is a critical 
gap in our knowledge of human immune responses to filarial infections and one crucial 





of blood samples taken from cattle infected with O ochengi under conditions of known 
exposure (Makepeace, Tanya, 2016). 
The ML pipeline does have certain limitations, one of them being sample size. The 
dataset used have relatively large sample sizes compared to other microarray studies 
using traditional statistical methods, which usually contain 2 or 3 samples per 
treatment group (Zhou et al., 2016), but our data sets are smaller than many studies 
using machine learning techniques where data analyses rarely contains less than 100 
samples. Increasing sample size will increase accuracy and stability (Kim, 2009) but 
while sample sizes of 500-800 are suggested, such numbers would be prohibitively 
expensive and unfeasible in the case of experimental mouse studies. 
To mitigate against the relatively small numbers, murine studies could be better 
designed to maximise difference between control and test groups. For example, in the 
case of filarial infections, this would mean comparing mice presenting with specific 
and divergent parasite (Mf) loads. Furthermore, now that it is known that time points 
after immunisation are the most informative, gene expression could ideally be 
measured after each after immunisation time point and then after challenge. 
One of the major issues that concerns vaccine development is adverse reaction to the 
vaccination, since filarial infections can present with severe Th2 driven pathology 
(Brattig, 2004; Babu, Nutman, 2012). Therefore, detecting genes or pathways that 
determine the outcome of pathology will be important in developing a safe vaccine 





The work presented in this chapter demonstrates that machine learning techniques can 
be applied to highly dimensional microarray data from whole blood to understand the 
molecular events that happen in vivo to filarial infections. Such methods could be used 
to identify biomarkers of protection to vaccination, which would benefit vaccine trials 
(Nakaya et al., 2011a) particularly if such markers could predict outcome of 
vaccination within a relatively short period (e.g. within 3-4 weeks of final 
immunisation). Such characteristics would be particularly helpful in the case of 
onchocerciasis infections because of the long incubation period (18 months). The 
ability to accurately predict the immunogenicity of a vaccine within the first few days 
or weeks of a clinical trial would help determine the endpoint any clinical trial and 
ultimately save money and time. However, any biomarkers of protection would have 
to be well defined, as correlates of efficacy in healthy young adults may not be 
necessarily the same as biomarkers of protection in the elderly, or children under 5, 




Chapter 4. Structural modification of the CPI 
immunomodulator rescues DC function.  
4.1 Introduction 
Traditional vaccine development has largely been based on the use of inactivated or 
attenuated vaccines without knowing the vaccine’s exact mechanisms of protection. 
Despite attenuated vaccines (irradiated L3) for filarial parasites showing protection in 
animal models, it would not only be unethical but also unfeasible for use in humans. 
Thus, vaccine development has turned to the use of subunit vaccines, based on parasite 
antigens, however filarial nematodes are complex parasites, and the chances of finding 
effective antigens which confer protective immunity are low. Fortunately, knowledge 
of the immune responses induced by the filarial parasites can be used for a more 
rational approach to vaccine design. It is recognised that protection against filarial 
parasites is dominated by Th2 immune responses with some Th1 responses induced by 
Wolbachia (present within the nematodes); however filarial parasites induce a state of 
hypo-responsiveness that predisposes towards a chronic infection. Therefore, a vaccine 
strategy for filarial parasites has been to target the parasite’s immunomodulators that 
induce this state of hypo-responsiveness, as well as evoking a Th2 response.  
Vaccine candidates were selected based on their role in immunomodulation and their 
potential to induce protective immunity in several animal models of filariasis. With 
this strategy, a cysteine protease inhibitor (CPI) was identified (Table 4.1). In the L. 
sigmodontis model, Ls-CPI vaccine had no effect on protection nor was it able to 
generate strong specific immune response (Babayan et al., 2012). However, when 





consistently proven to be more protective than the native form of CPI. CPIm induces 
protection and increased immune stimulation (Table 4.1), in immunisation 
experiments with: a DNA vaccine in BALB/c mice against L. sigmodontis (Babayan 
et al., 2012); a recombinant protein vaccine in gerbils against B. malayi (Arumugam 
et al., 2014b); or in chamber model in BALB/c mice against O. volvulus (Hess et al., 
2014). 
Table 4.1. Immunisation experiments with CPI and mutated CPI (CPIm). 




B. malayi  
Jirds 
(permissive host) 
No protection but did alter adult 
worm migration and final niche 
location 
(Arumugam et al., 2014a) 
~48 reduction in worm 
burden, as well as reduced 
female fecundity (Arumugam 





No change in circulating Mf and 
failed to generate strong 
specific immune responses. 
(Babayan et al., 2012)  
Some reduction in circulating 
Mf on its own and 90% 
decrease in Mf when 
combined with other antigen. 
(Babayan et al., 2012) 
O. ochengi   
Cattle  
(permissive host) 
In combination with other 
antigens, 42% decrease in Mf 
numbers in dermis. (Makepeace 
et al., 2009) 
 
O. volvulus  
BALB/c mice – 
Diffusion 
chamber 
~49% reduction in L3 survival 
(Hess et al., 2014) 
 
 
Elucidating the mechanism that underlies vaccine induced protection can not only 
provide insight into the effectiveness of the vaccine candidate, but will also have 
implications for formulation of other and more efficacious vaccines. CPI is known to 
interfere with antigen processing in the histocompatibility complex class II (MHC-II) 
antigen pathway in vitro (Manoury et al., 2001). In different nematodes such as 





the differentiation and activation of bone-marrow-derived dendritic cells (BMDC); 
interferes with antigen and MHC-II molecule processing; and interferes with Toll-like 
receptor (TLR) signalling pathways, resulting in functionally deficient dendritic cells 
(DC) (Sun et al., 2013). This may render DC ineffective at initiating strong adaptive 
immune responses, similar to effect of B. malayi L3 on DC in vivo (Sharma et al., 
2016). Therefore, it was proposed that CPIm induces greater protection in 
immunisation experiment, by rescuing DC activity, which leads to increased protective 
immune responses, seen as a decrease in parasite burden at the end of a vaccine trial. 
This would fit with what was previously observed, that mechanisms induced 6 hours 
after immunisation are the most predictive of the outcome of infection (Chapter 3). 
These observations also agree with earlier work with L. sigmodontis, which identified 
early changes in immune responses to be determinants of the outcome of infection, 
with either the induction of protective or regulatory phenotypes (Taylor et al., 2009; 
Babayan et al., 2010). Since DC are professional antigen presenting cells and are key 
for the development of an adaptive immune response, it was suggested that DC are 
involved in the induction of either adaptive Th2 responses (Balic et al., 2004; Smith et 
al., 2012; Guigas, 2014; Cook et al., 2015) or modulatory Treg responses (Carvalho et 
al., 2009; Everts et al., 2010). Therefore, an intervention, such as a vaccine, that can 
boost DC responses at the early stages of infection, could provide protection and 
reduce pathology. 
The present study was designed to examine how Ls-CPIm vaccine, previously shown 
to be protective, affects the early stages of the adaptive immune response, and therefore 





in vivo and in vitro. Consistent with the hypothesis that mutation of CPI provides an 
early advantage in activation of DC, in vitro increased expression of cell surface MHC-
II and CD86 were detected, as well as an increase in IL-6 and IL-12p40 production 





4.2 Methods & Materials 
4.2.1 Ethics statement  
All procedures involving animals were approved by the University of Edinburgh and 
the University of Glasgow ethical review committee, and performed under license 
from the UK Home Office in accordance with the Animals (Scientific Procedures) Act 
1986.  
4.2.2 Mice  
All mice used to prepare bone marrow-derived dendritic cells (BMDC), harvest naïve 
T cells and in the vaccination experiment were female BALB/c mice that were 
obtained from either the Anne Walker Animal unit of the University of Edinburgh or 
purchased from Charles River (UK). Mice were housed in individually ventilated cages 
(IVC) at either the University of Edinburgh or the University of Glasgow. In each 
vaccination experiment the treatment groups were randomly allocated to avoid any 
cage effects. All mice were between 6-8 weeks of age before the start of any procedure. 
4.2.3 Generation of bone marrow-derived DC 
Bone marrow-derived dendritic cells (BMDC) were collected by flushing out the bone 
marrow of the femurs and tibias of BALB/c mice with PBS using a 1ml syringe fitted 
with 23G needle. Bone marrow was then suspended in 5ml of complete-RPMI 
(cRPMI): RPMI-1640 (Sigma-Aldrich); 10% heat-inactivated foetal bovine serum 





L-glutamine (Gibco). Red blood cells in the suspended bone-marrow were lysed by 
adding 2ml RBC lysis buffer (Sigma-Aldrich) for 5 minutes and lysis stopped using 
10ml of cRPMI, and cells were then collected by centrifuging at 400 x g for 5mins at 
4°C. Cells were re-suspended in 5ml cRPMI which was further supplemented with 20 
ng/ml of granulocyte-macrophage colony-stimulating factor (GM-CSF, PeproTech), 
and the cell concentration was determined using a haemocytometer (VWR).  
The cells were suspended to a concentration of 2x105 cells/ml in cRPMI with GM-
CSF, and cultured in batches of 10ml for 10 days at 37°C with 5% CO2 by: feeding 
the cells with 10ml of fresh cRPMI and GM-CSF on day 3; and then changing the 
media on days 6 and 8, by removing 9ml of media (carefully not to aspirate any cells) 
and adding 10ml of fresh cRPMI and GM-CSF. On day 10, non-adherent cells were 
harvested by aspirating all the media without removing any cells stuck to the plates, 
adherent cells were washed by centrifuging at 400 x g for 5mins at 4°C, and re-
suspended in cPRMI containing 5ng/ml of GM-CSF; these cells were used as immature 
DC. 
4.2.4 In vitro BMDC stimulation assays 
The immature DC harvested on day 10 were re-suspended in a 96-well U-bottom plate 
(ThermoFisher) at 1.1x105 cells/well and stimulated for 24hrs (day 11) with either: a) 
50 µg/ml of recombinant proteins CPI or CPIm treated with 10µg/ml polymyxin B 
(PmB, Sigma-Aldrich) to ensure no residual contamination with liposaccharides 
(LPS); b) 50 µg/ml of ovalbumin (OVA) also treated with PmB as a Th2 responses 





left unstimulated by adding cRPMI. After 24 hours of DC stimulation, cells were 
centrifuged at 400 x g for 5mins at 4°C and half of the supernatant fluid was collected 
for cytokine quantification, and the remaining supernatant was used to re-suspend the 
cells for T-cell co-cultures. 
All recombinant proteins used were produced by Creative Biomart (Shirley, NY, USA) 
by cloning CPI and CPIm into pET24a and pET28a respectively. These plasmids were 
used to transform E. coli BL21 (DE3) cells, and expression of encoded proteins was 
induced by incubation in the presence of IPTG for 12 hours at 16°C. Expressed 
proteins were detected by SDS-PAGE and purified from bacterial lysates by affinity 
over a polyhistidine column. 
4.2.5 T cell isolation and co-culture with BMDC 
Spleens were harvested from BALB/c mice and placed in 5ml cRPMI. Naïve T cells 
were isolated from the spleens by first homogenising spleen cells between two pieces 
of 70µm nylon mesh (Fisher Scientific) using forceps to obtain a single cell 
suspension. Red blood cells were then removed from the single cell suspension by 
adding 2ml of RBC lysis buffer for 5mins; the reaction was stopped by adding 10ml 
of cRPMI and centrifuged at 400 x g for 5mins at 4ºC. The supernatant was poured off 
and cells re-suspended in 2ml of cRPMI to determine their concentration using a 
haemocytometer.  
The Pan T cell isolation kit II (MACS) was used to isolate T cells from the spleen cell 
suspension by depleting non-target cells. The first step was to label non-target cells 





CD19, CD45R, CD49b, CD105, MHC class II and Ter-119. Once the cells were 
labelled with biotin-conjugated antibodies, anti-biotin monoclonal antibodies 
conjugated to MicroBeads were added. The cells were then washed through a magnetic 
MACSÒ Column in the magnetic field of a MACS Separator. The labelled cells are 
retained within the column and the wash through was collected as unlabelled T cells. 
The concentration of T cells was determined using a haemocytometer and re-
suspended to a concentration of 1x104cell/µl in T cell buffer. T cell buffer: sterile 
1xPBS (GibcoTM) containing 0.5% bovine serum albumin (BSA, Sigma-Aldrich), 
2mM EDTA (UltraPureTM, ThermoFisher), pH 7.2, and degassed using a sterile bottle 
top filter with a 0.45µm pore size (NalgeneTM, ThermoFisher).  
For DC and T cell co-cultures, naïve T cells were added to the stimulated BMDC 
(1x106 cells/well) in 96 well plates, at a ratio of 1:10 of DC to T cells (1x107 cells/well). 
The T cells and DC were left in co-cultures for either 24 hours, 48 hours or 96 hours, 
and after each time point the cells were centrifuged at 400 x g for 5mins at 4°C, and 
the supernatant fluid was collected for cytokine quantification by ELISA and cells 
harvested for FACS analysis. 
4.2.6 Immunisation protocol 
All DNA plasmids for immunisation were cloned following the recommendations of 
the pcDNA 3.1 Directional TOPO Expression Kit (Invitrogen). CPI (AF229173.1) was 
amplified from L. sigmodontis cDNA, and the mutation in CPIm was obtained by site 
directed mutagenesis, as previously describe (Babayan et al., 2012). The pIL-4 and 












pCPI pcDNA3.1 Accession: AF229173.1 Vaccine antigen 
pCPIm pcDNA3.1 
Mutated form of L. sigmodontis CPI-2. 
(Accession: AF229173.1) 
Point mutation of asparagine at position 
66 to lysine  
Vaccine antigen 
pIL-4 pcDNA3.1 
Mus musculus IL-4  
(NCBI Gene ID: 16189) 
Adjuvant 
pMIP1α pcDNA3.1 
Mus musculus MIP1α  
(Accession: M73061.1]) 
Adjuvant 
pEmpty pcDNA3.1 - Non-coding plasmid control 
 
In immunisation experiments, 24 BALB/c mice were split into four groups (n=6), with 
three groups receiving DNA vaccines or pEmpty control, whereas the fourth group 
received no DNA vaccine (Naïve). Since DNA vaccines (purified plasmids) were 
stored at -20°C, the day before vaccination the plasmids were placed in a 4°C fridge 
to allow them to thaw out slowly. The day of immunisation the concentration of the 
plasmids were quantified and vaccine cocktails were made up to total of 80µg of DNA, 
with equal quantities of each plasmid, this meant that the quantity of each individual 
plasmid decreased as the number of different plasmids were added to a vaccine cocktail 
(Table.4.3). The plasmids were delivered in 50µl doses and elution buffer (QIAGEN: 
10mM Tris-Cl, pH 8.5) was used to make up the volume.  
DNA vaccine cocktails were administered to the tibialis anterior muscle of the left leg 
with a 27G needle, immediately followed by electroporation with an ECM 830 





200 V/cm, 40ms duration with 460ms intervals. During the vaccination process mice 
were under anaesthesia using gas inhalation of isoflurane and placed on heat pads. To 
wake mice, the gas inhalation was removed and mice recovered naturally on heat pads. 
The treatments were randomised per cage so that each cage had at least one of each of 
the treatment groups. The mediastinal and parathymic lymph nodes and spleens were 
harvested 24 hours following vaccination and placed in 5ml of cRPMI. 
 Table 4.3. Amount of plasmid added to the different vaccine cocktails in a DNA vaccine 
experiment. 
 DNA plasmid 
Vaccines pCPI pCPIm pIL-4 pMIP1α pEmpty Total DNA 
Ls-CPI (Adj) 40µg - 20µg 20µg - 80µg 
Ls-CPIm (Adj) - 40µg 20µg 20µg - 80µg 
pEmpty (Adj) - - 20µg 20µg 40µg 80µg 
Naive - - - - - - 
4.2.7 Processing of spleens and lymph nodes 
Lymph nodes and spleens collected following immunisation were dissociated to obtain 
a single cell suspension by grinding them through a 70µm nylon mesh (Fisher 
Scientific) using forceps in a petri-dish. The single cell suspensions were given a red 
blood lysis treatment, by centrifuging the cells at 400 x g for 5mins at 4ºC, removing 
the supernatants and suspending the cells in the remaining cRPMI and treating these 
with 2ml of RBC lysis buffer (Sigma-Aldrich) for 4 mins. The RBC lysis buffer was 
stopped by adding 10ml of cRPMI and cells centrifuged at 400 x g for 5mins at 4ºC, 
the supernatant poured off and cells re-suspended in 2ml of cRPMI. The cell 





were made up to a concentration of 106 cells/ml using cRPMI, which were then used 
for FACS analysis. 
4.2.8 Cytokine quantification by ELISA 
Concentrations of IL-12p40, IL-6, IL-10, IL-4 and IFNg were measured by sandwich 
ELISA, in the supernatant fluids of DC cell cultures 24 hours after DC stimulation, 
and in DC and T cell co-cultures either after 24 hours, 48 hours, or 96 hours after the 
addition of T cells. Flat bottom NUNC plates (Thermo Scientific) were coated with 
50µl/well of coating antibody in their respective buffer (Table 4.4), and left in the dark 
at 4°C overnight. The following day plates were washed four times in wash buffer: 
1xPBS containing 0.05% Tween-20 (Sigma-Aldrich). Coating antibodies were 
blocked by incubating the plates for 1hr at 37°C in the dark with 200µl/well of 4% 
BSA in 1xPBS. The plates were then washed four times with the wash buffer before 
adding 50µl/well of either the samples (DC supernatants) in triplicate and the standards 
for each cytokines which were serially diluted (1 in 2) in their appropriate buffer (Table 
4.4) these were used to determine the concentration of the samples. The plates were 
then left overnight at 4°C in the dark. 
The next day the plates were washed four times in wash buffer, and 50µl/well of 
biotinylated detection antibodies were added to the plates at the recommended 
concentration and buffer (Table 4.4). These were then incubated at 37°C for 1hr in the 
dark, and washed four times using wash buffer. Then AMDEX streptavidin-peroxidase 
(Sigma-Aldrich) was added to each well (50µl) in a 1/6000 dilution in the same buffer 





at 37ºC. Once the final incubation was done the plates were washed five times in wash 
buffer, and 50µl/well of TMB-H2O2 (Merck Chemicals) was added to the plate and left 
to develop in the dark at room temperature for 5-10mins until a gradient of blue is seen, 
the reaction was then stopped by adding 100µl of H2SO4 (1M). Absorbance was 
measured at 405nm and the concentration of cytokine levels in the samples were 
determined using the standard curve made using the O.D. values of the standards 
against their known concentrations (Figure 4.1). 
Table 4.4. Concentrations (conc) and buffers used for the antibodies in the sandwich 
ELISA for IL-12p40, IL-6, IL-10, IL-4 and IFNg quantification.  
Cytokine Concentration (µg/ml) Buffer Clone/ Isotype 
IL-12p40 
Coating 2 0.2M Na2HPO4, pH6.5 C15.6/Rat IgG1 1 
Standard start conc: 0.005  10% NCS* in PBS N/A 2 
Detection 0.5 10% NCS* in PBS C17.8/Rat IgG2ak 3 
IL-6 
Coating  1 0.1M Na2HPO4, pH12 MP5-20F3/Rat IgG1 1 
Standard start conc: 0.025 10% NCS* in PBS N/A 2 
Detection  0.5 10% NCS* in PBS MP5-32C11/Rat IgG2a 1 
IL-10 
Coating  4 0.2M NaHPO4, pH6.5 JES5-16E3/Rat IgG2bk 4 
Standard start conc: 0.05 10% NCS* in PBS N/A 2 
Detection 0.25 10% NCS* in PBS JES5-2A5/Rat IgG2bk4 
IL-4 
Coating  1.2 1xPBS 11B11/Rat IgG 5 
Standard start conc: 0.008 10% NCS* in PBS N/A 2 
Detection 0.25 10% NCS* in PBS BVD6-24G2/Rat IgG13 
IFNg 
Coating  1.5 0.1M NaHCO3, pH9.6 AN-18/Rat IgG13 
Standard start conc: 0.05 10% NCS* in PBS N/A 2 
Detection 1 10% NCS* in PBS R4-6A2/Rat IgG13 
*NCS, newborn calf serum (ThermoFisher); 1BD Bioscience, 2Peprotech, 3BioLegend, 






Figure 4.1. Cytokine ELISA standard curve. An example of a standard curve used to 
calculate cytokine concentration in samples, this was the standard curve for IL-12p40, and was 
used to determine the IL-12p40 levels in the wells. 
4.2.9 Flow cytometry analysis 
Flow cytometry was used to analyse cell surface markers on DC and T cell from co-
cultures, and DC from spleens and lymph nodes following immunisation. From the 
single cell suspension, 106 cells of cells were added to FACS tubes and non-specific 
binding was blocked using anti-CD16/32 (BD Pharmingen) at 5µg/ml in 1/20 mouse 
serum for 30mins in the dark at 4°C. These cells were then washed in FACS buffer 
(PBS with 2% FBS), centrifuged at 400 x g for 5mins at 4°C, supernatant discarded 
and re-suspended before adding the staining antibodies for the surface markers, all 
diluted 1/400 (Table 4.5. ). Stained cells were left for 30mins in the dark at 4°C 
followed by a wash in FACS buffer, centrifuged at 400 x g for 5mins at 4°C, 
supernatant discarded and cells were resuspended in 170µl FACS buffer. Cells were 
analysed using an LSR II (BD Biosciences), running FACSDiva software (BD 





beads (Affymetrix, eBioscience) were stained with each individual staining antibody 
in a 1/400 dilution as the compensation control. Analysis of the flow cytometry was 
performed using Flowjo (Tree star).  
Table 4.5. Multicolour panel for flow cytometry of DC and T cell from co-cultures and 
lymph nodes (LN) and spleens harvested from mice 24hrs following immunisation.  
For in vitro DC and T cell co-cultures  For LN and spleen cell suspensions 
DC stain T cell stain DC stain 
CD11c – APC 4 CD3–PeCy7 3 CD3–APC/Cy71 
CD40 – PE1  CD4–FITC 3 CD11c–BrilliantViolet4211 
CD80 – PeCy71 CD19- PE4 CD11b–BrilliantViolet7111 
CD86–BrilliantViolet605 4 CD8 – AF700 1 CD19 –AlexaFluor7004 
F4/80 – AF700 1  CD40 – FITC1 
MHCII–Violet500 1  CD80 –APC1 
  CD86–PE 4 
  F4/80–PE/Cy7 1 
  Gr1–BrilliantViolet605 1 
  MHCII–PerCP 1 
1BioLegend; 2BD Horizon; 3BD Pharmingen; 4eBiosciences 
4.2.10 Microarray datasets 
Human microarray datasets are the same as in Chapter 3. These reveal gene expression 
patterns of individuals living in two different foci in Ghana: one endemic for O. 
volvulus; and the other W. bancrofti. Whole blood human samples were collected and 
RNA extracted by the E PIAF collaborators Dr Sabine Specht (University Hospital 
Bonn, Germany), Prof Achim Hoerauf (University Hospital Bonn, Germany), Dr Alex 
Debrah (Kwame Nkrumah University, Ghana), Dr Laura Layland (University Hospital 
Bonn, Germany) and Gnatoulma Katataw (University Hospital Bonn, Germany, and 





Science and Technology (Kumasi, Ghana). The RNA samples were hybridised to 
Illumina HumanHT12 BeadChip arrays (HumanHT12_V4_0_R2_15002873_B) by 
FIOS Genomics, Edinburgh who also conducted quality control on the samples. All 
samples that failed the quality control (QC) were removed from the dataset (Table 4.6).  
Individuals were split into infected and endemic normal (EN) groups; EN are 
individuals that show no clinical or parasitological signs of infection. Therefore in O. 
volvulus foci individuals with no detectable Mf in skin snips or nodules were classified 
as EN, and in W. bancrofti foci individuals with no detectable Mf in their blood and 
no circulating filarial antigen (CFA) to W. bancrofti were classified as EN. 
The raw microarray files were processed in R programming language (R Development 
Core Team,, n.d.) using the lumi Bioconductor package (Du et al., 2008), in the same 
manner as chapter 3. Briefly, the neqc function in the limma Bioconductor package 
(Ritchie et al., 2015) was used for background correction using negative controls 
(normexp) (Ding et al., 2008; Xie et al., 2009), followed by between-array quantile 
normalisation and log2 transformation, as this was found to be the best pre-processing 
strategy giving the best precision for a given bias (Shi et al., 2010).  
To find the genes associated with the probes on the Illumina microarrays, the probe 
identifiers were converted to nuID annotation using the lumi package (Du et al., 2008). 
Genes associated with the MHC class II (R-HSA-2132295.3), CD28 co-stimulatory 
(R-HSA-388841.2) and TCR signalling (R-HSA-388841.2) pathways were extracted 
from the Reactome database (www.reactome.org), and used to subset the datasets, so 





Table 4.6.Information on samples used in human microarray. 
 O. volvulus endemic foci W. bancrofti endemic foci 
Number of samples which passed 
QC 
166 162 
Number of samples 
classified as:  
• Infected 118 109 
• EN 48 53 
Other parameters recorded: • Age 
• Co-infection with 
helminths (none were co-
infected with other filarial 
nematodes) 
• Co-infection with 
protozoa 
• Rounds of Ivermectin 
• Age 
• Co-infection with protozoa 
• Rounds of Ivermectin (none 
received doxycycline) 
• Presence of nodules 
 
4.2.11 Statistical analysis 
All statistical analyses were performed in R (Ihaka, Gentleman, 1996). Generalised 
linear models (GLM) followed by the Shapiro-Wilk normality test to assess the 
normality of the residuals, were used to compare the effects of the different vaccines 
on DC in vivo, and the different treatments on DC stimulation in vitro. For in the in 
vitro data, means± SE are shown. For microarray analysis, GLMs were also used to 
detected differences between infected and endemic normal individuals, since there 
were 137 genes for MHC-II signalling, 89 genes for CD28 co-stimulation signalling 
and 138 genes for TCR signalling, GLMs were looped through and multiple testing 
was accounted for using the qvalue package in Bioconductor (Storey, 2015). All 





4.3.1 Modifying CPI rescues pro-inflammatory cytokine 
production by DC in vitro  
To assess whether modifying the immunomodulator CPI effects DC activation, 
immature BMDC were stimulated with either recombinant Ls-CPI or its modified 
counterpart which has a mutation, asn66 to lys66 (Ls-CPIm). The immature BMDC 
were stimulated for 24 hours with either Ls-CPI, Ls-CPIm, OVA a Th2 control, LPS 
as Th1 control, or left unstimulated (Media). Overall immature BMDC stimulated with 
the different antigens showed an increased in activation over unstimulated cells, seen 
as an increase in cytokine production. Treatment with Ls-CPIm increased (non-
significant) the production of the pro-inflammatory cytokines IL-12p40 (0.23 ± 0.19) 
and IL-6 (0.52 ± 0.42) compared to its native form Ls-CPI (Figure 4.2), whereas 
treatment with Ls-CPI showed increased levels of IL-10 cytokine production compared 






Figure 4.2. Cytokine production by BMDC in response to stimulation with either Ls-CPI 
or Ls-CPIm. Bone marrow cells were cultured for 10 days with GM-CSF, to obtain immature 
DC. Immature DC were harvested and cultured for 24 hours with either: Ls-CPI (50 µg/ml) 
with polymixin B (PmB) to deplete lipopolysaccharides (LPS); Ls-CPIm (50 µg/ml) with 
PmB; Ovalbumin (OVA) (50 µg/ml) with PmB as a Th2 control; LPS as Th1 control; or media 
(complete RPMI) as an unstimulated control. Supernatants were harvested and cytokines IL-
12p40, IL-6 and IL10 concentration were measured using sandwich ELISA. Data represented 
as means (± SE) of 5 independent experiments for IL-12p40 and IL-6, whereas IL-10 could 
only be measured in 3 independent experiments. GLM were used to compare statistical 
significant differences taking into account the independent experiments, however no 






4.3.2 Increased DC antigen presentation with Ls-CPIm 
stimulation 
For the adaptive immune responses to be triggered, DC must deliver a series of defined 
signals to naive T cells, including the process of antigen presentation via MHC class 
II to naive T cells with the appropriate co-stimulation signals (CD86, CD80 and 
CD40). CPI’s immunomodulatory property is its ability to inhibit antigen presentation 
by MHC class II molecules, therefore to assess if mutating CPI restores DC ability to 
present antigens to naive T cells, immature BMDC were stimulated with either Ls-CPI, 
Ls-CPIm, OVA, LPS or left unstimulated (media control) for 24hrs to obtain mature 
DC, which were then cultured with naive T cells for either 24, 48 and 96 hours. The 
BMDC and T cells co-cultures were harvested, and stained for flow cytometry 
analysis. CD11c was used to select for DC populations of cells, and the expression of 
MHC-II and co-stimulatory molecules were analysed.  
The number of CD11c+ dendritic cells in cultures increased over time following 
addition of T cells (Figure 4.3.A). Since there was only one experiment for each time 
point, and similar trends in expression of MHC-II and CD86 were seen across the time 
points, expression was calculated as a fold change over unstimulated (media) controls 
per time point, as to combine experiments and analyse the difference between 
treatment groups. Treatment with Ls-CPIm significantly increased the expression of 
MHC-II on CD11c+ cells, with a 0.5 fold increase in expression (Figure 4.3.B) and a 
0.4 fold increase in CD86 expression compared to BMDC treated with Ls-CPI (Figure 





The expression of CD40 and CD80 was only measured at the 24-hour time point, but 
only CD40 showed a change in expression between unstimulated and stimulated cells, 
with BMDC stimulated with Ls-CPIm having increased expression over Ls-CPI 
stimulated cells (Figure 4.3. C), since CD40 expression was only measured once it is 
not possible to conclude that it is increased. 
Changes in naive T cell differentiation were also assessed, by measuring the fold 
change in CD4+ T cells between the treatment groups, although there was an increase 
in CD4+ T cell differentiation between stimulated and unstimulated (media) cells, no 









Figure 4.3. Effects of recombinant Ls-CPI and Ls-CPIm on expression of MHC-II and 
co-stimulatory molecules on BMDC following co-culture with naïve T cells. Immature 
BMDC obtained from 10-day old bone marrow cell cultures, were stimulated for 24 hours with 
either: Ls-CPI (50 µg/ml) with polymixin B (PmB) to deplete lipopolysaccharides (LPS); Ls-
CPIm (50 µg/ml) with PmB; Ovalbumin (OVA) (50 µg/ml) with PmB as a Th2 control; LPS 
as Th1 control; or media (complete RPMI) as an unstimulated control. Following stimulation, 





48 hours or 96 hours. Co-cultured cells were harvested and stained for DC using CD11c, MHC-
II and co-stimulatory molecule CD86, and analysed by flow cytometry. A) Number of DC 
(CD11c+ cells) harvested at 24, 48, and 96 hours of co-culture. B) Fold change of mean 
fluorescence intensity (MFI) of CD86 and MHC-II expression by CD11c+, between stimulated 
and media control (unstimulated) BMDC. Data shown are means (± SE) of the three BMDC 
and T cell co-cultures ending at 24, 48 or 96 hours of co-culture. C) FACS histograms of 
expression of CD40 on CD11+c cells from BMDC and T cell co-cultures, at the 24-hour time 
point, expression shown as MFI between unstimulated (shaded grey) and either Ls-CPI 
(+PmB), Ls-CPIm (+PmB), OVA and LPS (black line). Statistical significant differences were 
measured using GLM with experiment end points as a random effect, * P-value < 0.05. The 








Figure 4.4. Expansion of CD4+ T-cells, induced by BMDC stimulated with either Ls-CPI 
or Ls-CPIm. Immature bone-marrow derived DC (BMDC) were stimulated with either: Ls-
CPI (50 µg/ml) with polymixin B (PmB) to deplete lipopolysaccharides (LPS); Ls-CPIm (50 
µg/ml) with PmB; ovalbumin (OVA) (50 µg/ml) with PmB as a Th2 control; LPS as Th1 
control; or media (complete RPMI) as an unstimulated control, for 24 hours. The stimulated 
BMDC were then co-cultured with naïve T cells for 24-hours, 48-hours or 96-hours. A) Gating 
strategy for the detection of CD4+ T cells. B) Differences in CD4+ T cells (CD3+CD4+ cells) 
harvested from co-cultures with BMDC, were measured as fold changes over unstimulated 
cells (Media) at each time point to compare all three experiments together. Data is presented 
as mean (± SE) fold change of the three independent experiments (time points). The 48 and 96 






4.3.3 Change in cytokine profiles in DC and T cell co-cultures  
Changes in cytokine production after the addition of naïve T cells, were measured as 
fold changes over unstimulated cells, as there was variation between the independent 
experiments. Although numbers of CD11c+ DC in cultures increased over time (Figure 
4.5. A), production of IL-12p40 and IL-6 peaked at 48 hours after the addition of T 
cells, furthermore IL-10 could only be detected at 48 hours. A slight increase in IL-
12p40 production by Ls-CPIm treated cells was detected, similar to what was seen 
before the addition of naive T cells (Figure 4.5.B), however no difference in IL-6 
production nor IL-10 production after the addition of T cells was detected (Figure 
4.5.B,C). Furthermore, levels of IL-4 and IFN-P were undetectable, therefore it is hard 






Figure 4.5.Effects of recombinant Ls-CPI and Ls-CPIm on cytokine production by 
BMDC following co-culture with naïve T cells. Immature BMDC obtained from 10-day old 
bone marrow cell cultures, were stimulated for 24 hours with either: Ls-CPI (50 µg/ml) with 
polymixin B (PmB) to deplete lipopolysaccharides (LPS); Ls-CPIm (50 µg/ml) with PmB; 
Ovalbumin (OVA) (50 µg/ml) with PmB as a Th2 control; LPS as Th1 control; or media 
(complete RPMI) as an unstimulated control. Following stimulation, BMDC were harvested 
and co-cultured with naïve T cells (1:10 of DC to T cells) for 24-hours, 48-hours or 96-hours. 





levels are represented as fold change over media cultured BMDC (unstimulated BMDC) to 
compare cytokine production between the different co-culture end points. Since, 48 hours of 
BMDC and T cell co-cultures produced the greatest levels of cytokines, this time point was 
repeated. B) Production of IL-12p40 (µg/ml) and IL-6 (µg/ml) at 48 hour of BMDC and T cell 
co-cultures, presented as means (± SE) of four independent experiments; and C) production of 
IL-10 (µg/ml) at 48 hour of BMDC and T cell co-cultures, presented as means (± SE) of three 
independent experiments. The first 48 and 96 hour time points experiments were done by 
Marjorie Besençon. 
4.3.4 Undetectable changes in DC activation following 
immunisation in vivo 
The effects of the native and modified CPI on DC maturation were investigated in vivo 
by immunising BALB/c mice with a DNA vaccine containing ether the Ls-CPI or Ls-
CPIm antigen in combination with adjuvant plasmids for IL-4 and MIP1a. Spleens 
and lymph nodes were harvested 24 hour following immunisation, flow cytometry was 
used to measure the expression of MHC class II and the co-stimulatory molecules 
CD86, CD80 and CD40 on CD11c+ DC present in the spleen and lymph nodes. 
However, no change in expression of MHC-II nor the co-stimulatory molecules could 
be detected between the immunisation groups, on CD11c+ cells from the spleen (Figure 
4.6) or lymph nodes (data not shown). This could be due the complex nature and poorly 
controlled factors inherent to in vivo settings (e.g. baseline variation, timing of 








Figure 4.6.In vivo expression of MHC-II and co-stimulatory molecules on CD11c+ DC 
following immunisation with either Ls-CPI or Ls-CPIm. Female BALB/c mice were 
immunised with DNA vaccines intramuscularly, and spleens were harvested for flow 
cytometry to measure expression of MHC-II, CD86, CD80 and CD40 on DC, classified as 





adjuvant, Ls-CPIm with adjuvant or an empty pcDNA3.1 plasmid (pEmpty) with adjuvant, or 
were left non-immunised termed as Naïve. Adjuvant plasmids contained inserts for IL-4 and 
MIP1a. A) Represents the gating strategy used to isolate DC population and measure the 
fluorescence intensity of MHC-II, CD86, CD80 and CD40. B) Expression was measured as 
geometric mean fluorescence intensity (MFI). Data presented are medians (horizontal line), 
interquartile (bars), extreme values (vertical lines), and individual values/mice (points), with 
an n=5-6 per group.  
4.3.5 Changes in gene expression associated with DC and T 
cell activation in humans 
Since in vivo immunisation experiments in mice failed to detect differences in DC 
activation, more likely due to difficulties in isolating the correct DC population. It was 
then suggested that examination of human gene expression data, might reveal 
differences in DC activation, considering that using the machine learning pipeline 
(Chapter 3), pathways involved in T cell activation were found to be important at 
differentiating between infected and endemic normal individuals living in areas 
endemic for onchocerciasis and lymphatic filariasis. 
The microarray gene expressions data available was obtained from whole blood, 
therefore it is impossible to select for specific cells and measure expression of genes 
within them. Instead expression of genes involved in MHC-II signalling (R-HSA-
2132295.3) and CD28 co-stimulation (R-HSA-388841.2) according to the reactome 
database (Croft et al., 2011) were investigated, by comparing expression in naturally 
protected (EN) and infected individuals using generalised linear models (GLMs). To 
verify that GLMs could detect differences in expression, genes involved in TCR 





learning pipeline detected. Two datasets were available, one from individuals living in 
onchocerciasis (O. volvulus) endemic areas in Ghana with Mf numbers measured per 
mg of skin, the other dataset was from individuals living in lymphatic filariasis (W. 
bancrofti) endemic areas in Ghana with Mf numbers and detection of circulating W. 
bancrofti antigens measured in the blood. Neither dataset had co-infections with filarial 
nematodes. 
In individuals living in onchocerciasis endemic areas, no differences in expression of 
genes specific for MHC-II and CD28 co-stimulation signalling, such as HLA-DRA 
and CD86, were detected (Figure 4.7). There were differences in expression of genes 
associated with T cell receptor signalling, such as increased expression of ICOS and 
CD3E in EN, although not significant when accounting for multiple testing (Figure 
4.7). ICOS is an inducible T-cell co-stimulator found expressed on activated T cells 
and CD3E, is a gene encoding the CD3e which forms part of the CD3 T cell co-
receptor. 
In individuals living in lymphatic filariasis endemic areas, expression of HLA-DRA, 
ICOS and CD74 were significantly increased in infected compared to naturally 
protected EN (Figure 4.8). Although ICOS expression was higher in infected 
individuals, it was negatively associated with Mf burden (Figure 4.9), HLA-DRA and 
CD74 also have a negative correlation but not as strong. HLA-DRA gene encodes for 
the DR alpha chain of MHC class II and CD74 encodes the invariant chain involved 







Figure 4.7. Expression of HLA-DRA, CD86, ICOS and CD3e in whole blood from 
individuals living in O. volvulus endemic areas. Gene expression were measured using 
Illumina microarray plates, and differences in expression between infected (Mf) and naturally 
protected endemic normal (EN) were analysed using GLMs. HLA-DRA is a component of the 
MHC-class II receptor; CD86 is a receptor found on dendritic cells which induces the 
proliferation and activation of T cells; ICOS is an inducible T-cell co-stimulator; and CD3e is 
a component of the T cell receptor. Individuals were classified as EN if no Mf were present in 







Figure 4.8.Expression of HLA-DRA, CD86, ICOS and CD3e in individuals living in W. 
bancrofti endemic area of Ghana. Gene expressions were measured using Illumina 
microarray plates, and differences in expression between infected and naturally protected 
endemic normal were analysed using GLMs. HLA-DRA is a component of the MHC-class II 
receptor; CD86 is a receptor found on dendritic cells which induces the proliferation and 
activation of T cells; ICOS is an inducible T-cell co-stimulator; and CD74 encodes the 
invariant chain protein which is associated with the formation and transport MHC-II. 
Individuals were classified as EN if no Mf were present in their blood and no circulating 







Figure 4.9. Expression of ICOS compared to microfilariae counts found in blood of 
individuals living in lymphatic filariasis endemic areas. Gene expression were measured 
using Illumina microarray plates, and GLM were used to measure the association between 
ICOS and Mf numbers present in the blood (samples without Mf present were removed). ICOS 
is an inducible T-cell co-stimulator and is negatively associated with Mf numbers found in the 






Vaccination experiments with the immunomodulator L. sigmodontis cysteine protease 
inhibitor (Ls-CPI), which has been shown to inhibit antigen presentation in MHC class 
II molecules (Manoury et al., 2001), induced little protection against challenge 
infection. However, when genetically modified to remove its immunomodulatory site, 
CPIm showed a greater efficacy, with a reduction in circulating microfilariae compared 
to CPI and non-vaccinated controls (Babayan et al., 2012). As it has been demonstrated 
that the early immune responses in infection or following immunisation determine the 
outcome of infection (Chapter 3) (Taylor et al., 2009; Babayan et al., 2010), and that 
CPI affects antigen presentation on cells such as dendritic cells (DC), changes in DC 
activation following stimulation/immunisation with CPI or CPIm were investigated in 
vitro and in vivo. This demonstrates how antigen (CPI) modification can affect the 
activation of dendritic cells and priming of T cells.  
In vitro experiments with bone-marrow derived DC (BMDC), showed an increase in 
DC activation following stimulation with CPIm, with increased levels of IL-6 and IL-
12p40 production. Both cytokines are frequently associated with Th1 immunity but 
since helminths generally fail to induce DC production of pro-inflammatory cytokines, 
often with minimal changes in DC messenger RNA expression, in this section IL-
12p40 and IL-6 are simply used to measure the change in DC activation (Cook et al., 
2015).  
Due to the lack of cytokine production by DC, it was proposed that Th2 responses in 
helminths  infections (and allergens) were induced as the default pathway when Th1 





molecules have been associated with DC ability to induce Th2 immunity (Cook et al., 
2015), such as CD40 (MacDonald et al., 2002), CD80/86 (Whelan et al., 2000), 
OX40L (Jenkins et al., 2007), CCL17 (Medoff et al., 2008), RELMa (Cook et al., 
2012) and NF-kB (Artis et al., 2005). This demonstrates that DC can prime a Th2 
response to helminth and allergens, however the specific mechanisms are unknown. 
In filarial infections IL-10 has been linked to parasite-driven immunomodulation 
(Satoguina et al., 2002; Simons et al., 2010; Specht et al., 2011b), and in the 
experiments described above an increase in IL-10 production by DC stimulated with 
CPI was also detected. In other nematode infections IL-10 has been directly linked to 
DC, such as in  Ascaris suum infections where their ES products have the ability to 
modulate the antigen presenting ability of DC via an IL-10 mediated mechanism (Silva 
et al., 2006) and in H. polygyrus with ES-treated BMDC generate regulatory T cells 
that produced high levels of IL-10 (Segura et al., 2007). This demonstrates that CPI 
could be pushing DC to a more regulatory phenotype whereas CPIm causes an increase 
in DC maturation. 
DC are critical for the development of an effective adaptive immune responses, as they 
are one of the main antigen-presenting cells, delivering a series of defined signals to 
naive T cells (Liu, 2001b). In DC and T cell co-cultures, there were significant 
increases in MHC class II antigen presentation and an increase in CD86 expression 
when DC were stimulated with CPIm. Furthermore, a small increase in CD40 
expression was detected on BMDC treated with CPIm, and together with MHC II and 
CD86, these molecules have been shown to be required for DC mediated Th2 induction 





In attempts to identify similar changes in DC activation following immunisation in 
vivo, mice were immunised with either L. sigmodontis CPI (Ls-CPI) or the Ls-CPIm. 
However, no differences between the immunised groups could be detected. DC are a 
complex population of cells, contrary to in vitro bone-marrow derived DC which are 
homogenous. In vivo, mice have several subpopulations of migratory and lymphoid-
resident DC, each with different phenotypes and functional properties (Segura, 
Villadangos, 2009). Therefore, the fact that no change in expression were detected in 
vivo, in this instance could be because specific DC subsets were not being isolated 
before the expression of activation markers were measured. In studies with B. malayi 
L3 infection, it was observed that lymphoid DC and CD8+ plasmacytoid DC peaked at 
day 7 post infection in spleens and mesenteric lymph nodes of infected mice (Sharma 
et al., 2016), therefore it could also be possible that looking at 24hrs post immunization 
is too short to detect any changes in DC activation or looking at mesenteric is too far 
away for DC to travel on such a small immune response induced by plasmid vaccine. 
The role of CPI in immunomodulation has previously been demonstrated, in in vitro 
experiments, spleens cells exposed to CPI (cystatin) from L. sigmodontis, showed 
decreased antigen specific responsiveness (Pfaff et al., 2002), and in experiments using 
human PBMC, stimulation with CPI (onchocystatin) from O. volvulus, suppressed 
antigen driven proliferation, with increased production of IL-10, decrease in IL-12p40, 
reduced expression of HLA-DR and costimulatory molecule CD86, corroborating the 
in vitro experiments with Ls-CPI and BMDC (Schönemeyer et al., 2001).  
Although CPI shows similar effect on human cells as with mice cells, early modulation 





it is impossible to identify individuals that have just been infected, as infected 
individuals are detected by the presence of Mf or adult parasites. Humans however do 
exhibit naturally induced protection (Hoerauf, Brattig, 2002; Brattig, 2004), and in 
chapter 3 pathways involved in T cell activation were found to be important at 
differentiating between infected and EN individuals living in areas endemic for 
onchocerciasis and lymphatic filariasis. Therefore, taking a candidate gene approach, 
genes involved in MHC-II, CD28-costimulatory and TCR signalling were 
investigated, however only genes involved in TCR signalling were detected as being 
important, supporting the results from machine learning approach taken in chapter 3. 
Using a system biology approach, the adaptive T-cell immune response induced by 
vaccination was successfully predicted using transcriptomic data obtained from DC 
(sorted spleen DC), 6 hours following vaccination (Dérian et al., 2016). Therefore, it 
is possible to use early changes in DC gene expression to predict adaptive immune 
responses and protection, but using a more focused approach such as investigating 
individual cell population. 
The work presented in this chapter shows that by modifying the immunomodulatory 
CPI antigen, DC responses are rescued, seen as an increase in DC maturation and 
activation, leading to increased protection seen at later stage of infection. This may 
suggest that DC can indeed prime the immune system towards Th2 pathways at the 
very early stages on infection, and that by boosting the immune response to DC 
following immunisation, would provide protection, such circumstances have 






• Structural modifications to CPI induces an increase in DC activation in vitro. 
• Early changes in DC activation could explain increased protection seen late on 




Chapter 5. General discussion 
Current control of onchocerciasis relies on annual mass drug administration (MDA) 
with Ivermectin, (Mectizan donation project, (Thylefors, 2008)), whose widespread 
distribution in mass treatment campaigns has reduced the incidence of skin and eye 
disease in some foci in Latin America (World Health Organization, 2016b) and West 
Africa (Mali, Senegal (Diawara et al., 2009) and Nigeria (Tekle et al., 2012)). Such 
success led to the speculation that Ivermectin treatment alone could eliminate (and 
possibly eradicate) onchocerciasis. However, after more than 25 years of distribution 
of Ivermectin, onchocerciasis remains endemic across 27 countries in Africa, including 
in areas where Ivermectin treatment has been given continuously for over 15 years 
(Katabarwa et al., 2013; Lamberton et al., 2015; Wanji, 2015; Kamga et al., 2016). 
Mathematical modelling has demonstrated that relying on MDA alone for the 
elimination of onchocerciasis in Africa will not be sufficient (Turner et al., 2013; 
2014b). Several factors contribute to the persistence of onchocerciasis:  
• Ivermectin only kills the Mf and any interruption of their production is 
temporary (Basáñez et al., 2008), 
• In areas with high prevalence, such as forest areas, Ivermectin cannot 
completely interrupt transmission (Cupp et al., 2011; Cheke, 2017), 
• There is growing evidence for the emergence of Ivermectin resistance (Osei-
Atweneboana et al., 2011; Pion et al., 2013), 
• Ivermectin cannot be used in areas with O. volvulus and L. loa co-endemicity. 
Individuals infected with both parasites are at risk of severe and possible fatal 





implementation of control programmes using MDA with this drug (Chesnais 
et al., 2017), 
• The drug cannot be given to children under 5 or pregnant women, therefore 
this leaves a reservoir of the infection, even in areas where MDA has been 
implemented (Stolk et al., 2015b). 
If onchocerciasis is to be eliminated, and perhaps eradicated, new interventions are 
required, such as a novel drug that kills adult worms or a vaccine. Mathematical 
modelling has shown that a vaccine against onchocerciasis would complement MDA 
efforts and decrease the chances of re-emergence of O. volvulus infections, especially 
in foci where onchocerciasis has been successfully controlled (Turner et al., 2015). It 
would also protect the considerable financial investment in onchocerciasis control that 
has been made over the decades. 
Filarial nematodes are multi-cellular organisms that induce an immunomodulatory 
milieu, allowing them to establish chronic infections that may last up to 20 years 
(Doetze et al., 2000; Hoerauf et al., 2005). However, it is also apparent that a small 
proportion of individuals develop protective immunity that keeps them free of parasites 
and disease despite a life-time of exposure (Hoerauf, Brattig, 2002; Brattig, 2004). 
This protective immunity is associated with a Th2 response, which is also responsible 
for the protective immunity induced by vaccination in murine models of filarial 
infections (Allen et al., 2008; Katawa et al., 2015; Kwarteng, Ahuno, 2017). 
A strategy has been proposed to target parasite-driven immunomodulators and allow 
the host to mount a protective Th2 responses (Babayan et al., 2012; Nisbet et al., 2013). 





induce full protection, thus it has been suggested that the inclusion of a second antigen 
could induce greater protection.  
Over the years of O. volvulus research, several potential vaccines candidates have been 
identified and tested in animal models (Morris et al., 2013). The most promising of 
these are: Ov-RAL-2 (Lustigman et al., 1992b; Bradley et al., 1993; Hess et al., 2014), 
Ov-103 (Lustigman et al., 1992b; Hess et al., 2014) and mutated Ov-CPI-2 (CPIm 
(Babayan et al., 2012; Arumugam et al., 2014b)). Each have consistently conferred 
high levels of protection (Babayan et al., 2012; Arumugam et al., 2014b; Hess et al., 
2014; Arumugam et al., 2016).  
CPIm, is derived from CPI-2, a known immunomodulator (Manoury et al., 2001; Vray 
et al., 2002; Gregory, Maizels, 2008), which has been modified to remove its 
modulatory residues (Murray et al., 2005). In immunisation experiments in the L. 
sigmodontis model, using Ls-CPIm DNA vaccines reduced the numbers of circulating 
Mf (Babayan et al., 2012), and in B. malayi model using Bm-CPIm recombinant 
protein vaccine, induced a 48% reduction in worm burden (Arumugam et al., 2014b), 
providing evidence that targeting the immunomodulatory molecules of the parasites is 
a feasible vaccine strategy. 
With this result in mind, the excretory and secretory (E/S) molecules of adult female 
worms were investigated to identify other potential immunomodulators (Armstrong et 
al., 2014), as adult females have been shown to be responsible for the survival of Mf 
(Hoffmann et al., 2001). From these analyses, a protein containing six ShK domains 





L. sigmodontis (Armstrong et al., 2014) and homologues of Ls-ShK have been 
hypothesised to be able to modulate memory T cells (Beeton et al., 2011; Chhabra et 
al., 2014). 
Initial DNA vaccine experiments with Ls-ShK in the L. sigmodontis model, showed 
promise by inducing protection in an initial experiment, as no Mf were detected the 
blood of Ls-ShK immunised mice (Duprez. J, MRes Thesis, 2013, University of 
Edinburgh). However, in repeat immunisation experiments, Ls-ShK failed to induce 
any protection, perhaps because of its immunomodulator properties (Armstrong et al., 
2014; Chhabra et al., 2014). It was demonstrated that removing suppressive functions 
of immunomodulator vaccine candidates (e.g. CPI) could induce significant protection 
(Babayan et al., 2012; Arumugam et al., 2014b). Therefore, in subsequent vaccination 
experiments Ls-ShK was modified, in the hope that this would increase specific 
immune response and therefore induce protection. 
DNA vaccines were chosen to screen vaccine candidates, in part because they are 
relatively easy and cheap to produce. However, it must be noted that DNA vaccines 
do not always induce strong protective immunity despite being able to generate 
specific immune responses (Donnelly et al., 2005). Therefore, peptide vaccines were 
used to further investigate the candidate antigens. Peptides are an attractive alternative, 
as they encode specific epitopes of an antigen, and as consequence they are able to 
induce a highly targeted immune responses while eliminating possible allergic or 





Peptides derived from Ls-RAL and Ls-103 were grouped together as these are highly 
immunogenic candidates, and peptides from known or hypothesised 
immunomodulators, Ls-CPI-2, Ls-ShK and Ls-Tgh2 were grouped together. This was 
done because individual peptides would take too long to test and immunising with a 
single antigenic epitope might not be enough to elicit an appropriate immune response.  
Immunisation with the immunogenic or immunomodulatory peptide vaccine resulted 
in decreased numbers of circulating Mf in the blood. In contrast, the numbers of adult 
worms appeared unaffected by any vaccination protocol. This suggests that the 
peptides vaccines are affecting the Mf life stages only. Investigation of adult female 
fecundity revealed that the immunomodulatory and immunogenic groups of peptides 
are affecting either the development of Mf in uteri or the number (density) of Mf 
produced. This reduced adult female fecundity can also be seen in other immunisation 
experiments, such as in L. sigmodontis model with either DNA vaccination with Ls-
CPIm (Babayan et al., 2012) or the Mf life stage (Ziewer et al., 2012); in B. malayi 
model with Bm-CPIm protein recombinants (Arumugam et al., 2014b); as well as with 
immunisation with B. malayi ES in gerbils (Zipperer et al., 2013). Suggesting that the 
vaccine candidates, are inducing protection by reducing female fecundity, instead of 
affecting adult worm survival. 
These early results show promise and prompted questions about the use of a 
combination of antigens in a single inoculum. The groups which received all peptides 
in an immunisation dose showed no protection, but we know that combination of Ov-
Ral-2 and Ov-103 does increase protective efficacy over individual antigens (Hess et 





essential, and different combinations of immunogenic and immunomodulatory 
antigens will have to be investigated in the future. 
The vaccine candidates were selected based on their protective efficacy in several 
animal models (measured as a decrease in parasite burden), however the mechanisms 
by which they induce protection and correlates of vaccine-induced immunity remain 
unknown. Identifying correlates of vaccine-induced protective immunity that are 
predictive of vaccine efficacy would aid in the screening of vaccine candidates, 
because currently vaccine efficacy is determined as decrease in parasite burden, 
measured late in a vaccination time course. Therefore, if vaccine efficacy could be 
predicted in the early stages of infection or even before infection, time and money 
could be saved (Mastelic et al., 2013). 
Several studies have taken a “systems biology/vaccinology” approach to identify 
correlates of vaccine induced immunity. Systems vaccinology consists of using high-
throughput technologies including DNA microarrays, protein arrays and deep 
sequencing to enable systems-wide measurements, combined with predictive 
modelling. The advantage of a systems-wide approach versus conventional 
immunological methods which only analyse a single or small numbers of components 
of the immune system at a given time, is that by measuring changes across a whole 
system the full complexity and dynamics of the human immune system can be 
analysed. 
To identify correlates of protection following immunisation in the L. sigmodontis 





an immunisation experiment, with either irradiated L3 or microfilariae immunisations 
(Le Goff et al., 2000; Ziewer et al., 2012), and RNA from these samples were 
hybridised to Illumina microarrays, allowing the expression of tens of thousands of 
genes to be measured.  
Machine learning methods were used to analyse the gene expression datasets over 
more commonly used methods such differential fold change or weighted gene 
correlation networks (WGCNA) (Langfelder, Horvath, 2008), because the microarray 
datasets produced were highly dimensional (many gene measured compared to sample 
numbers), with complex interaction between genes working within 
networks/pathways, for which the other methods were not well suited or powerful 
enough to detect changes (Butte, 2002; Huynh-Thu et al., 2012; Sundarrajan, 
Arumugam, 2016). Machine learning has been used for a variety of tasks in biomedical 
sciences, such as classifying cancer subtypes (Anaissi et al., 2013), to predicting 
outcomes of treatment (Gim et al., 2016), with a newer role in vaccinology, such as 
predicting antibody responses to potential HIV vaccines (Choi et al., 2015).  
Using machine learning (ML), biologically relevant gene signatures were successfully 
detected following immunisation with either irradiated L3 and Mf. Gene signatures 
identified after immunisation with irradiated L3 were associated with neutrophil 
migration and chemotaxis. In in vivo studies, neutrophils recruitment to site of L3 
infection have also been associated with protection (Pionnier et al., 2016).  
Immunisation with Mf elicited changes in gene expression, associated with antigen 





Immune responses to Mf are known to be linked to IFN-g (Lawrence et al., 2000; 
Saeftel et al., 2003; Ziewer et al., 2012), and has also been successfully identified by 
the ML pipeline. The ML pipeline also further identified IFN-a and IFN-b as being 
involved with Mf immunity, to date, activity of these cytokines has not been linked to 
filarial infection. However, in schistosomiasis IFN-b was produced by DC in response 
to Schistosoma mansoni eggs and is thought to be an immune evasion strategy 
(Trottein et al., 2004), and IFN-b produced by DC stimulated with LPS was suggested 
to generate regulatory T cells (Wang et al., 2014).  
This study has shown that it is feasible to use a system wide approach to detect 
correlates of protection and information on the mechanism triggered by the vaccines 
in blood sampled during filarial infections. Furthermore, it demonstrates that it is the 
time points after immunisation that are the most predictive of vaccine efficacy. This 
approach has also been applied to commercially available vaccines such as: live 
attenuated vaccine YF-17D against yellow fever (Gaucher et al., 2008; Querec et al., 
2008); the trivalent inactivated influenza vaccine (TIV) (Bucasas et al., 2011; Nakaya 
et al., 2011b); and a two vaccines against meningitis (MPSV4 and MCV4) (Li et al., 
2013b), and similar to this study, they found that the early gene signatures were 
predictive of vaccine immunogenicity, although mechanism of action did differ. 
The results presented revealed that the best time point to identify immune correlates of 
protection was immediately after immunisation, and not when infection has been 
established. This can also be demonstrated when measuring antibody levels, which are 





numbers. Similarly changes in gene expression measured late in infection, using either 
qPCR arrays (Chapter 2) or high-throughput techniques such as microarrays (Chapter 
3), is too late to detect any changes associated with protection, and detectable changes 
in expression of immune genes were positively association with parasite burden. 
Most investigations of immune responses against murine and human filarial infection 
have been carried out during chronic infections (once infection has been established), 
as often this is the only point infection can be detected. However, this could mean that 
interpretation of results and identification of protective responses may be difficult, 
since we have demonstrated that it is the early time point in infection that are the most 
informative. This is consistent with Taylor et al who showed that early priming of the 
immune system was important in determining the outcome of infection (Taylor et al., 
2009). 
A wide range of pathways were found associated with protection using the ML pipeline 
on human gene expression data. Gene activity involved in the defence against other 
pathogens, humoral immune responses, DNA dependent replication and cell cycle 
pathways were detected in blood taken from onchocerciasis patients. In W. bancrofti 
infections, gene activity associated with protection appeared to be primarily involved 
with T cell receptor signalling. One of the reasons for which gene signatures associated 
with protection in humans is more varied, is because humans can be re-infected, have 
co-infections with other diseases, vary in age, unlike mice experiments, which are 





Despite the human dataset being noisier, the ML analysis detected common 
activity/pathways between the murine and human filarial infections. These results 
further increases confidence in the use of the L. sigmodontis mouse model for vaccine 
studies. Being able to bridge the gap between mice and humans will be tremendously 
helpful for vaccine development and indeed in the interpretation of any processes 
where model systems must be used. Mouse models have been useful and are necessary 
at identifying immune responses to filarial infections and evaluating potential vaccine 
candidates. Murine models exhibit much less variation in gene responses to infection 
than found in human subjects and hence results of murine studies provide a convenient 
starting point for analysis of human data. 
However, there are significant differences in both the innate and adaptive arm of the 
immune system between humans and mice (Mestas, Hughes, 2004) and these should 
be carefully considered when interpretation gene expression data. Translating vaccine 
research from animal models to human trials is not always as straightforward. Some 
vaccines that have showed promise in mouse models, lacked efficacy in human trials 
(Gray et al., 2011; Tameris et al., 2013; Kaufmann et al., 2014) or raised safety 
concerns during clinical trials (Diemert et al., 2012).  
Now that it has been shown that whole blood is a feasible sample to measure correlates 
of protection, these methods could be applied during vaccine trials. As filarial parasites 
have long life cycles, the ability to predict the immunogenicity of a vaccine within the 
first few days or weeks of a clinical trial, would help predict protection levels at the 
endpoint and ultimately save money and time if the vaccine candidate is deemed 





well defined, as correlates of efficacy in healthy young adults may not be necessarily 
the same as biomarkers of protection in the elderly or children under 5 which are the 
targeted population (Nakaya et al., 2011a).  
Identifying biomarkers or signatures of safety will also be critical for successful 
vaccine development and to avoid adverse reactions in clinical trials. The human data 
set used in the studies describe here lacked information on pathology and therefore 
identification of potential signatures of adverse reactions was limited. 
Since the microarray analysis identified the early time points following immunisation 
as being the most predictive of vaccine efficacy, the effect of Ls-CPIm (one of the 
vaccine candidates) on dendritic cells (DC) was investigated. Dendritic cells are a 
population of professional antigen presenting cells that have the ability to sense foreign 
pathogens and initiate a type 1, type 2 or regulatory immune response (Motran et al., 
2016). Pathogens have evolved strategies to modulate DC, such as the 
excretory/secretory products produced by filarial nematodes, which have shown to 
impair DC function, and suppress both Th1 and Th2 adaptive immune response as well 
as inducing regulatory T cells (Segura et al., 2007; Carvalho et al., 2009; Terrazas et 
al., 2013). Ls-CPIm is derived from CPI-2, which is known to affect antigen 
presentation by MHC II molecules on antigen presenting cells such as DC (Manoury 
et al., 2001). Immunisation with the native CPI shows little protection in L. 
sigmodontis models (Babayan et al., 2012), and in B. malayi model, immunisation with 
CPI changes the migratory patterns of adult worms and but confers no protection 





increase in protection seen following immunisation (Babayan et al., 2012; Arumugam 
et al., 2014b).  
In vitro bone marrow derived DC cultures were used to show that the mutation of CPI 
rescues DC activation and maturation. Since DC are a key link between innate and 
adaptive immunity (Liu, 2001a), it was suggested that CPIm works by increasing the 
activation of DC and hence increasing adaptive immunity, which eventually leads to 
protective immunity. Although this could not be demonstrated in vivo, this was most 
likely due to lack of sensitivity associated with a presumed small population of DC 
that have taken up the CPI or CPIm. Measuring changes in gene expression in whole 
blood is ideal to detect systemic changes, however if one wants to measure a more 
specific cellular response to immunisation, such as ones by DC, then cells must first 
be isolated. Therefore, to determine if CPIm vaccine is indeed rescuing DC activation 
in vivo, then changes in gene expression would need to be investigated within isolated 






Figure 5.1. Overview of thesis. 1) Vaccine candidates were tested in the L. sigmodontis mouse 
model, either using DNA or peptide vaccines. Vaccine efficacy or protection is measured as a 
change in adult worm and microfilariae numbers, at the end of a vaccination time course, in L. 
sigmodontis model this is around 65-days post challenge infection. Immunological readouts 
such as percentage of cell types, cytokine levels and antibody levels were also measured at the 
end of the time course, although these are not always predictive of vaccine efficacy. 2) 
Determine correlates of vaccine induced protection can be beneficial for vaccine trials, such 
as identifying early predictors of vaccine efficacy could help speed up clinical trials. The 
simplest method to identify correlates of protection would be to identify gene signatures in 
blood using high-throughput techniques (microarrays), but whether these could be measured 
in blood during filarial infection remained unknown, and if possible at what point during 
infection, since at the end it is too late to detect any changes. Therefore, blood was collected 
at several time points in a vaccination time course, RNA was extracted and hybridised to 
Illumina microarrays to measure the expression of tens of thousands of genes. Since the 
microarrays generated complex datasets, a machine learning pipeline was created to detect 
changes in gene signatures between immunised and non-immunised mice. This pipeline 
successfully detected changes in gene expression that were known to be induced by these 





techniques can detect biologically significant changes in gene expression. Furthermore, time 
points following immunisation showed to be the most informative, therefore in the future these 
can be used to predict vaccine efficacy. Parallel to mice studies, blood samples were collected 
from naturally protected and infected individuals living in foci endemic for O. volvulus and W. 
bancrofti, using microarrays and the machine learning pipeline, correlates of protection in 
human were investigated and some overlap was found between vaccine induced immunity in 
mice and natural protection in humans. 3) Most vaccine candidates were chosen without 
knowing their mechanism of action, since one of the vaccine candidates, Ls-CPIm, was derived 
from CPI-2, an immunomodulatory known to affect antigen presentation on cells such as DC. 
Therefore, the effect of Ls-CPI and mutated Ls-CPI (CPIm) on bone-marrow derived DC 
(BMDC) were compared, finding that Ls-CPIm rescues DC activation. Showing that increased 
protection induced by Ls-CPIm is due to increased DC activity, although this was not shown 
in vivo. With the microarrays analysis that shows that is the early time points following 
immunisation that determines the outcome of vaccination, it could be suggested that it is the 
early activation of cellular response, such as DC that are necessary to induce immune response 







The work presented in this thesis shows that targeting immunomodulatory molecules 
is a feasible strategy for vaccination against onchocerciasis. Experience suggest that it 
might be necessary to modify the native molecule to remove their immunomodulatory 
properties as part of the formulation of any vaccine. This was done to one of the most 
promising vaccine candidate, CPI. A mutated form of CPI that lacks 
immunomodulatory activity evoked greater protection which was associated with 
increased DC activation. The correct formulation of any vaccine will be a critical 
component for successful development of a vaccine. 
The use of a systems approach and machine learning has demonstrated that changes in 
gene expression can be detected in whole blood following exposure to and 
immunisation against filarial infections. This opens many possibilities for vaccine 
development, by more rapidly understanding the mechanisms associated with 
successful immunisation and formulation to optimise the immunogenicity and efficacy 
of vaccines, to achieve stronger and longer protection. The potential to recognise and 
predict possible adverse reactions to specific molecules will improve safety of any 
vaccine. This approach also brings the possibility of identifying early predictors of 
vaccine efficacy and this knowledge could greatly speed up vaccine trials. 
It has been demonstrated that early changes in the immune system immediately 
following exposure to infection or immunisation are critical in determining the 
outcome of infection. These observation questions the value of many earlier 
investigations of immune response to filariae that have used material collected from 





if an immunisation is successful, a detailed investigation of responses immediately 
after exposure to infection is needed. This can be done in murine models but for 
humans studies the focus must now turn to the examination of very young children 
living in endemic areas. 
These studies have, by necessity, focussed on the capacity of experimental vaccines to 
reduce worm burden. A vaccine that reduces the number of microfilariae in the skin 
will reduce morbidity. However, if onchocerciasis is to be eliminated from any region, 
or even eradicated. The reduction in microfilariae loads must be such as to block 
transmission. The aim is to vaccinate individuals currently omitted from MDA, such 
as pre-school children, and by including this cohort in an integrated control programme 
with Ivermectin distribution could be a major step towards elimination of 
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Appendix A. Supplementary Tables from 
Chapter 2. 
Table S1. Supplementary list of genes used in qPCR array 
Gene Symbol Gene RefSeq Gene Symbol Gene RefSeq 
Apcs NM_011318 Ifng NM_008337 
C3 NM_009778 Ifngr1 NM_010511 
C5ar1 NM_007577 Il10 NM_010548 
Casp1 NM_009807 Il13 NM_008355 
Ccl12 NM_011331 Il17a NM_010552 
Ccl5 NM_013653 Il18 NM_008360 
Ccr4 NM_009916 Il1a NM_010554 
Ccr5 NM_009917 Il1b NM_008361 
Ccr6 NM_009835 Il1r1 NM_008362 
Ccr8 NM_007720 Il2 NM_008366 
Cd14 NM_009841 Il23a NM_031252 
Cd4 NM_013488 Il4 NM_021283 
Cd40 NM_011611 Il5 NM_010558 
Cd40lg NM_011616 Il6 NM_031168 
Cd80 NM_009855 Irak1 NM_008363 
Cd86 NM_019388 Il-33 NM_033439.3 
Cd8a NM_001081110 Irf7 NM_016850 
Crp NM_007768 Itgam NM_008401 
Csf2 NM_009969 Jak2 NM_008413 
Cxcl10 NM_021274 Ly96 NM_016923 
Cxcr3 NM_009910 Lyz2 NM_017372 
Il-3 NM_000588.3 Mapk1 NM_011949 
Fasl NM_010177 Mapk8 NM_016700 
Foxp3 NM_054039 Mbl2 NM_010776 
Gata3 NM_008091 Mpo NM_010824 
H2-Q10 NM_010391 Eotaxin NM_011330.3 
H2-T23 NM_010398 Myd88 NM_010851 
Icam1 NM_010493 Nfkb1 NM_008689 
Cxcl1 NM_001511 Nfkbia NM_010907 
Ifnar1 NM_010508 Lta NM_001159740.2 





Gene Symbol Gene RefSeq Gene Symbol Gene RefSeq 
Nod2 NM_145857 Tlr2 NM_011905 
Rag1 NM_009019 Tlr3 NM_126166 
Rorc NM_011281 Tlr4 NM_021297 
Ltb NM_002341.1 Tlr5 NM_016928 
Stat1 NM_009283 Tlr6 NM_011604 
Stat3 NM_011486 Tlr7 NM_133211 
Stat4 NM_011487 Tlr8 NM_133212 
Stat6 NM_009284 Tlr9 NM_031178 
Tbx21 NM_019507 Tnf NM_013693 
Ticam1 NM_174989 Traf6 NM_009424 







Appendix B. Supplementary results from 
chapter 3 (functional pathway analysis of 
machine learning pipeline and WGCNA results)   
Table S2. Full list of over-represented Reactome pathways from the WGCNA analysis of 
Mf immunity. Time points Day -21, Day -14 and Day 67 in the Mf immunity dataset had 
significantly over-represented pathways. Multiple testing was adjusted for using the 
Benjamini-Hochberg method to give an adjust P-value, an adjusted P-value < 0.05 and a Q-
value < 0.2 was used as the significance cut-off point for significant.  
Description of Reactome Pathway Found by ML pipeline 
Day -21 (6 hours after 2nd Immunisation) 
Adaptive Immune System  
Antigen Presentation: Folding, assembly and peptide loading of class 
I MHC  
Antigen processing-Cross presentation  
Class I MHC mediated antigen processing & presentation  
Endosomal/Vacuolar pathway  
ER-Phagosome pathway  
Immune System  
Immunoregulatory interactions between a Lymphoid and a non-
Lymphoid cell  
Interferon gamma signaling  
Interferon Signaling  
Generation of second messenger molecules  
PD-1 signaling  
Phosphorylation of CD3 and TCR zeta chains  
Translocation of ZAP-70 to Immunological synapse  





ERK/MAPK targets  
ERKs are inactivated  
MAP kinase activation in TLR cascade  
MAPK targets/ Nuclear events mediated by MAP kinases  
MyD88 cascade initiated on plasma membrane  
MyD88 dependent cascade initiated on endosome  
MyD88-independent TLR3/TLR4 cascade  
MyD88:Mal cascade initiated on plasma membrane  
Nuclear Events (kinase and transcription factor activation)  
RHO GTPases Activate Formins  
Toll Like Receptor 10 (TLR10) Cascade  
Toll Like Receptor 2 (TLR2) Cascade  
Toll Like Receptor 3 (TLR3) Cascade  
Toll Like Receptor 4 (TLR4) Cascade  
Toll Like Receptor 5 (TLR5) Cascade  
Toll Like Receptor 7/8 (TLR7/8) Cascade  
Toll Like Receptor 9 (TLR9) Cascade  
Toll Like Receptor TLR1:TLR2 Cascade  
Toll Like Receptor TLR6:TLR2 Cascade  
TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 
or 9 activation  
TRAF6 Mediated Induction of proinflammatory cytokines  
TRIF-mediated TLR3/TLR4 signaling  
Day -14 (6 hours after 3rd Immunisation) 
Interferon gamma signaling  






Endosomal/Vacuolar pathway  
Immunoregulatory interactions between a Lymphoid and a non-
Lymphoid cell  
Interferon gamma signaling  







Table S3. Full list of over-represented Gene Ontology Terms of biological processes from 
the WGCNA analysis of Mf immunity. Time point day -21, day 0, day 49 and day 67 in the 
Mf immunity dataset had significantly over-represented GO terms. Multiple testing was 
adjusted for using the Benjamini-Hochberg method to give an adjust P-value, an adjusted P-
value < 0.05 and a Q-value < 0.2 was used as the significance cut-off. 
GO Description Identified in ML pipeline 
Day -21 (6 hours after 2nd Immunisation) 
response to interferon-beta  
Day 0 (6 hours post challenge)
nuclear body organization  
PML body organization  
nucleus organization  
Day 49 (post challenge) 
response to external stimulus  
Day 67 (post challenge) 
antigen processing and presentation  
response to interferon-beta  
cellular response to interferon-beta  
defense response to other organism  






Table S4. Full list of over-represented Gene Ontology Terms of biological processes in 
the Mf immunity dataset found by the ML Pipeline. Time point day -21, day -14 and day 
49 in the Mf immunity dataset had significantly over-represented GO terms. Multiple testing 
was adjusted for using the Benjamini-Hochberg method to give an adjust P-value, an adjusted 
P-value < 0.05 and a Q-value < 0.2 was used as the significance cut-off. 
BP GO 





Genes selected by 
pipeline 
Day -21 (6 hours after 2nd immunisation) 
GO:0035456 response to interferon-beta 7 9.39E-06 Gbp2b, Gbp2, Gbp3, 
Ifit3, Ifitm3, Igtp, Irf1 
GO:0035458 cellular response to interferon-
beta 
6 4.87E-05 Gbp2b, Gbp2, Gbp3, 
Ifit3, Igtp, Irf1 
GO:0048002 antigen processing and 
presentation of peptide antigen 
6 4.32E-03 B2m, Cd74, H2-D1, 
H2-Q6, H2-Q8, H2-
T23 
GO:0071345 cellular response to cytokine 
stimulus 
13 6.38E-03 Cd74, Cdc37, 
Coro1a, Gbp2b, 
Gbp2, Gbp3, Ifit3, 
Ifitm3, Igtp, Irf1, 
Irf7, Robo1, Tpr 
GO:0002474 antigen processing and 
presentation of peptide antigen 
via MHC class I 
5 6.46E-03 B2m, H2-D1, H2-Q6, 
H2-Q8, H2-T23 
GO:0034341 response to interferon-gamma 6 6.86E-03 Cdc37, Gbp2b, Gbp2, 
Gbp3, Ifitm3, Irf1 
GO:0002250 adaptive immune response 11 6.86E-03 B2m, Cd74, Cd79b, 
Cd8b1, Csk, H2-D1, 
H2-T23, Irf1, Irf7, 
Serpina3g, Unc13d 
GO:0034112 positive regulation of homotypic 
cell-cell adhesion 
8 6.86E-03 Ank3, Cd74, Coro1a, 
H2-T23, Irf1, Lck, 
Tgfbr2, Thy1 
GO:0098542 defense response to other 
organism 
13 8.95E-03 B2m, Gbp2b, Gbp2, 
Gbp3, H2-T23, Ifit3, 







GO:0071346 cellular response to interferon-
gamma 
5 8.95E-03 Cdc37, Gbp2b, Gbp2, 
Gbp3, Irf1 
GO:0042110 T cell activation 12 8.95E-03 B2m, Cd2, Cd3d, 
Cd74, Coro1a, Csk, 
Fcgr4, H2-T23, Irf1, 
Lck, Tgfbr2, Thy1 
GO:0070489 T cell aggregation 12 8.95E-03 B2m, Cd2, Cd3d, 
Cd74, Coro1a, Csk, 
Fcgr4, H2-T23, Irf1, 
Lck, Tgfbr2, Thy1 
GO:0071593 lymphocyte aggregation 12 8.95E-03 B2m, Cd2, Cd3d, 
Cd74, Coro1a, Csk, 
Fcgr4, H2-T23, Irf1, 
Lck, Tgfbr2, Thy1 
GO:0034109 homotypic cell-cell adhesion 13 8.95E-03 Ank3, B2m, Cd2, 
Cd3d, Cd74, Coro1a, 
Csk, Fcgr4, H2-T23, 
Irf1, Lck, Tgfbr2, 
Thy1 
GO:0070486 leukocyte aggregation 12 9.76E-03 B2m, Cd2, Cd3d, 
Cd74, Coro1a, Csk, 
Fcgr4, H2-T23, Irf1, 
Lck, Tgfbr2, Thy1 
GO:0045088 regulation of innate immune 
response 
8 1.19E-02 Arf6, Cd74, Cdc37, 
H2-T23, Irf1, Irf7, 
Samhd1, Trafd1 
GO:0022409 positive regulation of cell-cell 
adhesion 
8 1.20E-02 Ank3, Cd74, Coro1a, 
H2-T23, Irf1, Lck, 
Tgfbr2, Thy1 
GO:0007159 leukocyte cell-cell adhesion 12 1.46E-02 B2m, Cd2, Cd3d, 
Cd74, Coro1a, Csk, 
Fcgr4, H2-T23, Irf1, 
Lck, Tgfbr2, Thy1 
GO:0002483 antigen processing and 
presentation of endogenous 
peptide antigen 
3 1.46E-02 B2m, H2-D1, H2-
T23 
GO:0019882 antigen processing and 
presentation 







GO:0006414 translational elongation 4 1.47E-02 Secisbp2, Eef1a1, 
Eef1b2, Yrdc 
GO:0050870 positive regulation of T cell 
activation 
7 1.47E-02 Cd74, Coro1a, H2-
T23, Irf1, Lck, 
Tgfbr2, Thy1 
GO:0034110 regulation of homotypic cell-cell 
adhesion 
9 1.47E-02 Ank3, Cd74, Coro1a, 
Csk, H2-T23, Irf1, 
Lck, Tgfbr2, Thy1 
GO:0044406 adhesion of symbiont to host 3 1.47E-02 Gbp2b, Gbp2, Gbp3 
GO:0050830 defense response to Gram-
positive bacterium 
5 1.58E-02 B2m, Gbp2b, Gbp2, 
Gbp3, H2-T23 
GO:0050778 positive regulation of immune 
response 
11 1.58E-02 Arf6, B2m, Cd74, 
Cd79b, Csk, H2-D1, 
H2-T23, Irf1, Irf7, 
Lck, Thy1 
GO:0019883 antigen processing and 
presentation of endogenous 
antigen 
3 1.58E-02 B2m, H2-D1, H2-
T23 
GO:1903039 positive regulation of leukocyte 
cell-cell adhesion 
7 1.58E-02 Cd74, Coro1a, H2-
T23, Irf1, Lck, 
Tgfbr2, Thy1 
GO:0035455 response to interferon-alpha 3 2.15E-02 Ifit3, Ifitm3, Tpr 
GO:0032845 negative regulation of 
homeostatic process 
7 2.41E-02 Cd74, Coro1a, Csk, 
Lck, Mcoln1, Rtel1, 
Thy1 
GO:0032844 regulation of homeostatic 
process 
11 2.41E-02 Ank3, B2m, Cd74, 
Coro1a, Csk, Ets1, 
Hcar2, Lck, Mcoln1, 
Rtel1, Thy1 
GO:0002819 regulation of adaptive immune 
response 
6 2.41E-02 B2m, Cd74, H2-D1, 
H2-T23, Irf1, Irf7 
GO:0001916 positive regulation of T cell 
mediated cytotoxicity 
3 2.47E-02 B2m, H2-D1, H2-
T23 
GO:0051497 negative regulation of stress 
fiber assembly 





GO:0060337 type I interferon signaling 
pathway 
3 2.47E-02 Cdc37, Ifitm3, Irf7 
GO:0002821 positive regulation of adaptive 
immune response 
5 2.53E-02 B2m, Cd74, H2-D1, 
H2-T23, Irf1 
GO:0071357 cellular response to type I 
interferon 
3 2.66E-02 Cdc37, Ifitm3, Irf7 
GO:0001909 leukocyte mediated cytotoxicity 5 2.66E-02 B2m, Coro1a, H2-
D1, H2-T23, Unc13d 
GO:0050863 regulation of T cell activation 8 2.67E-02 Cd74, Coro1a, Csk, 
H2-T23, Irf1, Lck, 
Tgfbr2, Thy1 
GO:0051235 maintenance of location 8 2.90E-02 Ank3, Coro1a, Lck, 
Mcoln1, Pfn1, Sorl1, 
Thy1, Sun2 
GO:1903037 regulation of leukocyte cell-cell 
adhesion 
8 3.38E-02 Cd74, Coro1a, Csk, 
H2-T23, Irf1, Lck, 
Tgfbr2, Thy1 
GO:0032232 negative regulation of actin 
filament bundle assembly 
3 3.57E-02 Clasp2, Dlc1, Pfn1 
GO:0071426 ribonucleoprotein complex 
export from nucleus 
4 3.77E-02 Ddx39b, Rps15, 
Thoc6, Tpr 
GO:0001914 regulation of T cell mediated 
cytotoxicity 
3 3.77E-02 B2m, H2-D1, H2-
T23 
GO:0035740 CD8-positive, alpha-beta T cell 
proliferation 
2 3.77E-02 H2-T23, Irf1 
GO:0002449 lymphocyte mediated immunity 7 3.79E-02 B2m, Cd74, Coro1a, 
H2-D1, H2-T23, Irf7, 
Unc13d 
GO:0071166 ribonucleoprotein complex 
localization 
4 3.86E-02 Ddx39b, Rps15, 
Thoc6, Tpr 
GO:0045785 positive regulation of cell 
adhesion 
9 3.86E-02 Ank3, Cd74, Coro1a, 
H2-T23, Irf1, Lck, 
Tgfbr2, Thy1, 
Unc13d 





GO:0001906 cell killing 5 4.14E-02 B2m, Coro1a, H2-
D1, H2-T23, Unc13d 
GO:0022407 regulation of cell-cell adhesion 9 4.15E-02 Ank3, Cd74, Coro1a, 
Csk, H2-T23, Irf1, 
Lck, Tgfbr2, Thy1 
GO:0002460 adaptive immune response based 
on somatic recombination of 
immune receptors built from 
immunoglobulin superfamily 
domains 
7 4.15E-02 B2m, Cd74, H2-D1, 
H2-T23, Irf1, Irf7, 
Unc13d 
GO:0002757 immune response-activating 
signal transduction 
7 4.15E-02 Arf6, Cd79b, Csk, 
Irf1, Irf7, Lck, Thy1 
GO:0042742 defense response to bacterium 7 4.15E-02 B2m, Gbp2b, Gbp2, 
Gbp3, H2-T23, 
Nlrp1a, Plac8 
GO:0006488 dolichol-linked oligosaccharide 
biosynthetic process 
2 4.15E-02 Alg12, Dpagt1 
GO:0043320 natural killer cell degranulation 2 4.15E-02 Coro1a, Unc13d 
GO:0046784 viral mRNA export from host 
cell nucleus 
2 4.15E-02 Ddx39b, Thoc6 
GO:0051251 positive regulation of 
lymphocyte activation 
7 4.29E-02 Cd74, Coro1a, H2-
T23, Irf1, Lck, 
Tgfbr2, Thy1 
GO:0042832 defense response to protozoan 3 4.47E-02 Gbp2b, Gbp2, Gbp3 
Day -14 (6 hours after 3rd immunisation) 
GO:0040029 regulation of gene expression, 
epigenetic 
9 3.42E-05 Arid4a, Hist1h2ad, 
Hist1h2af, Hist1h2ah, 
Hist1h2ai, Hist1h2an, 
Hist2h2ac, Spi1, Xist 
GO:0045814 negative regulation of gene 
expression, epigenetic 




GO:0035458 cellular response to interferon-
beta 






GO:0042832 defense response to protozoan 5 6.53E-05 Gbp2b, Gbp2, Gbp3, 
Irgm2, Slc11a1 
GO:0001562 response to protozoan 5 8.76E-05 Gbp2b, Gbp2, Gbp3, 
Irgm2, Slc11a1 
GO:0035456 response to interferon-beta 5 1.00E-04 Gbp2b, Gbp2, Gbp3, 
Ube2k, Irf1 
GO:0006342 chromatin silencing 6 1.67E-04 Hist1h2ad, Hist1h2af, 
Hist1h2ah, Hist1h2ai, 
Hist1h2an, Hist2h2ac 
GO:0034341 response to interferon-gamma 6 2.19E-04 Gbp2b, Gbp2, Gbp3, 
Irgm2, Irf1, Slc11a1 
GO:0098542 defense response to other 
organism 
12 2.52E-04 B2m, Gbp2b, Gbp2, 
Gbp3, H2-K1, Irgm2, 
Irf1, Oasl2, Plac8, 
Prf1, Slc11a1, 
Slc25a19 
GO:0042742 defense response to bacterium 8 9.22E-04 B2m, Gbp2b, Gbp2, 
Gbp3, H2-K1, Irgm2, 
Plac8, Slc11a1 
GO:0048002 antigen processing and 
presentation of peptide antigen 
5 1.15E-03 B2m, H2-D1, H2-K1, 
H2-Q6, Slc11a1 
GO:0019885 antigen processing and 
presentation of endogenous 
peptide antigen via MHC class I 
3 2.20E-03 B2m, H2-D1, H2-K1 
GO:0009617 response to bacterium 10 2.32E-03 B2m, Casp1, 
Cd209b, Gbp2b, 
Gbp2, Gbp3, H2-K1, 
Irgm2, Plac8, 
Slc11a1 
GO:0002483 antigen processing and 
presentation of endogenous 
peptide antigen 
3 2.93E-03 B2m, H2-D1, H2-K1 
GO:0002824 positive regulation of adaptive 
immune response based on 
somatic recombination of 
immune receptors built from 
immunoglobulin superfamily 
domains 






GO:0044406 adhesion of symbiont to host 3 3.37E-03 Gbp2b, Gbp2, Gbp3 
GO:0002474 antigen processing and 
presentation of peptide antigen 
via MHC class I 
4 3.47E-03 B2m, H2-D1, H2-K1, 
H2-Q6 
GO:0002821 positive regulation of adaptive 
immune response 
5 3.47E-03 B2m, H2-D1, H2-K1, 
Irf1, Slc11a1 
GO:0019883 antigen processing and 
presentation of endogenous 
antigen 
3 3.48E-03 B2m, H2-D1, H2-K1 
GO:0016458 gene silencing 6 4.38E-03 Hist1h2ad, Hist1h2af, 
Hist1h2ah, Hist1h2ai, 
Hist1h2an, Hist2h2ac 
GO:0001916 positive regulation of T cell 
mediated cytotoxicity 
3 6.33E-03 B2m, H2-D1, H2-K1 
GO:0071346 cellular response to interferon-
gamma 
4 7.62E-03 Gbp2b, Gbp2, Gbp3, 
Irf1 
GO:0019882 antigen processing and 
presentation 
5 7.68E-03 B2m, H2-D1, H2-K1, 
H2-Q6, Slc11a1 
GO:0001914 regulation of T cell mediated 
cytotoxicity 
3 1.07E-02 B2m, H2-D1, H2-K1 
GO:0002822 regulation of adaptive immune 
response based on somatic 
recombination of immune 
receptors built from 
immunoglobulin superfamily 
domains 
5 1.07E-02 B2m, H2-D1, H2-K1, 
Irf1, Slc11a1 
GO:0002819 regulation of adaptive immune 
response 
5 1.57E-02 B2m, H2-D1, H2-K1, 
Irf1, Slc11a1 
GO:0050830 defense response to Gram-
positive bacterium 
4 1.64E-02 B2m, Gbp2b, Gbp2, 
Gbp3 
GO:0002456 T cell mediated immunity 4 2.26E-02 B2m, H2-D1, H2-K1, 
Slc11a1 
GO:0002711 positive regulation of T cell 
mediated immunity 
3 2.44E-02 B2m, H2-D1, H2-K1 
GO:0002484 antigen processing and 
presentation of endogenous 





peptide antigen via MHC class I 
via ER pathway 
GO:0002485 antigen processing and 
presentation of endogenous 
peptide antigen via MHC class I 
via ER pathway, TAP-dependent 
2 2.44E-02 H2-D1, H2-K1 
GO:0001913 T cell mediated cytotoxicity 3 2.47E-02 B2m, H2-D1, H2-K1 
GO:0002250 adaptive immune response 7 2.70E-02 B2m, H2-D1, H2-K1, 
Irf1, Nedd4, 
Serpina3g, Slc11a1 
GO:0001912 positive regulation of leukocyte 
mediated cytotoxicity 
3 4.20E-02 B2m, H2-D1, H2-K1 
GO:0001771 immunological synapse 
formation 
2 4.21E-02 Lgals3, Prf1 
Day 49 (49 days after challenge) 
GO:0006342 chromatin silencing 5 4.99E-02 Hist1h2ad, Hist1h2af, 
Hist1h2ai, Hist1h2an, 
Hist2h2ac 
GO:0045814 negative regulation of gene 
expression, epigenetic 








Table S5. Full list of over-represented Gene Ontology Terms of biological processes in 
the O. volvulus endemic area dataset, identified by the ML Pipeline. 58 BP GO terms were 
found over-represented in the O. volvulus dataset. Multiple testing was accounted for using the 
Benjamini-Hochberg method to give an adjust P-value, an adjusted P-value < 0.05 and a Q-
value < 0.2 was used as the significance cut-off. 
BP GO 





Genes selected by 
pipeline 
GO:0001906 cell killing 8 1.14E-03 
CAMP, CTSG, DEFA1, 
DEFA1B, DEFA3, 
DEFA4, ELANE, GNLY 
GO:0006261 DNA-dependent DNA replication 10 3.18E-04 
CCNE2, CDC45, CDT1, 
DACH1, GINS2, LONP1, 
MCM2, MCM4, SLBP, 
TOP2A 
GO:0032508 ↳ DNA duplex unwinding 5 3.81E-02 CDC45, GINS2, MCM2, MCM4, TOP2A 
GO:0006270 ↳ DNA replication initiation 6 5.38E-04 CCNE2, CDC45, CDT1, GINS2, MCM2, MCM4 
GO:0006268 ↳ DNA unwinding involved in DNA replication 3 8.23E-03 MCM2, MCM4, TOP2A 
GO:0033260 ↳ nuclear DNA replication 5 6.28E-04 CDC45, CDT1, DACH1, GINS2, SLBP 
GO:0044786 ↳ cell cycle DNA replication 5 2.05E-03 CDC45, CDT1, DACH1, GINS2, SLBP 
GO:0006260 ↳ DNA replication 12 2.61E-03 
CCNE2, CDC45, CDT1, 
DACH1, GINS2, 
KIAA0101, LONP1, 
MCM2, MCM4, RBBP4, 
SLBP, TOP2A 
GO:0006959 humoral immune response 8 1.70E-02 
C4BPA, CAMP, CD46, 
DEFA1, DEFA1B, 
DEFA3, DEFA4, PHB 
GO:0031640 killing of cells of other organism 8 3.56E-07 
CAMP, CTSG, DEFA1, 
DEFA1B, DEFA3, 
DEFA4, ELANE, GNLY 






killing of cells in other 
organism involved in 
symbiotic interaction 
3 1.28E-02 CAMP, CTSG, ELANE 
GO:0051852 ↳ disruption by host of symbiont cells 3 5.28E-03 CAMP, CTSG, ELANE 
GO:0051818 ↳ 
disruption of cells of other 
organism involved in 
symbiotic interaction 
3 1.28E-02 CAMP, CTSG, ELANE 
GO:0044364 ↳ disruption of cells of other organism 8 3.56E-07 
CAMP, CTSG, DEFA1, 
DEFA1B, DEFA3, 
DEFA4, ELANE, GNLY 
GO:0000082 G1/S transition of mitotic cell cycle 12 5.38E-04 
AURKA, BRD7, CCNE2, 
CDC45, CDCA5, CDKN3, 
CDT1, FBXO31, ID2, 
MCM2, MCM4, TYMS 
GO:0098813 ↳ nuclear chromosome segregation 12 1.63E-03 
AURKB, CDC20, CDCA5, 
CENPI, DLGAP5, KIFC1, 
NCAPG, NUSAP1, PRC1, 
PTTG3P, TOP2A, UBE2C 




GO:0044772 ↳ mitotic cell cycle phase transition 16 1.14E-03 
AURKA, BRD7, CCNB2, 
CCNE2, CDC45, CDCA5, 
CDKN3, CDT1, DLGAP5, 
FBXO31, HMMR, ID2, 
MCM2, MCM4, TYMS, 
UBE2C 
GO:0044770 ↳ cell cycle phase transition 16 2.04E-03 
AURKA, BRD7, CCNB2, 
CCNE2, CDC45, CDCA5, 
CDKN3, CDT1, DLGAP5, 
FBXO31, HMMR, ID2, 
MCM2, MCM4, TYMS, 
UBE2C 
GO:0000070 ↳ mitotic sister chromatid segregation 8 5.14E-03 
AURKB, CDCA5, 
DLGAP5, KIFC1, 
NCAPG, NUSAP1, PRC1, 
UBE2C 
GO:0000083 ↳ 
regulation of transcription 
involved in G1/S transition of 
mitotic cell cycle 





GO:0045931 ↳ positive regulation of mitotic cell cycle 6 4.42E-02 
AURKA, CDC45, CDCA5, 
DLGAP5, NUSAP1, 
UBE2C 
GO:0007067 ↳ mitotic nuclear division 14 5.92E-03 
AURKA, AURKB, 
CCNB2, CDC20, CDCA2, 
CDCA5, DLGAP5, KIFC1, 
NCAPG, NUSAP1, OIP5, 
PRC1, UBE2C, ZC3HC1 
GO:0007076 ↳ mitotic chromosome condensation 3 1.82E-02 
CDCA5, NCAPG, 
NUSAP1 
GO:0044843 ↳ cell cycle G1/S phase transition 12 6.28E-04 
AURKA, BRD7, CCNE2, 
CDC45, CDCA5, CDKN3, 
CDT1, FBXO31, ID2, 
MCM2, MCM4, TYMS 
GO:0000819 ↳ sister chromatid segregation 11 1.14E-03 
AURKB, CDC20, CDCA5, 
CENPI, DLGAP5, KIFC1, 
NCAPG, NUSAP1, PRC1, 
TOP2A, UBE2C 




GO:0071103 DNA conformation change 11 5.85E-03 
CDC45, CDCA5, CENPI, 
GINS2, MCM2, MCM4, 
NCAPG, NUSAP1, OIP5, 
RBBP4, TOP2A 
GO:0032392 ↳ DNA geometric change 5 4.71E-02 CDC45, GINS2, MCM2, MCM4, TOP2A 
GO:0006323 ↳ DNA packaging 8 2.73E-02 
CDCA5, CENPI, MCM2, 
NCAPG, NUSAP1, OIP5, 
RBBP4, TOP2A 
GO:0030261 ↳ chromosome condensation 4 1.84E-02 CDCA5, NCAPG, NUSAP1, TOP2A 
GO:0032091 negative regulation of protein binding 5 4.54E-02 
ACE, AURKA, AURKB, 
CAMK1, CCL23 
GO:0007059 chromosome segregation 14 5.38E-04 
AURKB, CDC20, CDCA2, 
CDCA5, CENPI, 
DLGAP5, KIFC1, 
NCAPG, NUSAP1, OIP5, 
PRC1, PTTG3P, TOP2A, 
UBE2C 
GO:0002251 organ or tissue specific immune response 4 1.75E-02 









dependent protein catabolic 
process 
5 4.42E-02 AURKA, AURKB, CDC20, FBXO31, UBE2C 
GO:0002443 leukocyte mediated immunity 10 1.92E-02 
ACE, C4BPA, CD46, CLC, 
CTSG, ELANE, FES, 
GAPT, KDM5D, UNG 
GO:0050832 defense response to fungus 7 1.82E-05 
CTSG, DEFA1, DEFA1B, 
DEFA3, DEFA4, ELANE, 
GNLY 
GO:0009620 ↳ response to fungus 7 1.54E-04 
CTSG, DEFA1, DEFA1B, 
DEFA3, DEFA4, ELANE, 
GNLY 
GO:0009617 ↳ response to bacterium 13 4.85E-02 
ARG1, CAMP, CD24, 
CEBPE, CSF3, CTSG, 
DEFA1, DEFA1B, 
DEFA3, DEFA4, ELANE, 
GNLY, IDO1 
GO:0042742 ↳ defense response to bacterium 9 2.27E-02 
CAMP, CEBPE, CTSG, 
DEFA1, DEFA1B, 
DEFA3, DEFA4, ELANE, 
GNLY 
GO:0050830 ↳ defense response to Gram-positive bacterium 6 8.23E-03 
CAMP, CTSG, DEFA1, 
DEFA1B, DEFA3, DEFA4 
GO:0019730 ↳ antimicrobial humoral response 5 8.23E-03 
CAMP, DEFA1, DEFA1B, 
DEFA3, DEFA4 
GO:0019731 ↳ antibacterial humoral response 5 5.85E-03 
CAMP, DEFA1, DEFA1B, 
DEFA3, DEFA4 
GO:0035821 modification of morphology or physiology of other organism 9 3.56E-04 
CAMP, CTSG, DEFA1, 
DEFA1B, DEFA3, 
DEFA4, ELANE, GNLY, 
TYMS 
GO:0044146 
negative regulation of growth of 
symbiont involved in interaction 
with host 
3 2.09E-02 CAMP, CTSG, ELANE 
GO:0044116 ↳ growth of symbiont involved in interaction with host 3 3.78E-02 CAMP, CTSG, ELANE 






modulation of growth of 
symbiont involved in 
interaction with host 
3 2.44E-02 CAMP, CTSG, ELANE 
GO:0002227 innate immune response in mucosa 4 5.39E-03 CAMP, DEFA1, DEFA1B, DEFA3 
GO:0002385 ↳ mucosal immune response 4 1.47E-02 CAMP, DEFA1, DEFA1B, DEFA3 
GO:0002526 acute inflammatory response 7 1.75E-02 
ADAM8, C4BPA, CD46, 
ELANE, MRGPRX1, PHB, 
PTGER3 
GO:0002673 ↳ regulation of acute inflammatory response 5 2.77E-02 
ADAM8, C4BPA, CD46, 
PHB, PTGER3 
 
